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Abstract 
Bacteriophage (phage), bacterial viruses, have been improved as non-human 
pathogenic viral vectors for the purpose of introducing genetic materials into 
mammalian cells. Previously, our group generated a novel Adeno-associated 
virus/Phage (AAVP) hybrid vector as a valuable tool for targeted gene transfer to 
mammalian cells. However, the efficacy of bacteriophage-based vectors is 
considered relatively poor, meaning that ways of improving it are of considerable 
interest.  
First approach to improve AAVP-mediated gene delivery is through chemical 
modification. We showed that the transduction efficiency of AAVP was increased 
by the complexation of phage vectors with cationic molecules and calcium 
phosphate co-precipitation. Application of the bacteriophage complex carrying a 
cytotoxic gene resulted in eradication of cultured brain tumour cells. The 
chemically modified vector showed superior gene delivery over the conventional 
vector and can thus be regarded as an improved version of phage-based vector that 
has promise in cancer gene therapy. 
Next, we demonstrated that Extracellular Matrix (ECM) presents an obstacle for 
AAVP. Using brain cancer cell lines as a model, AAVP transduction was 
significantly increased by collagenase and hyaluronidase-mediated degradation of 
ECM, which can subsequently be translated into tumour cell eradication through 
AAVP-mediated gene therapy. Our findings prove that combination of AAVP 
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vectors with ECM depletion represents a powerful strategy to advance phage-
guided gene transfer. 
Finally, we engineered the prototype bacteriophage-based multifunctional vector as 
a proof-of-concept model that can simultaneously display three different peptides 
and carry a mammalian transgene cassette. Our results show that bacteriophage 
can be used as a scaffold for constructing multifunctional carriers that integrate 
multiple functions, which may have great potential for gene delivery applications. 
Together, the data demonstrate the potential for improved AAVP-based gene 
transfer to mammalian cells focusing on the use of chemical modification, 
manipulation of ECM, and the generation of multifunctional phage vectors. 
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1. Introduction 
1.1. Overview 
Introduction of genetic materials into mammalian cells is a key approach in cell 
and molecular biology. Expression of transgenes in cell culture or animal models 
provides a suitable system to determine the regulation and function of a desired 
gene.1 The interest in this research area has also dramatically increased with the 
development of other biomedical technologies such as gene therapy. Many gene 
transfer methods are based on viruses as a means to deliver genes into target cells. 
The most commonly used viral vectors for gene transfer are derived from 
adenoviruses, adeno-associated viruses (AAV), retroviruses, lentiviruses, and 
herpes simplex viruses (HSV).2 Though viruses were evolutionarily designed to 
transfer their genetic material into host cells efficiently with various tissue 
tropisms, their use as vectors for therapeutic gene delivery is hindered by a number 
of limitations including deoxyribonucleic acid (DNA) packaging capacity3, 
immunogenic concerns1,4, and the potential for insertional mutagenesis, which can 
be oncogenic5,6, whereby the latter two significantly restrict their clinical use. 
Although most recombinant viral vectors are replication-deficient and require 
helper virus functions for propagation, they are amenable to replication-competent 
virus breakthrough, raising biosafety concerns.7 In addition, the co-infection of 
packaging cells with a wild type helper virus to produce infectious viral particles is 
required for some viruses (AAVs and HSV), resulting in a contamination with the 
helper virus, which often cannot be fully eliminated during preparation of the viral 
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stock8 and can have cytotoxic effects9. Although commercial kits are available, 
replication-defective systems still require transfection steps or cloning of packaging 
cell lines which is time consuming to generate virus stocks, and subsequent 
purification of the virus particles.  Important limitations also include a limit to the 
size of the DNA that can be engineered into their genome10 and complex protein 
structures, effectively creating an expensive and complicated manufacturing 
process.10  In order to reduce side effects and lower the amount of viral vectors 
required, infection must be restricted to target cells, also known as cell targeting or 
transductional targeting.10  Although animal viruses have been shown to have 
potential for ligand-targeted gene delivery, eliminating their native tropism and re-
targeting them to different receptors substantially reduce their efficacy.11,12 
Alternatively, transgene expression can be achieved by transfection of target cells 
using non-viral vectors such as naked DNA, cationic liposomes, cationic polymers, 
and synthetic peptides.13 The most commonly used in vitro gene delivery method is 
DNA plasmid containing a gene of interest. However, this approach requires a 
large quantity of plasmid DNA with expensive commercial transfection reagents.7 
Although these non-viral vectors are highly effective in gene transfer to in vitro 
cultured cells, they appear to be significantly less effective in vivo.13 
The prokaryotic single-stranded DNA bacteriophage virus, which only infects 
bacteria, has also been proposed as a gene delivery vector.14,15 One of the major 
advantages of the bacteriophage as a gene delivery vector is its simple, fast, and 
cost effective production. Phage vectors carrying a gene of interest can be easily 
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produced with high titres in the supernatant of Escherichia coli (E.coli) host cell 
cultures and can be purified on a large scale.16 In contrast to replication-deficient 
animal viral vectors in which helper functions are used to produce virus, the phage-
based system provides a good compromise. The phage is propagated in bacterial 
cells; thus any risk of breakthrough of replication-competent virion can be avoided. 
In addition, they are safe, having long been used for both prophylaxis and 
treatment of bacterial infection, both in adults and children, with no safety 
concerns being identified.17 They have also been approved by the U.S. Food and 
Drug Administration (FDA) to be used as safe antibacterial food additives.18 
Interestingly, a recent study has found a new form of symbiosis at mucosal surface 
of many animal species including humans with bacteriophage, which provides non-
host-derived immunity against bacterial infection.14   In terms of their packaging 
capacity, bacteriophages do not seem to have a defined packaging limit because 
they possess a capsid composed of the major pVlll coat protein arranged in an 
almost perfect α-helical array, which can be extended to accommodate larger DNA 
constructs.19  
Despite their attractive advantages, phage-based vectors are still considered to be 
poor vectors for gene transfer which restricts their application in a broad range of 
disciplines. It is clear that the phage has evolved to exclusively infect bacterial cells 
and has no optimized strategies to transfer and express transgenes in mammalian 
cells. However, the phage-based vector, due to its genetic and structural simplicity, 
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is uniquely suited to methods that use directed evolution to improve its 
performance.20  
New generations of gene delivery vectors have incorporated elements from 
different vectors in order to obtain the ideal vector with the desired attributes. 
These hybrid or chimeric vectors are expected to outperform their conventional 
counterparts by adding new abilities or replacing certain undesirable elements.21 
Previously, our group reported a novel adeno-associated virus/phage (AAVP) 
hybrid vector system by combining bacteriophage with attributes of the AAV 
animal virus.22 Phage is a prokaryotic virus, which has no natural tropism for 
eukaryotic mammalian cells.23 Targeting peptides genetically inserted into phage 
coat proteins alter its tropism and can transduce mammalian cells.24  AAV vector 
genomes serve as an excellent eukaryotic expression cassette due to their long-term 
transgene expression without problems associated with insertional mutagenesis and 
has enabled a number of clinical trials using this gene delivery system.25 
Incorporating the genetic cis-elements inverted terminal repeat (ITR) from AAV2 
into the phage genome resulted in altered transgene cassette and subsequently in 
improved gene transfer efficacy of bacteriophage.26 The resulting AAVP can 
efficiently transduce target cells and has a long-term stable transgene expression. 
Finally, AAVP titres can reach approximately 1010-1011 bacterial transducing 
unit/μl. 
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1.2. Background review 
1.2.1. Gene delivery 
Gene transfer is the introduction of nucleic acids into cells. This technology 
provides the ability to genetically manipulate the target cells, and has contributed to 
a number of applications.2  A major approach in the field of cell biology is the 
transfer of genes of interest in selected cell cultures or animal models, with the aim 
to study the gene’s function by overexpressing a gene of interest, knocking down 
target proteins via micro-ribonucleic acid (miRNA) or RNA interference (RNAi), 
or expressing mutant versions of genes.4 Moreover, the production of 
biopharmaceutical proteins, such as hormones, growth factors, cytokines, and 
immunoglobulins that is used to treat a broad spectrum of diseases largely relies on 
the expression of recombinant proteins in cultivated mammalian cells.5 The most 
important contribution of gene transfer innovation involves the direct use of 
genetic material as a therapeutic agent to treat or prevent diseases. This so-called 
‘gene therapy’ holds the promise for curing a large number of monogenic 
disorders, cardiovascular diseases, infectious diseases, cancer, and many others.7 
Most importantly, it has been realized that development of gene carriers or vectors 
that can safely and efficiently transport the therapeutic payload selectively to 
disease sites is a bottleneck in clinical applications of human gene therapy.27,28 
Generally, vectors for gene delivery are classified into two categories; viral- and 
nonviral-based vectors. Viral vectors are derived from natural viruses, whereas 
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non-viral vectors generally consist of DNA (usually plasmid DNA) delivered to 
target cells with the aid of delivery vehicles such as cationic lipids or polymers. 
1.2.2. Viral-based gene delivery vector  
At present, gene transfer is achieved with modified viruses (Figure1.1). The 
characteristics of the three most commonly used viral vectors for gene transfer are 
summarised in Table 1.1. Adenoviral vectors are useful for gene transfer due to 
their broad infection spectrum and high levels of gene delivery compared to other 
available vectors. Adenoviral vectors are easily manipulated using recombinant 
DNA techniques.29 Another commonly used viral vector, the non-pathogenic 
AAV, serves as an excellent gene delivery vector due to its long-term transgene 
expression without problems associated with insertional mutagenesis.25 Other 
vectors of interest include retroviruses and lentiviruses, a subset of the retrovirus 
family. Lentiviruses (e.g., human immunodeficiency virus type 1, HIV-1) are of 
particular interest because they can integrate their genome into the host cell 
genome, allowing stable, long-term transgene expression.30  
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Figure 1.1:  The annotated graphical representation of the viral-based gene delivery. The 
most commonly used viral vector is the modified AAV. The DNA makes its way to the nucleus, 
where it predominantly forms episomes. In contrast, integrating viruses insert their DNA into 
the host genome. The lentivirus, for example, delivers its payload to the cytoplasm, where a 
reverse transcription occurs. The DNA then enters the nucleus, where it integrates into the 
genome. 
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Table 1.1: Features of viral-based gene delivery systems. (Modified from Waehler, R. et al. 
2007)31 
 
Adenoviral vectors 
Adenovirion consists of a ~36 kilobases (kbs) linear double stranded DNA 
genome encapsulated in a non-enveloped icosahedral particle of 70-100 
nanometres (nm) in diameter (Figure 1.2a). The viral genome contains nine major 
complex transcription units divided into early (E1A, E1B, E2-E4) and late (L1-L5) 
transcripts flanked by ITR (Figure 1.2a). The deletion of the E1 and nonessential 
region of E3 allows 7-8 kb of transgene to be inserted into the vector genome.32 
Adenovirus enters cells via Coxsackievirus and adenovirus receptor (CAR)-
mediated binding followed by internalisation via receptor-mediated endocytosis. 
After endosomal escape into the cytosol where capsid disassembly occurs, viral 
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DNA is transported into the nucleus through the nuclear envelope pore complex. 
The viral DNA is not integrated into the host genome, but is rather maintained as 
an episome. 
Adeno-associated virus vectors (AAV) 
A recombinant AAV is originally derived from a non-pathogenic parvovirus, a 
satellite virus of human adenovirus.33 The small icosahedral particle is 
approximately 18-26 nm in diameter and contains either the sense or antisense of a 
single strand of DNA of 4-5 kb in size with equal efficiency (Figure 1.2b).33 The 
AAV particle enters the cell via receptor-mediated endocytosis after which its 
genome is released into the nucleus where the single-stranded DNA is converted 
to double-stranded vector genome form. Viral genome DNA is composed of two 
open reading frames; the rep and the cap regions17 both of which are replaced by  
the transgene sequences in order to construct AAV vectors. Each end of the viral 
genome has a 145-base long ITR sequence responsible for integration of AAV 
genome into a specific site in chromosome 19, although AAV exist primarily in 
episomal form (Figure 1.3). 
To date, many strategies have been developed to improve targeting or retargeting 
desired cells only.  This includes not only chemical engineering34, , chimeric 
vectors35 and so on, but also novel methods involve direct evolution of capsid 
proteins36, direct display of random peptides on the AAV capsid37, etc. However, it 
is still challenging to eliminate some AAV intrinsic restrictions, such as incomplete 
viral native tropism, and low packaging titre.38  
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Retroviruses 
Retroviruses are enveloped viruses with nucleocapsids of 80-130 nm in diameter 
containing two copies of a linear, positive stranded 7-11 kb RNA genome.39 The 
most commonly used retroviral vectors include the gammaretrovirus (or simple 
retrovirus) and lentivirus (or complex retrovirus) (Figure 1.2c, d). The viral 
genome is encapsulated within the capsid along with the viral reverse transcriptase 
and the integrase enzyme. Replication elements are replaced by the transgene, 
while retaining all the necessary RNA regions, primarily the long terminal repeat 
(LTR) that is associated with packaging, reverse transcription, and integration. 
Such vectors can accept up to 7 kb of an exogenous gene sequence (Figure 1.2c, 
d).39,40  Following attachment and internalisation via receptor-mediated 
endocytosis, viral reverse transcriptase mediates the conversion of the viral genome 
to a double stranded DNA provirus, which is subsequently inserted into the host 
genome with the help of the integrase enzyme.39,41 Due to its ability to stably 
integrate, allowing long-term expression, retroviral vectors have been used 
theoretically for single administration that could have a sustained long-term 
curative effect. 
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Figure 1.2: Diagram of the viral particles and organisation of the recombinant genome of 
the modified viral vectors. a) Adenovirus, b) AAV, c) Retrovirus, and d) Lentivirus (Modified 
from Sheridan, 2011)42 
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Figure 1.3: Fate of adeno-associated virus (AAV) genome. a) Structure and sequence of an 
inverted terminal repeat (ITR) in the single-stranded genome encapsulated in the AAV particle. 
b) The single-stranded DNA is converted into double-stranded through DNA synthesis and/or 
annealing. The AAV concatamer is formed by head-to-tail, head-to-head, and tail-to-tail 
intermolecular ligations. The AAV genome predominantly remains as episomes. Integration can 
occur with low frequency, most probably at chromosomal double-stranded breaks. (Modified 
from Schultz, B.R. and Chamberlian, J.S. 2008)43 
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1.2.3. Nonviral-based gene delivery vector 
While viruses have been used successfully for gene transfer, the use of non-viral 
vectors has been explored as an alternative method to deliver transgenes into cells. 
The process of introducing nucleic acids into cells by non-viral methods (also 
defined as transfection) can be achieved by neutralizing or obviating the issue of 
introducing negatively charged nucleic acid into cells with negatively charged 
surface membrane. Cationic polymers and lipid-based reagents as well as calcium 
phosphate, which neutralize or even create an overall positive charge in the 
complex, facilitate efficient binding of complexes to cell surfaces and make it easier 
to cross the cell membranes. In this chapter, we will discuss some of the most 
commonly used non-viral gene delivery vectors which are included in Figure 1.4.  
Calcium phosphate (CaPi) precipitation 
Calcium phosphate (CaPi) co-precipitation was the first non-viral technique widely 
used to transfect foreign DNA into cells mainly due to its simplicity and 
inexpensiveness.44 This technique is based upon DNA precipitation on the cell 
surface.  The protocol involves mixing DNA, calcium chloride (CaCl2), and a 
buffered saline/phosphate solution in a controlled manner. The CaPi-DNA 
precipitates are dispersed onto cultured cells and are taken up by cells via 
endocytosis or phagocytosis. However, CaPi co-precipitation is not suited for in 
vivo gene delivery. Moreover, the transfection efficacy of CaPi method can be 
compromised by small pH changes (±0.1).45  
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Cationic polymers 
Another category of non-viral gene delivery vectors is cationic polymers. One of 
the first cationic polymers used to deliver nucleic acids into mammalian cells in vitro 
was diethlyamioethyl-dextran (DEAE.DEX). This method is based upon the 
complex formation (referred to as polyplex) between the negatively charged DNA 
and the positively charged polymer (Figure 1.5). An excess of positive charge 
contributed by the polymer content in the DNA:polymer complex leads to 
adherence of the complex to the negatively charged cell surface and subsequent 
endocytosis. Other synthetic cationic polymers have been used to transfect DNA 
into cells, including polylysine.46 Polylysine has been shown to form complexes 
with DNA as a result of an electrostatic bridge between the negative charge of 
DNA and the positive charge of amino groups of the lysine residues.47 However, in 
vivo application of polylysine, leads to non-specific interactions between the 
positively charged complex and blood components, resulting in failure of safe and 
efficient gene delivery.48,49 Among the most widely used cationic polymers as gene 
carriers are polyethyleminines (PEIs). Linear or branched PEIs have been 
efficiently used for in vitro gene transfer. Similar to that of polylysine, these 
complexes have been shown to suffer from high degree of cytotoxicity, rapid 
clearance and self-aggregation.50 This technique is widely used because the 
components are easily available and inexpensive in addition to protocol being 
simple, rapid and reproducible. Other synthetic cationic polymers have been 
employed to transfect DNA into cells, including polybrene (PB)51 and dendrimers 
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52,53. Cationic polymers serving as DNA carriers can be conjugated with receptor-
recognizing molecules capable of directing DNA into eukaryotic cells via receptor-
mediated pathways. Conjugates of corresponding ligands with cationic polymers 
are taken up by various cells and exhibit high transfection activity. Both the uptake 
and transfection efficiency correlate with the level of receptors.54 Transferrin and 
insulin receptors have been used for receptor-mediated transfection.55   
Although these polyplexes are favourable for in vitro gene delivery efficiency, their 
in vivo application is hampered by their relatively low efficiency when compared to 
viruses, and by the necessity of an overall net positive charge.  This results in 
potentially low bioavailability and lack of cell specificity.48 Upon systemic delivery, 
the charged polyplexes interact with the blood components and non-target tissues, 
reducing targeting ability and triggering toxic effects.48,56-58 To improve properties 
of this class of gene delivery vectors, various surface modified derivatives of 
caitionic polymers have emerged. Surface conjugation of cationic polymers with 
polyethylene glycol has been shown to prevent their aggregation, lower toxicity, 
increase circulation time, and improve systemic gene delivery.56,59-64 Unfortunately, 
masking the surface charge of polyplexes by PEGylation appears to reduce their 
transfection efficiency due to reduced interactions with cell surfaces.63,65,66 Such in 
vivo problems of gene delivery can also be overcome by targeted transfection.  It is 
a complementary approach where the target cells can be selected based on specific 
interactions, e.g. ligand receptor, with the transfecting complex. Conjugates of 
sugar moieties (e.g., lactose or galactose) with poly-lysine allow polyplexes to target 
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asialoglycoprotein, unique receptors of hepatocytes.67,68 In addition, folate 
receptors overexpressed on cancer cells can also be used as targets for folate-
grafted gene delivery vectors.69 There have also been efforts to conjugate 
antibodies (e.g., anti-JL1 antibody) to polylysine polyplexes allowing efficient 
leukemia-specific cell internalisation and specificity.70  
Liposome-based gene delivery systems 
The most effective nonviral gene delivery vectors developed so far are made of 
liposomes. The term “liposome” refers to an artificially-prepared spherical vesicle 
with bilayer membrane structure composed of natural or synthetic amphiphilic 
lipid molecules.71 Nucleic acids are encapsulated within liposomes by the reverse 
phase evaporation method (REV).72 However, the production of liposomes 
containing the DNA molecules inside requires multiple challenging steps. Another 
possible problem associated with liposomes is that small-sized liposomes may be 
incapable of encapsulating large amounts of DNA. Therefore, stable cationic 
liposomes spontaneously interacting with nucleic acids and therefore forming 
liposome/nucleic acid complexes (referred to as lipoplexes)  have been developed 
to overcome some of the mentioned shortcomings of liposomes. It is believed that 
the negatively charged DNA interacts with the positively charged groups of the 
liposomes. The most widely used cationic lipid is dioleoyltrimethylammonium-
propane (DOTAP).73 Lipoplexes can be easily prepared by the addition of DNA to 
liposomes dispersed in solution.74 The lipid to DNA ratio and overall lipid 
concentrations are important factors for efficient transfection and vary with 
P a g e  | 32 
 
applications.75 To date, a number of cationic liposome formulations are 
commercially available, such as Fugene, Lipofectin, Lipofectamine, and many 
others are under development.76,77 
 
Figure 1.4: Structures of non-viral vectors for gene delivery. 
 
Figure 1.5: Formation of polymer-plasmid DNA polyplexes. a) Polyplexes are formed by 
electrostatic interactions between cationic polymers and negatively charged DNA. For gene 
delivery, an excess of positively charged polymers generates particles with a positive surface 
charge which favours cellular uptake and transfection. b) Transmission electron micrograph of 
polyplexes (Modified from Pack, D.W. et al. 2005)78 
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1.2.4. Extracellular Barriers to gene delivery vectors 
Successful gene delivery to target cells is not a simple task because there are many 
barriers encountered by both viral and nonviral-based gene delivery vectors. 
Vectors must first overcome the extracellular barriers, such as rapid clearance 
and/or degradation of vector before it reaches its target cells. Extracellular barriers 
faced by gene delivery vectors after systemic administration are schematically 
depicted in Figure 1.6. 
Packaging of nucleic acids 
Naked nucleic acids as macromolecules are generally difficult to deliver, primarily 
due to their sensitivity to environmental conditions such as pH or enzymes (e.g., 
nucleases) that can degrade and destroy them. DNA condensation provides size 
reduction and protection against degradation. Viral vectors are natural systems 
capable of condensing nucleic acids into their capsid efficiently as they have highly 
evolved machinery for protecting and delivering their genomes to host cells.  
Cationic polymers or lipids are widely used to condense negatively charged nucleic 
acids by electrostatic interaction into small particles (i.e., polyplexes, lipoplexes), 
for protecting nucleic acids from degradation. However, the synthesis procedure 
for polyplexes or lipoplexes is less controllable compared to viral vectors which 
relies on precise mechanism of biosynthesis. The presence of excessive amounts of 
nitrogen residues compared to phosphate groups on DNA yields positive charges 
on the complexes, facilitating their binding to the negatively charged cell surface. 
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This electrostatic interaction promotes endocytosis and subsequently, high levels 
of gene expression. 
Opsonisation and phagocytosis 
Opsonisation is the process of coating a foreign organism or particle with 
phagocytosis-enhancing molecules called opsonins. The blood plasma proteins 
involved in opsonisation are primarily albumins, fibronectins, fibrinogens, 
complement proteins, immunoglobulins and apolipoproteins.67,70,79,80 This process 
makes the opsonin-coated particles or microbes more immunologically ‘visible’ and 
susceptible to phagocytic cells (e.g. monocytes, macrophages, neutrophils, and 
dendritic cells).  Following opsonisation, phagocytosis can efficiently occur, leading 
to destruction or removal of foreign materials from circulation by the mononuclear 
and polymorphonuclear phagocyte systems.68 Particles can be opsonized within 
minutes upon exposure to blood, depending on their intrinsic surface 
characteristics, such as charge and hydrophobicity. Typically, phagocytes are unable 
to recognize foreign particles without adsorbed opsonin proteins. Adsorption of 
opsonin proteins on particles results in conformational changes from an inactive to 
activated form of protein structure that can be subsequently recognized by 
phagocytes.81 In addition to facilitating particle recognition by the immune cells, 
opsonisation alters the effective size of the particle diameter referred to as the in 
vivo hydrodynamic diameter, which may be larger than the in vitro particle diameter. 
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Renal clearance 
In order to avoid the possible side effects resulting from catabolism or breakdown, 
renal excretion is a desirable pathway for the removal of particles from the vascular 
compartment of the human body. In general, intravascular molecules with a final 
hydrodynamic diameter smaller than 5 nm are filtered by glomerular filtration 
resulting in rapid and efficient urinary excretion, while increased hydrodynamic 
diameter by over 8 nm prevents renal excretion. Glomerular filtration of molecules 
with the intermediate hydrodynamic diameter of 6-8 nm depends upon both size 
and charge of the particle. The effect of surface charge on glomerular filtration is 
due to at least 2 factors: (i) adsorption of serum proteins resulting in increased 
hydrodynamic diameter82, and (ii) direct interaction between charged particles and 
fixed charge within the glomerular capillary wall.83 The increase in size significantly 
reduces glomerular filtration and likely shifts the route of renal excretion to the 
liver. Macromolecules that are too large to be filtered through the glomerular pores 
tend to accumulate in the liver due to its loose structure and high blood 
perfusion.84  
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Figure 1.6: Summary of the extra-and intracellular barriers faced by gene delivery vectors 
following systemic administration. Gene transfer efficacy of gene delivery vectors has been 
hindered by numerous obstacles. a) After systemic administration, vectors must overcome rapid 
clearance and/or degradation of the vector before it reaches its target tissue. b) Intracellular 
barriers include plasma membrane and endocytosis, endosome escape, and nuclear translocation. 
(Modified from Pecot, C.V. et al. 2011)85 
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Reticuloendothelial system organ uptake and retention 
The reticuloendothelial system (RES) is a part of the immune system, comprised of 
phagocytic cells such as monocytes and macrophages located in different organs of 
the body. Specialized macrophages located in the liver, termed Kupffer cells, and 
in the spleen rapidly take up opsonin-coated materials as these cells possess 
receptors for endocytosis of complement proteins and for the Fc fragment of 
IgG.86 These particles are taken up by the liver, spleen, or other parts of RES 
depending on their physical characteristics such as size and charge. This function 
of RES involves the efficient capture and elimination of particles on the scale of 
10-20 nm including virus particles.82  
To achieve adequate circulation time, surface modifications of particles may be 
required to prevent or lessen opsonisation. Particles with more hydrophilic 
surfaces (> 35 nm diameter) show much less uptake by the liver and spleen than 
hydrophobic particles.87 One widely used approach is molecular modification via 
the attachment of polyethylene glycol (PEG) polymer to particles referred to as 
PEGylation. Although reduction of particle size and stabilization of particles with a 
layer of amphiphilic polymers are promising, a complete avoidance of the RES 
system has not been possible.88 Another promising approach to prevent serum 
protein adsorption is zwitterionic coating. Creating particles with zwitterionic 
surface charges provides the highest solubility and smallest hydrodynamic diameter 
and is therefore a useful strategy to obtain more favourable clearance properties of 
particles intended for clinical applications.  
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Extravasation  
Endothelial cells, which form the inner cellular lining of blood vessels, act as a 
semi-selective barrier that regulates exchange of fluid and molecules between the 
vascular compartment and the extravascular space.89 The leakage of intravascular 
agents into extracellular space of surrounding tissues, referred to as extravasation, 
is a result of intercellular openings between endothelial cells. Particles with 
hydrodynamic diameter less than 5 nm are rapidly removed from the circulation 
through the 5 nm-sized pore in normal intact endothelium.90 In contrast, larger 
particles have limited diffusion across the endothelium resulting in prolonged 
circulation times.  
Although endothelial pores have sizes that vary substantially by tissue throughout 
the body (from 10 to 1,000 nm)91,92, each microvasculature has a characteristic 
pore-size distribution.93 These pore sizes provide each microvessel with a particular 
restriction of permeation of macromolecules across a capillary wall. More 
particularly, the abnormal tumour vasculature is more permeable to larger 
particles.94,95 However, the vasculature of each tumour type has its own range of 
endothelial pores.96 For example, the pore size for a brain tumour may be ~7 nm 
versus less than 1 nm for normal brain tissues96, whereas in breast or pancreatic 
tumours they might be ~50-60 nm versus ~5 nm for normal breast or pancreatic 
tissues.97-99 Therefore, the pore-size heterogeneity of the vasculature in a specific 
tissue and its tumour is a critical consideration for the design and development of 
nano-sized objects for biomedical applications. 
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Blood brain barriers (BBB) 
Another major challenge is the BBB, which is formed by the endothelial cells that 
line cerebral microvessels if the target site is located in the central nervous system 
(CNS) (Figure 1.7a). Unlike capillaries elsewhere in the body, the structure of the 
BBB is characterized by the tight-junctions that are tightly resistant to ion or small 
molecule exchange. In addition to the interendothelial tight junctions, the altered 
expression of trans-endothelial transporter contributes to the barrier properties. 
Moreover, a large number of pericytes and perivascular antigen-presenting cells 
around the endothelial cells play an important role in regulating the barrier 
functions of BBB. Therefore, the BBB represents the main determinant of 
effective delivery of therapeutic agents to the CNS.  
The BBB in brain tumours is compromised due to a loss of tight intercellular 
junctions and poorly developed astrocytic pericapillary sheath, all of which 
contribute to its increased permeability. However, this disrupted BBB still acts as 
an obstacle for many therapeutic agents.100 Therefore, the capacity of compounds 
to penetrate the BBB is a crucial factor for drug choice in the treatment of brain 
tumours (Figure 1.7b). Small and lipophilic molecule drugs (e.g., temozolamide, 
TMZ and carmustine) can cross the BBB by transmembrane diffusion.101 Certain 
endogenous large molecules (i.e., insulin, transferrin) cross the BBB via a specific 
receptor-mediated transcytosis.102 Alternatively, molecules that not cross the BBB 
are coupled to molecules that can be used to improve pharmacokinetic profile of a 
substance. Therefore, the so-called trojan-horse strategy can enable BBB transport 
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of large molecule drugs or plasmid DNA.103 Another pathway that provides a 
means for brain delivery of therapeutic agents across the BBB is adsorptive-
mediated transcytosis. This mechanism enables binding and uptake of positively 
charged molecules to the luminal surface of endothelial cells, followed by 
exocytosis at the abluminal surface.102 The conversion of the protein carboxyl 
groups to primary amino groups (referred to as cationization), or the attachment of 
cationic import peptides to proteins using either chemical conjugation or genetic 
fusion is therefore a promising strategy to trigger transport across the BBB via this 
pathway.104 
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Figure 1.7: The blood brain barrier. a) A schematic diagram of the blood brain barrier (BBB) 
formed by endothelial cells and their associations with the perivascular endfeet of astrocytes. 
However, the BBB is disrupted in the setting of a brain tumour, allowing enhanced permeability 
of molecules. b) The main routes for molecular traffic across the BBB. (Modified from Abbott, 
N.J. 2006)102 
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Extracellular matrix (ECM)  
In most tissues, cells are surrounded by the ECM, which is a dense network mainly 
composed of fibrous proteins (i.e., collagen, laminin, fibronectin) and 
polysaccharides. The ECM plays an important role in regulating a number of cell 
functions. For example, ECM proteins bind to integrins and other cell surface 
receptors, triggering signal transduction that regulates cellular morphology, 
adhesion, migration, proliferation, and apoptosis. 
After a vector leaves the blood stream, it must diffuse through the ECM, which is 
the most immediate physical barrier that can create resistance to the transport of 
macromolecules.105 Diffusion through the ECM is hindered by steric, 
hydronynamic, and electrostatic interactions between particles and components of 
the ECM.106 In addition to the physiochemical properties of the ECM, the 
movement of particles in the tissue depends on their intrinsic characteristics (i.e., 
size, charge, and configuration).107 Several investigations have demonstrated that 
the transport of therapeutic agents through the ECM could be improved by 
degradation of ECM proteins.108 More particularly in tumours, increased amounts 
of matrix molecules such as collagen and hyarulonic acid can form a barrier that 
limits the distribution of therapeutic agents through the interstitial space (Figure 
1.8). These ECM molecules create pores of approximately 10-100 nm and can 
sterically block particles through hydrodynamic and electrostatic interactions.109 
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Figure 1.8: The transport barriers to delivery in tumours. a) Therapeutic agents enter a 
tumour through its blood supply. These particles must cross the blood vessel walls (extravasate) 
to penetrate into tissues and then diffuse through the interstitial space to reach their target cancer 
cells.. b) The interstitial space in normal tissue and tumours. The interstitium in tumours 
(bottom) is more disorganized and dense than in normal tissue (top) 
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1.2.5. Intracellular Barriers to gene delivery vectors 
Once the vector can avoid extracellular barriers and has reached its particular 
target, it must traverse the cell membrane, escape the endosome, and enter the 
nucleus in order for gene expression to occur. Intracellular barriers faced by gene 
delivery vectors are depicted schematically in Figure 1.6. 
Uptake mechanism 
The first interaction between a vector and a cell is crucial to promote 
internalisation. Viral vectors are known for their high efficiency in attachment and 
entry into host cells. The virus binds to a cell surface receptor and in some cases 
multiple receptors, triggering its subsequent endocytosis. Adenovirus binds to its 
cellular CAR through its globular knob of the C-terminal segment of the viral fiber 
protein. Subsequently, arginine-glycine-aspatic acid (RGD) peptide motif on the 
viral penton base (the capsid protein at the base of the fibre) interacts with the 
cellular integrins and facilitates cell entry by endocytosis (Figure 1.9a).110 The first 
interaction between the cell and AAV2 as shown in Figure 1.9b occurs between 
basic residues of capsid protein VP3 (positions R585 and R588) and heparin sulphate 
proteoglycan (HSPG).49 The second interaction is between the RGD motif on the 
viral penton base and the cellular co-receptor, which can either be an integrin 
(shown here), human fibroblast growth factor receptor or a hepatocyte growth 
factor receptor.58 In contrast, membrane fusion is the main mechanism of 
enveloped viruses such as retrovirus (lentivirus). Following initial non-specific 
attachment of the virus and cell surface64, envelope glycoproteins, which 
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determines the host range of retroviral vectors, binds specifically to their cognate 
receptors Figure 1.9c, resulting in fusion between the lipid membranes of the 
virus and the host cell after which the viral nucleocapsid is released into the 
cytoplasm.60,63 In some cases, membrane fusion is triggered by conformational 
changes in the viral proteins after receptor binding. In others, a conformational 
rearrangement of the viral fusion machinery is triggered by a reduction in pH in an 
endosomal compartment. 
For cellular uptake to occur, non-viral vectors must associate with the cell surface, 
either through nonspecific (for example, electrostatic attraction) or specific (ligand-
receptor) binding (Figure 1.9d).111 Nonspecific binding forces that promote 
cellular contact and particle uptake primarily result from intrinsic characteristics of 
vectors. For example, surface charge affects particles’ interactions with charged 
phospholipid head groups or protein domains on cell membranes.112 Other 
characteristics of particle surface (for example, size, shape, radius of curvature) also 
play an important role in their cellular uptake.113-115  In contrast, the specific 
binding results from interactions between certain ligands and complementary 
molecules or receptors on the cell membrane, leading to receptor-mediated 
endocytosis of vectors.115 Ligands can be either of biological origin (i.e., protein, 
peptide, and antibody) or abiotic ligands such as chemical moieties or surface 
functionalities (for example, polymeric substances such as polycationic PEI and 
polyamidoamine116), all of which promote binding affinity and subsequent 
internalisation. By exploiting the diversity of cell surface receptors, internalisation 
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and transfection efficiency can be enhanced by attachment of complementary 
ligands to gene delivery vectors. Incorporation of targeting ligands is expected to 
decrease the vector amount required to achieve an efficient transfection. Several 
studies have demonstrated that the use of targeting ligands functions to increase 
receptor-mediated internalization which is faster than non-specific uptake, and 
therefore improves intracellular accumulation.48,117-122 The most popular ligands are 
transferrin, RGD peptide recognized by integrins of tumour vasculature, lactose by 
the asialoglycoprotein receptors (ASGRP-R) of the hepatocytes, mannose by 
mannose receptors (MR) of macrophages and dendritic cells, and folic acid by 
folate receptors on certain tumour cells.123  
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Figure 1.9: Entry mechanisms of viral and non-viral vectors. a) Adenovirus virions bind to 
the coxsackie adenovirus receptor (CAR) and integrins on the plasma membrane through its 
fibre knob, and enter the cell by receptor-mediated endocytosis. b) AAV  binds to heparin 
sulphate proteoglycan (HSPG) and the co-receptor (integrins, human fibroblast growth factor 
receptor, or hepatocyte growth factor receptor), and is internalised by endocytosis. c) Retrovirus 
(lentivirus) utilises the membrane fusion mechanism to enter the cells and deliver its genome into 
the host genome. Following initial nonspecific binding of the virus particle to the cell membrane, 
viral glycoproteins bind specifically to their cognate receptors. d) Specific binding of non-viral 
vectors on cell membrane via ligand-receptor interactions, resulting in receptor-mediated 
endocytosis. This process is affected by factors (vector’s size and shape, cell membrane’s 
elasticity). 
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Many endocytosis pathways have been identified and their simple models are 
schematically shown in Figure 1.10. Large particles can be taken up by 
phagocytosis. This pathway is primarily found in specialised immune cells such as 
macrophages, dendritic cells, neutrophils, and monocytes. In contrast to 
phagocytosis, that is limited to a few cell types, most cells are capable of 
macropinocytosis.66 Activation of this pathway results in intense actin and 
microfilaments remodelling and membrane ruffling. The other well characterized 
mechanism is clathrin-mediated and caveolae-mediated endocytosis. Receptor-
mediated endocytosis is the most common route for both viral and non-viral gene 
delivery vectors and encompasses a variety of entry pathways using clathrin- or 
caveolin-coated vesicles in order to uptake vectors into the cell from the surface. 
These pathways are so-called clathrin- or caveolin-mediated endocytosis, 
respectively. Caveolin-coated vesicles are first transported to intermediate 
compartments called caveosomes, whereas clathrin-coated vesicles directly traffic 
to early endosomes.  Cargos are also endocytosed via a clathrin/caveolin 
independent entry pathway using clathrin- and dynamin-independent carriers 
(CLICs) derived from the plasma membrane, which subsequently traffic to glycosyl 
phosphatidylinositol-anchored protein enriched early endosomal compartments 
(GEEC), en route to the early endosome.  
Many viruses are known to use multiple endocytic pathways to enter cells. For 
example, AAV2 enters cells via one or more of the following pathways: 
CLIC/GEEC endocytosis, clathrin-mediated endocytosis  or caveolar 
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endocytosis.55 Members of the same family may use different pathways. Moreover, 
viruses may have adapted to in vitro cells and may use other pathways in vivo. In 
some cases, sequential binding of viruses to the cell surface triggers different 
signalling pathways within the cell, recruiting components normally observed to 
drive different endocytosis pathways. It is therefore difficult to determine whether 
they use multiple entry pathways or different components of one complex 
pathway. Similarly, the endocytic pathway of previously reported non-viral vectors 
greatly varies with the cell types and molecular component of the cell surface in 
addition to their intrinsic characteristics (e.g., charge and size, etc.), generating 
conflicting data regarding the internalisation mechanism used.124-126  
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Figure 1.10: Pathways of endocytosis.  Internalisation of large particles is facilitated by 
phagocytosis (a), whereas fluid uptake occurs through pinocytosis (b). Different cargos can be 
also internalised through several pathways, including caveolar-mediated endocytosis (c), clathrin-
mediated endocytosis (d) and clathrin-independent and caveolin-independent endocytosis 
(e)(Modified from Petros, R.A. and DeSimone, J.M.2010)127 
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Endosomal escape 
Regardless of cell entry pathways, virtually all particles will be localized within 
endocytic vesicles and fuse or at least interact with the early endosomes which is 
eventually trafficked to a late endosome. Transition from early to late endosome is 
marked by the rapid decrease in pH (pH 5-6) due to the action of the ATPase 
proton-pump enzyme located on endosomal membranes. Subsequent trafficking to 
lysosomal compartments leads to further acidification (pH 4) and the activation of 
various hydrolytic enzymes, which represent a hostile environment known to 
facilitate vector degradation.  
Various strategies are employed by different viruses to gain access to the cytosol. 
Endosomal escape of non-enveloped viruses requires a mechanism of membrane 
disruption via carper-like mechanism (for example, in adenovirus) or 
transmembrane pore formation via a barrel-stave mechanism (for example, 
parvovirus), whereas enveloped viruses use membrane fusion between the viral 
envelope and endosomal membrane.128 (Figure 1.11) This fusion is mediated by 
fusion proteins which undergo conformational changes in the acidic environment 
of endosome, and subsequently interact with the membrane bilayer, enabling 
cytosolic translocation of the viral genome.129  
In contrast to viral vectors, which have highly evolved endosomal escape 
mechanisms130, the endosomal entrapment and subsequent lysosomal degradation 
are still regarded as a major limitation for non-viral vectors. Design of gene 
delivery vectors with capability of endosomal escape is therefore critical for high 
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transfection efficiency. Integrating the viral mechanism into non-viral gene delivery 
system are main strategies being employed to facilitate endosomal escape. 
Influenza viruses escape the endosome with help from a short chain of N-terminal 
amphiphilic anionic peptide residues (termed hemaglutinin A2 HA2) (Figure 
1.11b).130 Modification of non-viral vectors with HA2 peptide facilitating 
endosomal escape resulted in significant augmentation of the delivery efficiency.69  
Synthetic peptides mimicking virus’s fusogenic peptides have also been designed 
for gene delivery system, leading to the enhanced transfection efficiency of non-
viral vectors. For example, the synthetic GALA peptide with a repeated amino acid 
sequence (i.e., glutamic-alanine-leucine-alanine) was designed to interact with lipid 
bilayers following a conformational change to give a helical structure at low pH.131 
Similarly, INF7 and H5WYG improved endosomal escape of non-viral vectors.132  
The endosomal escape of some non-viral vectors is dependent on the complexing 
material used. In case of polyplexes, cationic polymers provide high transfection 
efficiency due to their intrinsic endosomolytic activity. Escape of polyplexes into 
the cytosol is mediated by the proton sponge mechanism (Figure 1.12), which has 
been observed in certain cationic polymers with a high buffer capacity over a wide 
pH range. These polymers, which usually contain protonable secondary and/or 
tertiary amine groups with pKa close to endosomal pH, behaves as a sponge that 
absorbs protons, after which an influx of counter chloride ion against the proton 
accumulation leads to increased osmotic pressure, followed by flow of water and 
subsequent endosome swelling and rupture. However, recent studies suggested an 
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alternative mechanism where endosomal escape relies on time-dependent 
protonation-induced membrane permeabilization by tight binding of polyplex and 
the lumen side of the endosomal membranes. 
For cationic lipid-based delivery systems, the lipid mixing mechanism was 
proposed to be their endosomal escape mechanism (Figure 1.13). Following the 
electrostatic interaction between carrier lipids and the endosomal membranes, 
negatively charged lipids (mainly found in the cytoplasmic-facing leaflet) of the 
endosomal membrane laterally diffuse into cationic lipoplexes.  This leads to the 
formation of charge-neutral ion pairs with the lipoplex, thereby destabilizing the 
endosomal membrane organization and causing release of nucleic acids into the 
cytosol. The other proposed lipid mixing mechanism involves lipoplex 
degradation, followed by dissociation of lipid molecules that allows the passive 
release of nucleic acids. Subsequently, integration of free lipids results in transient 
pore formation and cytoplasmic transport of nucleic acids. 
P a g e  | 54 
 
 
Figure 1.11: Endosomal escape mechanism of non-enveloped and enveloped viruses. a) 
Two proposed mechanisms for endosomal escape of non-enveloped viruses; carpet-like or a 
barrel-stave mechanism. In the carpet mechanism, the peptides interact with the lipid head group 
and do not insert into the hydrophobic region of the membrane. With a barrel-stave mechanism, 
the peptides insert into the hydrophobic core of the membrane, resulting in the formation of 
transmembrane pores. b) Influenza virus, which is endocytosed into an endosome, is shown as 
an example. In the acidic endosomes, HA mediates the fusion of the viral and endosomal 
membranes. (Modified from Dimitrov, D.S. 2004 and Hurdle, J.G. et al. 2011)128,133 
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Figure 1.12: Schematic representation of classical and proposed proton sponge 
mechanisms. a) Classical mechanism b) proposed mechanism. 
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Figure 1.13: Schematic representation of classical and proposed lipid mixing 
mechanisms. a) Classical mechanism b) proposed mechanism. 
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Nuclear import 
The cell’s genetic material is separated from the surrounding cytoplasm by the 
nuclear envelope, which functions as a physical barrier for nuclear import of 
macromolecules. The nuclear pore complex (NPCs) that fuses the inner and outer 
membranes to form aqueous translocation channels tightly regulates 
nucleocytoplasmic trafficking and limits passive diffusion of molecules with sizes 
>30 kDa.134  The process is energy dependent and requires the nuclear localization 
signal (NLS) to allow nuclear translocation of macromolecules. Many NLS 
peptides have been used to increase nuclear import of DNA, showing 
improvements in gene expression. The well-characterized NLS in the field of gene 
delivery include a classical NLS peptide (PKKKRKV) derived from the large 
tumour antigen of the simian virus 40 (SV40)135 and the M9 sequence of the 
heterogeneous nuclear ribonucleoprotein (hnRNP) A1.136 
1.2.6. Gene therapy 
Gene therapy is considered to be the treatment of gene-associated diseases by 
transferring exogenous nucleic acids into the appropriate cells of patients.137 
Advances in molecular biology and biotechnology as well as the completion of 
Human Genome Project have led to the identification and characterization of 
numerous genes associated with diseases.27 A mutation in any gene can result in a 
disease, physical disability, or shortened life span. Therefore, the direct use of 
nucleic acid as a therapeutic agent to treat or prevent genetically-related diseases 
(so-called gene therapy) has attracted great interest over the past few decades. 
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Gene therapy holds the promise of cures for genetic defects such as cystic fibrosis, 
haemophilia, muscular dystrophy and sickle cell anaemia, complex acquired 
diseases such as cancers, cardiovascular diseases, sensory deficits such as blindness 
and hearing loss, infectious diseases such as anti-HIV gene therapy and DNA 
vaccine. 
On the website of the Journal of Gene Medicine, the number of gene therapy 
clinical trials having commenced worldwide for the past 20 years are shown (for 
updated information see http://www.wiley.co.uk/genmed/clinical/). In 2013, the 
total number of protocols reached 1,972 and the numbers per year have been 
stable. In the analysis of indication (Figure 1.14a), most of the trials have been 
developed against cancer, followed by monogenic diseases (those caused by 
inherited single gene defects). In the analysis of clinical phases (Figure 1.14b), 78.5 
% of clinical trials are Phase I or I/II, suggesting that a vast majority of the trials 
are early stage. However, 4.7 % of clinical trials are now at the late stages of clinical 
trial phase II/III or III and 0.1 % of all clinical trials have succeed in entering 
phase IV, which has been marketed and designed to assess any adverse effects 
associated with widespread use. These data suggest that clinical gene therapy is 
becoming more mature year by year. In the analysis of gene types (Figure 1.14c), 
the top gene type used is ‘antigen’, indicating that the DNA vaccine has recently 
been often investigated in clinical trials because vaccination is now a common 
therapy for infectious diseases and cancer. 
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Figure 1.14: Clinical gene therapy worldwide. a) Indications addressed by gene therapy 
clinical trials. b) Phases of gene therapy clinical trials. c) Gene types transferred in gene therapy 
clinical trials. 
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1.2.7. Strategies for Gene therapy of cancer 
Cancer development requires multiple altered genetic events, some of which 
include mutations of the tumour suppressor genes resulting in the loss of cell 
growth and apoptosis regulation.18 The restoration of the functional tumour 
suppressor gene through gene therapy is therefore a possible treatment. For 
example, a cell cycle regulatory protein p53 is frequently mutated in human 
cancers. The successful replacement of p53 gene in ovary cancer patients has 
caused upregulation of this gene and other enzymes downstream from p53.  Other 
well-characterized tumour-suppressor genes that have been used for cancer 
treatment include p16, p27, and PTEN.138-141 Another common cancer genetic 
event involves a mutation that causes the upregulation of oncogenes, which 
enables uncontrolled cell proliferation and survival, promotes angiogenesis, 
invasion and metastasis. One such oncogene frequenty mutated in cancers, K-Ras, 
has been targeted for suppression of tumour growth using siRNA.142 RNA 
interference can also be used to target other oncogenes such as the anti-apoptosis 
gene livin and cyclin-E.143 Another potential cancer gene therapy application is 
prodrug activation (Figure 1.15a). This strategy involves the expression of an 
exogenous enzyme within cancer cells that can convert a systemically administered 
non-toxic prodrug into a potent anti-cancer drug. An example of a commonly used 
enzyme-prodrug pair is the herpes simplex virus thymidine kinase (HSVtk) and 
phosphorylated ganciclovir (GCV). If GCV is delivered to a HSVtk-expressing cell, 
the thymidine kinase will phosphorylate the GCV converting it to a DNA synthesis 
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inhibitor.144 Some other enzyme-prodrug combinations that have been investigated 
for therapeutic efficacy include the DNA synthesis inhibitors cytosine deaminase 
and 5-fluorouracil, the DNA cross-linking reagents nitroreductase and CB1954, 
and hepatic cytochrome P450 and cyclophosphamide.144,145 Alternatively, the 
delivery of cytokine genes, such as Granulocyte-macrophage colony-stimulating 
factor (GM-CSF), interleukins or interferons, to activate or attract immune cells 
against the tumour, also hold potential for tumour therapy (Figure 1.15b).146-148 
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Figure 1.15: Major approaches employed for gene therapy of cancer. a) Delivery of a 
suicide gene to convert the prodrug into toxic compound capable of killing tumour cells. b) 
Delivery of cytokine or tumour antigen genes to activate or attract immune cells against the 
tumour. 
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1.2.8. Ligand-directed vector for targeted gene therapy of cancer 
The ability to target the delivery of nucleic acids or any therapeutic agents can 
minimize side effects, maximize treatment to the target site and allow for more 
flexibility in dosing limits.  Integrating high affinity, high specificity peptide ligands 
into gene delivery vectors that target tumours and avoid healthy tissues has the 
potential to make gene therapy a reality for cancer.149 Targeting peptides for a 
specific receptor can be obtained using knowledge of the naturally existing ligand’s 
binding site, sequence, and secondary structure to create a biomimic peptide, or by 
the screening of phage display peptide libraries. The latter technique has enabled 
the rapid selection of a bacteriophage expressing the appropriate peptide sequences 
as fusions to the coat proteins with a high affinity for any substrate of interest. To 
date, the screening of phage display peptide libraries is one of extensively used 
high-throughput technologies for the identification of tumour-specific markers. In 
most cases, the method involves in vitro selection by immobilizing the target 
molecules such as proteins or other macromolecules onto plastic or direct 
biopanning on cultured cells.150 On the other hand, in vivo phage selection involves 
the intravenous administration of the phage library into an animal and isolating 
phages that home preferentially to the target tissue or organs due to their binding 
to tissue-specific receptors (Figure 1.16). 
Anti-angiogenic gene therapy has emerged as a new modality to treat human 
cancers and has received much widespread attention.151 Endothelial cells associated 
with the tumour vasculature are particular suitable for anti-angiogenic therapy 
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because they are easily accessible to intravenously delivered agents and are less 
likely to accumulate mutations that render them resistant to therapy due to their 
more stable genetics than cancer cells.152  
Enzyme/prodrug-based gene therapy has been frequently used to target the 
tumour vasculature in order to deconstruct the tumour mass. Generally, solid 
tumours cannot grow beyond a few millimetres in a diameter without the support 
of blood vessels to provide essential elements as well as to facilitate the removal of 
metabolic wastes.153,154 Unique epitopes expressed on the tumour-associated 
endothelial cells, which allow the tumour vasculature to be distinguished from the 
normal vasculature, could serve as targets for tumour-specific binding of targeting 
agents.155 In contrast to most cancer-associated epitopes expressed on malignant 
cells inside the tumour compartment, these epitopes are readily accessible to the 
lumen of blood vessels, which mediate efficient targeting of therapeutic agents. 
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Figure 1.16: The workflow of in vivo phage display screening. The process starts with 
intravenous injection of the phage library, after which the target organ is isolated and 
homoginized. The homogenate is used for phage amplification for subsequent rounds of 
selection. The DNA encoding the expressed peptide is then sequenced. 
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1.2.9. Gene delivery with peptides targeting integrins 
One approach to targeted gene delivery for cancer treatment takes advantage of 
elevated levels of receptor expression in tumours. For example, the αvβ3 and αvβ5 
integrins which serve as receptors for RGD-containing protein have been found to 
be overexpressed on most tumour cells as well as tumour-associated endothelial 
cells during the formation of new capillary blood vessels (angiogenesis) (Figure 
1.17).156 The RGD motif is found in extracellular matrix components including 
fibronectin, vitronectin, laminin, and collagen. The motif is also found in the 
penton base of adenovirus capsid which is known to bind the αvβ3 integrin.
157  In 
this context, targeting the tumour vasculature or tumour cells by RGD-based 
strategies is a promising approach for delivering therapeutic agents for cancer 
treatment. It has been shown that the integrin αvβ3 is overexpressed not only on 
the tumour-associated endothelium but also on cancer cells.158,159  On the contrary, 
other largely described ligands such as folate or transferrin receptors are only 
expressed on cancer cells. The targeting mechanism of RGD-grafted therapeutic 
agents is schematically shown in Figure 1.18.  Moreover, αvβ3 integrins are known 
to be absent or barely detectable in non-angiogenesis endothelial cells, whereas 
transferrin is upregulated on cancer cells as well as on brain capillaries, endocrine 
pancreas, or hepatic kupffer cells.160 In addition, some ligands, such as folate which 
is supplied by food, show naturally high concentrations in the human body, 
resulting in the competition for binding of the drug-conjugated ligand to the target 
receptor, and therefore reducing the effective intracellular accumulation of the 
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delivered drug.161 The RGD4C peptide (ACDCRGDCFC), in which the RGD 
sequence is flanked by cysteines on either end and can therefore form two 
disulphide bonds, was originally identified via phage display of a random peptide 
library.162 In order to suppress tumour angiogenesis and growth, a great effort has 
been made to use RGD peptides as antagonists for several integrins, such as αvβ3 
and αvβ5.  Unfortunately, a cyclic RGD pentapeptide (cilengitide) did not meet its 
primary endpoint of significantly increasing overall survival when combined with 
the current conventional chemoradiotherapy regimen, ie temozolomide and 
radiotherapy in a Phase III clinical trial, indicating how challenging glioblastoma 
remains. However, the αvβ3 and αvβ5 integrins are still the ideal target for specific 
delivery of cancer therapeutics. In addition to their direct use as therapeutic targets, 
integrin-targeted nanoparticles with a broad spectrum of anti-cancer payloads also 
represent a particularly promising area for cancer treatment.158 The RGD peptides 
have been extensively used to functionalize a broad range number of nanoparticles, 
such as, polymers, gold nanoparticles, magnetic nanoparticles for molecular 
imaging and many other vectors such as liposomes for their efficient accumulation 
in tumour sites.149 These RGD-targeted nanoparticles have recently proven 
advantageous in delivering biopharmaceutical drugs (i.e., peptides, proteins, nucleic 
acids) and chemotherapeutic drugs. Several advantages are attributable to these 
RGD-targeted nanoparticles: (i) they may specifically address therapeutic agents to 
angiogenic endothelial cells and/or cancer cells by interaction between the RGD 
motif and αvβ3 overexpressed on these cells, allowing active targeting of the 
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tumours;163 (ii) RGD-targeted nanoparticles can be endocytosed via receptor-
mediated mechanism, which cannot be found with single peptide constructs or 
with nontargeted nanoparticles; this is particularly interesting for the intracellular 
delivery of therapeutic agents to cancer cells.164  (iii) the size of these nanoparticles 
(20-400 nm) leads to the passive targeting of tumour via the so-called enhanced 
permeability and retention (EPR) effect;165 (iv) the avoidance of renal filtration due 
to the size of these systems leads to  prolonged circulation times and longer ligand 
exposure to receptors within the target tissues.166 
 
 
Figure 1.17: Integrins in tumour cells and tumour-associated cells. a) Integrins, 
heterodimeric cell surface receptors, are formed by the combination of ɑ- and β-subunits. 
Certain integrins directly bind to the ECM components and regulate cell motility and invasion. 
In tumour cells, integrin signalling regulates a number of cellular functions including survival, 
proliferation, migration and invasion. b) In addition to tumour cells, integrins are also expressed 
on tumour-associated cells, such as the vascular endothelium and fibroblasts.  In endothelial 
cells, integrins are responsible for the migration, proliferation and survival necessary for the new 
formation of blood vessels (angiogenesis). The tumour-associated fibroblasts produce large 
amounts of collagen that may contribute to resistance to therapy in some tumours.(Modified 
from Danhier, F. et al. 2012)149 
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Figure 1.18: Schematic representation of targeting mechanisms of RGD-grafted vectors. 
Circulating RGD vectors can bind to integrins overexpressed on tumour-associated endothelial 
cells, followed by internalisation via receptor-mediated endocytosis. The release of therapeutic 
agents then leads to cancer cell killing. The tumour destruction is resulted from the 
antiangiogenic effect in which the death of tumour is induced by the lack of oxygen and 
nutrients. RGD vectors also enter the tumour via the EPR effect. The EPR effect combined 
with the active targeting of cancer cells leads to the anticancer effect of therapeutic agent-loaded 
RGD vector.  
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1.2.10. Bacteriophage vectors 
Bacteriophages, also abbreviated as phages, are the most abundant biological 
entities in the biosphere and exist in various environments as part of a microbial 
ecosystem.167 They can be found even in the human or animal bodies.139 These 
particles consist of a protein coat containing a DNA or RNA genome.  The 
routinely used and well characterized phages as gene delivery vectors are the 
filamentous M13 and lambda. However, filamentous bacteriophages have been 
used as gene delivery vectors in this study. Accordingly, this thesis will focus on 
filamentous phages despite fundamental difference from lambda phages and its 
relatives such as T4 and tailed. 
The virion of filamentous phages has a cylindrical shape with a length of 800 nm 
and a diameter of 6 nm and is composed of a circular single stranded DNA  
genome encapsulated by a tube made of five coat proteins, namely pIII, pVI, pVII, 
pVIII, and pIX. At one end, there are five copies of pIX and pVII and 5 copies of 
pVI and pIII at the other end (Figure 1.19). The body of the phage is composed 
of thousands of helically arrayed major coat protein pVIII subunits and represents 
98% of the phage mass. The M13 filamentous bacteriophage virus of the Ff family 
infects E. coli which is a vital component of the intestinal flora and uses host cells 
to assemble progeny phage without lysing and killing the host; instead, they are 
secreted into the environment. The life cycle of filamentous bacteriophages is 
shown in Figure1.20. 
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Peptides and proteins of interest can be fused to the phage coat protein and 
thereby displayed on the outer surface of the phage particles. This review will 
cover the display of foreign proteins on the most commonly used pIII and pVIII. 
Modes of displaying peptides can be classified into three systems. The first is based 
on the original filamentous phage genome. The sequence encoding the foreign 
peptide is inserted between the coding sequences for the signal peptide and the 
mature coat protein, without disturbing the protein reading frame. Peptides can be 
fused to all five copies of the pIII (type 3 display) or to all copies of pVIII (type 8 
display). Second, a hybrid system, in which the phage genome contains a 
recombinant gene in addition to a wild type gene, can be employed.168 In this 
system peptides or proteins can be displayed on one copy of pIII or on 
approximately 150 copies of pVIII, while the remaining pIII and pVIII subunits 
are wild type (type 33 or 88 display). The first two systems are shown in Figure 
1.21. The third system is the use of plasmid vectors (also known as phagemids), in 
which the wild-type and recombinant genes are carried on separate genomes 
present in the same cell.169,170   This system has been extensively used to display 
antibody and antibody fragment (i.e., Fv, scFv or Fab).169 The use of the phagemid 
system to display guest peptides will not be covered here. 
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Figure 1.19: Schematic representation of the structure and genome organization of 
filamentous bacteriophage. a) The localisation of filamentous bacteriophage coat proteins. b) 
Genetic map of the Ff phage. The gene products are grouped based on their known functions. 
 
 
Figure 1.20: Life cycle of filamentous bacteriophage. Following the binding of phage to the 
F-pilus of bacteria via pIII, the introduced ssDNA is converted to dsDNA. Gene expression is 
then initiated after which the assembly and release of the phage particles occurs at the bacterial 
membrane. 
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Figure 1.21: Modes of displaying foreign peptides fused to pIII or pVIII coat proteins. 
Recombinant genes carrying sequences encoding the guest peptides and their corresponding 
recombinant proteins displaying the guest peptide are coloured red and purple for pIII and pVI, 
respectively. 
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1.2.11. Hybrid AAVP 
Despite several advantages, the efficiency of transgene delivery by phage-based 
vectors has been considered poor compared to that of animal viral vectors because 
bacteriophage species have evolved to infect bacteria exclusively and have no 
optimised mechanisms for gene transfer to eukaryotic cells. Previously, our group 
has developed a hybrid vector that combined the advantageous features of 
bacteriophage with those of the AAV vectors.171 This was achieved by flanking a 
transgene cassette in the phage genome by ITR sequences from AAV2, resulting in 
a prokaryotic-eukaryotic hybrid vector termed AAVP.22 This is depicted 
schematically in Figure 1.22. In this vector, the phage particle serves as a vehicle 
displaying targeting peptides genetically incorporated into the capsid. The AAV 
vector has the potential for replication and integration of transgenes flanked by 
ITRs. Previous studies from our group have confirmed that the presence of AAV 
ITR in phage genome can mediate the concatamerization of AAV circular 
genomes and thereby confers sustained transgene expression in mammalian cells. 
In the reported studies, the efficiency of a hybrid vector was assessed by using the 
well-established double cyclic RGD4C motif genetically displayed on the pIII 
minor coat protein to facilitate active targeting of cancer cells as well as the 
associated endothelium via specific interaction between the RGD4C motif and the 
overexpressed αvβ3 integrin. As a proof of concept, transgene delivery and 
specificity of the so-called targeted RGD4C.AAVP vectors was confirmed using 
several animal models of cancer as well as in pet dogs with natural cancers.171-174 
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This hybrid vector showed superior gene delivery compared to the parental phage 
vectors with long-term transgene expression in vivo.  
To assess therapeutic efficacy of tumour-targeted RGD4C.AAVP vector, a number 
of preclinical experimentations have been performed on models of cancer in 
immunocompromised mice carrying xenograft tumours by using vector carrying a 
widely used suicide gene HSVtk and subsequent GCV treatment. Tumour growth 
in immunodeficient mice bearing human Karposi’s sarcoma (KS1767) as well as in 
immunocompetent BALB/c mice bearing subcutaneous EF43-FGF4 mammary 
tumours was remarkably suppressed by a single intravenous administration of the 
RGD4C.AAVP.171 Similarly, the inhibition of tumour growth was observed in 
nude mice bearing UC3-derived bladder carcinomas and DU145-derived prostate 
carcinomas.171 RGD4C.AAVP-HSVtk vector was also assessed in a model of 
human soft-tissue sarcoma in athymic rats (large rodents) and resulted in tumour 
growth suppression.172 
An additional experiment was carried out by researchers at the National Cancer 
Institute (NCI) to assess the cancer-targeting properties of RGD4C.AAVP in mice 
bearing melanoma xenograft. In this study, systemic administration of the vector 
carrying the gene encoding the antitumour agent tumour necrosis factor-α (TNF-α)  
resulted in significant reductions in the tumour volumes without any evidence of 
systemic toxicity to normal organs. Another investigation carried out under the 
direction of the NCI have proven that targeted RGD4C.AAVP-TNF-α provided 
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safe and effective treatment in domestic dogs, resulting in a reduction of tumour 
volumes with no notable cytotoxicity. 
 
Figure 1.22: Schematic representation of the AAVP hybrid vector. The vector displays the 
αv integrin-targeting RGD4C ligand on the pIII minor coat protein and a rAAV transgene 
cassette inserted in the phage genome. The AAVP vector can be easily produced and purified 
from the E.coli host cells. 
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1.3. Hypothesis 
 
Hypothesis 1: Chemical modification of the bacteriophage capsid could be 
applied to improve the capability of AAVP vectors to attach to cells and escape 
from endosomes, which are barriers for the effective gene delivery by 
bacteriophage. 
 
Hypothesis 2: Bacteriophage could be used as a multifunctional platform that 
integrates multiple ligands and peptides to escape a series of significant barriers in 
order to mediate the delivery of therapeutic/imaging genes into target cells. 
 
Hypothesis 3: The effectiveness of AAVP vectors is hindered by ECM through 
blocking diffusion and/or physical masking of target receptors on malignant cells 
and therefore ECM depletion could improve the transduction efficiency, with 
respect of two specific ECM molecules (i.e. collagen and hyaluronic acid). 
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1.4. Aims of thesis 
The main overall goal of this thesis is to investigate the application of modified 
bacteriophage as potential vectors for gene delivery to mammalian cells. 
Specific aims 
To achieve this goal, three specific aims were defined: 
Aim 1: This aim screened the effect of genetic modification and/or different 
chemical treatment of bacteriophage capsid, in AAVP-mediated gene transfer to 
mammalian cells. This aim also examined the role of chemical modification in 
AAVP attachment, internalisation, and intracellular trafficking in mediating 
efficient gene transfer. 
 
Aim 2: This aim designed and constructed a novel multifunctional bacteriophage 
through a series of genetic modifications of the capsid and evaluates these for 
improved gene delivery in vitro. 
 
Aim 3. This aim determined the role of ECM in bacteriophage-mediated gene 
delivery to tumour cells and evaluated the potential use of ECM modulation as a 
strategy to enhance phage-mediated gene delivery in tumours. 
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2. Materials and Methods 
2.1. Materials 
2.1.1. Chemical reagents 
Name Source 
DEAE-Dextran hydrochloride (DEAE.DEX, MW 500,000) Sigma 
Poly-D-lysine hydrobromide (PDL, MW 30,000-70,000) Sigma 
Polyethylenimine, Linear (PEI, MW 25,000) Polysciences 
Hexadimethrine bromide (polybrene; PB) Sigma 
Protamine sulfate salt from salmon (PS) Sigma 
Dioleoyltrimethylammonium-propane (DOTAP) Sigma 
FugeneTM Promega 
Lipofectamine®  Invitrogen 
Bafilomycin A1 from Streptomyces griseus Sigma 
Collagenase from Clostridium histolyticum Sigma 
Hyaluronidase from bovine testes Sigma 
ECM Gel from Engelbreth-Holm-Swarm murine sarcoma Sigma 
Table 2.1: Chemical reagents used during the investigation 
 
2.1.2. Kits 
Name Source 
ProFection® Mammalian Transfection System (Calcium phosphate) Promega 
Phusion Site-Directed Mutagenesis Kit ThermoScientific 
Sirius Red Total Collagen Detection Kit  Chondrex 
Steady-Glo® Luciferase Assay System  Promega 
CellTiter-Glo® Luminescent Cell Viability Assay Promega 
QIAprep Spin Miniprep Kit  Qiagen 
HiSpeed Plasmid Midi Kit  Qiagen 
QIAquick Gel Extraction Kit  Qiagen 
Table 2.2: Kits used during the investigation 
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2.1.3. Antibodies 
Primary Antibodies 
Name Conjugation Species raised Application Source 
Anti-fd phage - Rabbit IFM, FC, EM Sigma 
Anti-ɑV integrin - Rabbit IFM Sigma 
Secondary Antibodies 
Name Conjugation Species raised Application Source 
Anti-rabbit AlexaFluor-488 Goat IFM Invitrogen 
Anti-rabbit AlexaFluor-594 Goat IFM Invitrogen 
Anti-rabbit AlexaFluor-647 Goat IFM, FC Invitrogen 
Table 2.3: Antibodies used during the investigation 
IFM = Immunofluorescence Microscopy, FC=Flow cytometry, EM=Electron Microscopy 
 
2.1.4. Cell lines 
Name Tissue Origin Source 
HEK293 Human Embryonic Kidney American Type Culture Collection (ATCC) 
MCF-7 Human Breast adenocarcinoma Michigan Cancer Foundation 
M21 Human Melanoma Dr David Cheresh  
(University of California, La Jolla) 
9L Rat Glioma Dr Hrvoje Miletic  
(University of Bergen, Norway) 
C6 Rat Glioma  
LN229 Human Glioblastoma Dr Nelofer Syed (Imperial College London) 
SNB19 Human Glioblastoma Dr Nelofer Syed (Imperial College London) 
C2C12 Mouse Myoblast Dr Francesco Muntoni  
(University College London, UK) 
Table 2.4: Cell lines used during the investigation 
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2.1.5. Oligonucleotides 
Oligonucleotides (oligos) for peptide display on the recombinant pVIII coat protein. 
Primers Sequence 
Sense oligo 
Antisense oligo 
5’-AGCTTTGCCAACGTCXXXXXXXXXXXXXXXXXXXCCTGCA-3’ 
5’-GGXXXXXXXXXXXXXXXXXXXXXXXXXGACGTTGGCAA-3’ 
Table 2.5: Oligonucleotides used during the investigation. The sense and anti-sense oligos 
are 5’phosphorylated and the nucleotides X correspond to the sequence encoding for the peptide 
ligand of interest.  
 
 
Oligonucleotides (oligos) of peptides display on the wild type pVIII coat protein 
Primers Sequence 
Forward 
Reverse 
5’XXXXXXXXXGATCCCGCAAAAGCGGCCTTTG-3’ 
5’-AGCAGCGAAAGACAGCATCG-3’ 
Table 2.6: Primer sequences used in site-directed mutagenesis. Both primers are 
5’phosphorylated to avoid a spontaneous recircularization of the vector. Nucleotides in red (X) 
correspond to the peptide of interest.  
 
2.2. Methods 
2.2.1. AAVP preparation 
AAVP production (see figure 2.1 for procedure summarization) 
A loopfull of K91 from fresh Luria-Bertani (LB) plate containing 50 µg/ml 
kanamycin was used to inoculate 5 ml of LB broth without antibiotic, which was 
then grown at 37°C with shaking at 250 rpm until optical density reaches mid-log 
phase (A600 is between 1.6 – 2.0). An aliquot of 1 ml starter culture was incubated 
with AAVPs for 1 hour at room temperature after which the mixture was used to 
inoculate 450 ml LB broth containing 1mM Isopropyl-beta-D-
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thiogalactopyranoside (IPTG), 50 µg/ml kanamycin and 40 µg/ml tetracycline. 
This culture was then grown overnight at 37°C with continuous shaking. 
 
Figure 2.1: Production of AAVP viral particles 
 
Figure 2.2: Purification of AAVP viral particles 
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AAVP purification (see figure 2.2 for procedure summarization) 
The overnight cultures were centrifuged at 6,000g for 30 minutes at 4°C. The pellet 
of bacteria was discarded and the supernatant was collected and centrifuged again 
to remove the residual bacterial debris. Cold Polyethylene-glycol/Sodium chloride 
(PEG/NaCl) was added to the supernatant (15% of supernatant volume) and 
incubated on ice to precipitate the AAVP particles. Following 2-3 hours incubation 
on ice, the mixture was centrifuged for 30 minutes at 10,000g and the supernatant 
was then discarded. The pellet was re-suspended in 10 ml Phosphate buffer saline 
(PBS) by shaking for 30 minutes in a 37°C shaker incubator 250 rpm. After the 
pellet was dissolved, PEG/NaCl (15% of solution) was added to the resulting 
solution and incubated on ice. After 1 hour incubation, the mixture was 
centrifuged at 14,000g for 30 minutes at 4°C and aspirated off the supernatant. 
The pellet was re-suspended in 1 ml PBS by shaking for 30 minutes in 37°C shaker 
incubator 250 rpm. To remove most of the remaining bacterial debris, the AAVP 
solution was centrifuged at 13,000g for 10 minutes at room temperature and the 
supernatant containing AAVP particles was then filtered through a 0.45 µm-filter 
prior to titration of the resulting phage solution. AAVP stock solution was diluted 
in PBS to a final concentration of 5mg/ml as measured by a spectrophotometry 
method, which corresponds to 6 x1010 AAVP particles/μl. 
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2.2.2. Chemical modification of AAVP vectors 
The AAVP particles were mixed with chemical reagents at various ratios. Solutions 
were incubated for 15 minutes before cell transduction to allow the formation of 
complexes or precipitates. 
CaPi 
CaPi  is an inorganic based reagent. For optimisation studies, 0-0.5M CaCl2 was 
added to 25 μg of AAVP prepared in double distilled H2O. An equal volume of 2X 
Hepes-buffered saline solution (HBS) was then added to the AAVP/CaCl2 
solution to allow the formation of precipitates. 
Cationic polymers 
For optimisation studies, 25 μg of AAVP was complexed with 0-110 μl of either 
100 μg/ml DEAE.DEX or 100 μg/ml polybrene reagents, [reagents/AAVP ratio 
0-440 ng/1μg] in complete Dulbecco's Modified Eagle's medium (D-MEM). For 
PDL and PEI, 25 μg of AAVP was complexed with 0-90 μl of either 100 μg/ml 
PDL or 100 μg/ml PEI reagents, [reagents/AAVP ratio 0-360 ng/1μg] in 
complete D-MEM. 
Cationic peptide 
Protamine sulphate (PS) is a peptide based reagent. For optimisation studies, 25μg 
of AAVP was complexed with 0-90μl of 100μg/ml PS [reagent/AAVP ratio 0-
360ng/1] in complete D-MEM. 
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Cationic lipids  
For optimisation studies, 25 μg of AAVP was mixed with 0-25 μl of Fugene or 
Lipofectamine, [reagents/AAVP ratio 0.0-1.0μl/1μg] in complete D-MEM. For 
DOTAP, 25 μg of AAVP was complexed with 0-110 μl of DOTAP reagents, 
[reagents/AAVP ratio 0-4,200 ng/1μg] in complete D-MEM. 
2.2.3. Size and charge measurement 
Cationic polymers at a desired concentration were added to AAVP vector 
preparations, mixed gently and incubated for 15 minutes at room temperature to 
allow complex formation. ζ-potential charge measurements were conducted using 
ZetaPALS (Brookhaven Instruments Corporation, NY, USA) based on 
electrophoresis in 1 mM potassium chloride (KCl) electrolyte solution. The pH 
dependency of ζ-potential was measured by changing the pH of the electrolyte 
solution through the titration of 0.1N hydrochloric acid (HCl) or sodium 
hydroxide (NaOH). 
2.2.4. In vitro depletion assay 
HEK293 cells were seeded at a density of 5 x 104 cells/well in 48-well plates and 
allowed to grow until 70-80% confluent followed by treatment with AAVP 
prepared to optimal ratios. The plates were placed on ice for 1hr to prevent AAVP 
internalisation. Supernatants were extracted and serially diluted in 1X PBS. The 
number of AAVP particles was quantified using the K91 Kan bacterial infection 
method and counting transducing units, as previously reported.168 
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2.2.5. Internalisation assay 
After 2 hour treatment with AAVP vectors at 37°C, cells were placed on ice to 
stop endocytosis and washed by PBS 3 times to remove unbound AAVPs. Surface 
bound AAVPs were removed by trypsinization after which cells were pelleted by 
centrifugation at 2000 rpm for 5 minutes and fixed in 4% paraformaldehyde (PFA) 
for 10 minutes at room temperature.  Untreated cells were used as a negative 
control. To detect internalised AAVP, cells were blocked with 0.1% saponin in 2% 
bovine serum albumin in PBS (BSA-PBS) for 30 minutes followed by staining with 
rabbit anti-fd-phage antibody (diluted 1:1000) in 0.1% saponin in 1% BSA-PBS for 
1hr at room temperature. Cells were pelleted and re-suspended three times in 0.1% 
saponin in 1% BSA-PBS and then incubated with goat anti-rabbit AlexaFluor-647 
(diluted 1:500) in darkness for 1hr at room temperature. Finally, cells were washed 
twice with 0.1% saponin-PBS and re-suspended in PBS before analysis. 
Fluorescence-activated cell sorting (FACS) analysis was carried out using a BD 
FACscalibur Flow cytometer (BD Biosciences) equipped with an argon-ion laser 
(488nm) and red-diode laser (635nm. The mean fluorescence intensity was 
measured for at least 10,000 gated cells per triplicate well. Results were analysed 
using Flojo (TreeStar) software. 
2.2.6. Endosome buffering capacity measurements 
The acid-base titration method was used to determine the endosome buffering 
capacities of the AAVP-PEI prepared to their optimised ratios in sterile water to a 
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total of 20ml and the pH adjusted to pH10 by NaOH. Subsequent additions of 
HCl were used to titrate the solution to pH3 while changes in pH were recorded 
using a pH meter. Titrations of sodium chloride solution (NaCl), polymer solution 
and AAVP solutions were used as controls. The natural endosome pH range 7.4- 
5.1, was used to calculate the endosome buffering capacity of the AAVP/polymer 
complexes. 
2.2.7. Immunofluorescence staining 
Cells were seeded on 18 mm2 coverslips in 12-well plates and allowed to proliferate 
until 70-80% confluent. Cells were incubated with AAVP vectors for 4 hours, 
washed with PBS, and fixed in 4% PFA in PBS for 10 mins at room temperature. 
Cells were treated with 50 mm Ammonium Chloride (NH4Cl) to quench free 
aldehyde groups from fixation followed by permeabilisation with 0.2% triton X-
100. Cells were washed and blocked with PBS containing 2% BSA for 30 mins.  
Cells were then incubated for 1hr at room temperature with rabbit anti-fd 
bacteriophage (diluted 1:1000). For secondary staining, cells were incubated with 
goat anti-rabbit AlexaFluor-conjugated secondary antibodies (diluted 1:750 in 1% 
BSA-PBS) and with 4',6-diamidino-2-phenylindole (DAPI) (diluted 1:2000 in 1% 
BSA-PBS) for 1hr in darkness at room temperature. Finally, cells were mounted in 
Mowiol mounting medium (Invitrogen) and images were obtained with a 
fluorescent microscope. In addition confocal images were acquired using a Leica 
SP5 confocal microscope or a Zeiss Pascal confocal microscope fitted with Argon, 
P a g e  | 88 
 
UV and HeNe lasers, using 63x oil objectives. Images were processed using ImageJ 
and Adobe Photoshop (Adobe Systems). 
2.2.8. Cell culture 
Maintenance of cell stocks 
The cell lines used in this study are listed in Table 2.1. The HEK293, MCF-7, 9L, 
C6, LN229, and SNB-19 cell were cultured in D-MEM supplemented with 10% 
Foetal Bovine Serum (FBS) (Gibco), Penicillin (100 units/ml), Streptomycin (100 
µg/ml) and L-glutamine (2 mM). The FBS was heat-inactivated for one hour at 
56˚C to destroy complement before use. Cells were cultured as monolayers on 175 
cm2 tissue culture flasks at 37˚C in a humid atmosphere of 5% CO2. Cells were 
passaged twice a week or when they reached 80-90% confluence. The medium was 
removed and cells were washed in sterile 1X PBS before addition of 2 ml of 2 ml 
of trypsin-ethylenediaminetetra acetic acid (Trypsin-EDTA) and incubated at 37˚C 
for 1 – 2 minutes until the cells detached. Following the addition of 4 ml D-MEM 
to neutralise the trypsin, a 2 ml aliquot was transferred to a new flask containing 10 
ml complete D-MEM. Cells were tested for Mycoplasma contamination regularly by 
using the MycoAlert® Mycoplasma detection kit (Lonza).  
Storage of cell stocks 
Following trypsinizing of sub-confluent monolayer cultures grown in 175 cm3, the 
cell suspension was transferred to a 10 ml tube and centrifuged at 1000 revolutions 
per minute (rpm) for 5 minutes. The pellet was re-suspended in 10 ml of freezing 
medium containing 95% (v/v) FBS and 5% (v/v) dimethyl sulfoxide (DMSO). 
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Aliquots of 1 ml cell suspension were added to cryotubes.  The vials were promptly 
placed in cryofreezing containers lined with isopropanol placed at -80°C overnight 
and subsequently transferred to liquid nitrogen for long term storage. Cells were 
recovered from liquid nitrogen by thawing cells at 37°C. These were pelleted by 
centrifugation at 1000rpm and DMSO containing media was removed. The cell 
pellet was then re-suspended in 5 ml pre-warmed growth medium before transfer 
to a 75 cm3 flask for culture at 37˚C in the CO2 incubator. 
2.2.9. Mammalian cell transduction by AAVP 
Monolayer cell cultures 
The HEK293, MCF-7, 9L, C6, LN229, and SNB-19 cell cultures were trypsinized, 
counted by a haemocytometer. For monolayer cell culture, a suspension of 30,000 
cells in a total volume of 500 μl of complete D-MEM were seeded into 48-well 
flat-based plates (corning) and grown in CO2 incubator  at 37°C for 24-48 hours 
until the cells were 70-80% confluent. Different AAVP vector formulations were 
prepared as described above. Targeted (RGD4C) or non-targeted (NT) AAVP 
vectors without chemical treatments were used as negative controls. The medium 
was removed from tissue culture plate and replaced with 250 μl of chemically 
treated AAVP preparations. The plate was then incubated at 37°C in the CO2 
incubator for 4 hours and manually rotated every half an hour during incubation. 
Following 4 hour incubation, 250 μl of complete medium was added to each well. 
The plate was then incubated in the CO2 incubator at 37°C. The medium was 
renewed every two days. Depending on the experiment, transduction efficiency as 
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determined by the expression of reporter transgenes was assessed at various 
indicated time points. 
Multicellular spheroids (MCS) 
For spheroid generation, a suspension of 5,000 cells in a total volume of 200 μl of 
complete D-MEM was seeded into 93-well ultra-low attachment (ULA) surface 
plates. After 48 hour incubation, a multicellular spheroid spontaneously formed in 
each well. 100 µl media was removed from each well after which 100 µl of AAVP 
formulations prepared in complete D-MEM was added. Targeted (RGD4C) and 
non-targeted (NT) AAVP without chemical treatment were used as negative 
controls. The plates were incubated at 37°C in the CO2 incubator with 50% 
medium replenishment every two days. Depending on the experiment, 
transduction efficiency as determined by the expression of reporter transgenes  was 
assessed at various indicated time points. 
2.2.10. Generation of cells stably expressing the green fluorescence 
protein (GFP) gene 
Sub-confluent monolayer cells cultured in 12-well flat-based plates were transduced 
with 50 µg AAVP vectors carrying GFP gene and puromycin-resistant gene (puroR) 
or chemically treated vectors. At day 3 post transduction, cells were trypsinized and 
suspended in medium containing an appropriate dose of puromycin (7 µg/ml for 
9L cells and 1 µg/ml for MCF-7 and HEK293 cells). Parental non-transduced cells 
were used as controls. The medium containing puromycin was renewed every 2-3 
days. All the control cells were killed and the puromycin-resistant single cell clones 
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were visible after approximately 2 weeks. The puromycin-resistant cell clones were 
pooled to produce a population of stably transduced cells. All stable selected cells 
were monitored under a fluorescent microscope. 
2.2.11. Examination of reporter gene expression 
Luciferase assay 
The Promega Steady-Glo® luciferase assay kit was used to evaluate expression of 
the luciferase Luc reporter transgene in transduced cells. 72 hours post 
transduction, medium was removed, cells were then washed with 1x PBS followed 
by the addition of 110 µl of 1X Glo lysis buffer and incubation for 10 minutes to 
allow for complete cell lysis. 50 µl cell lysate was transferred to 96-well white 
opaque microplates followed by the addition of 50μl Steady-Glo® luciferase 
substrate  and incubation at room temperature for 10 minutes. Luciferase activity 
was quantified using a Promega plate reader. 
GFP analysis 
The cells were transduced as described with AAVP vectors carrying the GFP 
reporter gene and GFP expression was analysed using a Nikon Eclipse TE2000-U 
fluorescence microscope. Photographic images were obtained by using 2X 
magnification and fluorescent setting. Brightfield photographs were also obtained. 
2.2.12. Cell viability 
The Promega CellTiter-Glo® assay kit was used to evaluate the cell viability. After 
48 hour vector treatment, medium was removed. Cells were then washed with PBS 
followed by the addition of 110 µl of 1X Glo lysis buffer and subsequently 
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incubation for 10 minutes to allow for complete cell lysis. A 50 µl aliquot of cell 
lysate was transferred to 96-well white opaque microplates after which 50μl Steady-
Glo® luciferase substrate was added and allowed to incubate for 10 minutes at 
room temperature. Luminescence signal was quantified using a Promega plate 
reader. 
2.2.13. Determination of tumour cell killing In Vitro 
Cells were seeded in a 48-well plate and incubated for 48 hr, to reach 60%-80% 
confluence. Next, cells were transduced with AAVP vectors carrying the HSVtk 
gene. GCV was added to cells (10 µM) at day 3 post vector transduction and 
renewed daily. Viable cells were monitored under microscope and cell viability was 
measured at day 5 post GCV treatment by using the CellTiter-Glo® cell viability 
assay kit as described above. 
2.2.14. Design and construction of multifunctional phage 
Multifunctional phage particles were made through a series of genetic 
modifications of the capsid. The RGD4C.fUSE5 vector, in which the nucleotide 
encoding RGD4C peptide was fused in frame with the pIII gene as previously 
described in the detailed protocol22, was used as a targeted backbone phage vector 
for mammalian cell binding and internalisation through RGD4C binding to ɑVβ3 
integrin receptor. Next, a f88 vector-derived DNA fragment containing a 
recombinant gene VIII was inserted in the RGD4C.fUSE5 backbone vector, 
followed by insertion of oligonucleotide encoding the peptide of interest. 
Subsequently, nucleotide sequence encoding a peptide of interest was introduced 
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into the wild-type pVIII gene by site-directed mutagenesis. Finally, a mammalian 
transgene cassette was inserted in an intergenic region of the resultant vector.  
Construction of the RGD4C phage vector containing two major coat proteins 
Two existing phage vectors RGD4C.fUSE5 and f88-4, both of which have unique 
restriction sites present at similar locations in their DNA, were digested with the 
BamHI and XbaI restriction enzymes. Next, two fragments with the 
corresponding sequences; 1) a 3,925 bp fragment containing gene III fused in 
framed with RGD4C and the wild-type gene VIII from RGD4C.fUSE5 plasmid, 
2) a 5,630 bp flagment containing recombinant VIII gene, were ligated to create a 
chimeric RGD4C.fUSE5/f88-4. 
Insert preparation and cloning of peptides in the recombinant pVIII of RGD4C.fUSE5/f88-4 
The corresponding nucleotide sequence and its complementary sequence were 
designed. The sense and anti-sense oligonucleotides are 5’phosphorylated. The 
phosphorylated oligos were mixed (20 pmol/primer), heated to 95˚C for 5 min and 
gradually cooled at room temperature to allow annealing. Annealing of sense and 
anti-sense oligonucleotides generates the HindIII and PstI sticky ends, ready to be 
cloned in the digested RGD4C.fUSE5/f88-4 phage plasmids. An aliquot of 
ligation reaction was transformed into E.coli competent cells strain DH5α and 
inoculated on LB agar plate containing 50 μg/ml tetracycline. Single colonies were 
picked and their plasmids were isolated by using a QIAprep Spin Miniprep kit 
(QIAGEN). The positive clones were selected by sequencing analysis. 
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Display of peptides on the wildtype pVIII major coat protein 
Oligonucleotide sequences encoding a peptide of short length (up to 10 amino acid 
residues) were introduced into the wild-type VIII gene by using the Phusion Site-
Directed Mutagenesis Kit. Briefly, the 50 µl polymerase chain reaction (PCR) 
reaction was performed with 10 pg DNA templates, 0.5 μM 5’phosphorylated 
primer pairs, 200 μM dNTP and 0.02 U Phusion Hot Start II DNA polymerase. 
The reaction was initiated by pre-heating the reaction mixture to 98˚C for 30 s;  25 
cycles of 98˚C for 15 s, 61˚C for 30 s and 72˚C for 5 mins (30 s/500 bp). The PCR 
products were evaluated by agarose gel electrophoresis. The linear PCR product 
was circularized by ligation using the T4 Quick ligase. The positive clones were 
selected with the same procedure as described above. 
2.2.15. Standard protocol for molecular cloning 
DNA agarose gel electrophoresis 
1% agarose gels were prepared by dissolving 0.5g Agarose in 50 ml of fresh 1X 
Tris-acetate-EDTA (TAE) buffer and heating the suspension in a microwave oven 
until boiling. When hot agarose was completely melted and cooled to about 50 – 
55°C, 7 µl of Ethidium bromide (EtBr) was added, and poured into casting tray 
and then let stand for 30 minutes until it is solid. The gel was placed into the 
electrophoresis chamber of assembled electrophoresis apparatus with enough 1X 
TAE Buffer (about 2-3 mm of buffer over the gel). The sample was prepared by 
mixing 5 µl of each sample with 1 µl of 6X Sample Loading Buffer. Each 
sample/sample loading buffer and 10 µl of the DNA ladder standard were pipetted 
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into a separate well in the gel. Electrophoresis was carried out at 100V for 
approximately 45 minutes. DNA was visualised by illumination on a long wave UV 
light box and photographed. The size of the DNA fragments was estimated by 
comparing their relative mobility to that of the DNA ladder. 
Gel extraction and purification (QIAquick) 
Plasmid DNA or DNA fragments were extracted and purified by using the 
Qiaquick gel extraction kit. The DNA fragment of interest was excised from 
agarose gel with a clean and sharp scalpel. The slice of agarose gel was transferred 
to an eppendorf tube and weighted. Next, 3 volumes of buffer QG were added to 
1 volume of the agarose gel in order to dissolve the gel by incubating at 50°C for 
10 minutes. Subsequently, 1 gel volume of isopropanol was added to sample. A 
QIAquick spun column was placed in a provided 2 ml collection tube after which 
the sample was applied to the column, followed by centrifuging for 1 minute to 
discard the flow-through. The QIAquick column was washed to remove all traces 
of agarose by adding 0.5 ml Buffer QG and centrifuged for 30–60 seconds, 
followed by adding 750 µl of Buffer PE and centrifuging for 30–60 seconds. 
QIAquick column was then placed into a clean 1.5 ml eppendorf tube and 50 µl of 
Buffer EB (10 mM Tris-Cl, pH 8.5) was added to the centre of membrane and 
centrifuged for 1 minute to elute the DNA. 
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Ligation 
Ligations were carried with 30-50 ng of vector DNA and typically 1:5 molar ratio 
of vector to insert DNA was used (either a purified DNA fragment, or a pair of 
annealed oligonucleotides). All ligation reactions were performed in a final volume 
of 10 µl containing 1x Quick T4 DNA ligase buffer and 1µl Quick T4 DNA ligase 
(Fermentas). All reactions were incubated for 5 minutes at room temperature. 
Transformation of competent bacteria by heat shock method 
The tube of frozen NEB 5-alpha competent E.coli (BioLabs) were removed from -
80°C freezer and thawed on ice. The plasmid DNA was added to 50 µl of thawed 
competent cells. After 30 minute incubation on ice, cells were heat shocked at 
exactly 42°C for 30 seconds then immediately placed on ice for 2 minutes. Next, 
250 µl of super optimal broth (SOC) medium (Invitrogen) was added to the 
reaction and cells incubated in a shaking incubator at 37°C 250 rpm for 1 hr. 
Finally the cells were spread on LB-agar plates containing 40 µg/ml tetracyclin, and 
incubated at 37°C overnight. 
Restriction endonuclease digestions 
Restriction enzyme digests were performed in the recommended buffers and 
supplied by the manufacturer’s instruction. A 50 µl reaction included 1 µg DNA, 5 
µl of 10X NEB buffer, and 10 units of each restriction enzyme. The reaction was 
incubated at recommended temperature for 1 hour. For analysis of digestion 
products, reactions were terminated by inactivating enzymes at denaturing 
temperature, followed by gel electrophoresis to check the digestion products. 
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2.2.16. Infectivity assay (see figure 2.2 for procedure summarization) 
A loopfull of E.coli K91 was used for inoculating 7 ml culture, which was then 
grown at 37°C with shaking (250 rpm) for approximately 1.5 – 2 hours or until 
mid-log phase of bacterial growth (A600 is between 1.5 – 2.0). Phage stock was 
serially diluted in PBS and the 5 µl of diluted phage preparation was added 1 ml of 
K91. Then, the mixture was incubated at room temperature for 20 minutes 
without shaking to allow infection, and 200 µl of the mixture was plated out on LB 
agar plates containing 100 µg/ml kanamycin and 40 µg/ml tetracycline. The plate 
was then incubated at 37°C overnight. The resulting bacterial colonies formed on 
LB agar plates were counted to determine their infectivity. 
 
Figure 2.3: Infectivity assay 
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2.2.17. Collagen depletion assay 
9L, M21, and MCF-7 cells were grown in 12-well plates at a density of 120,000 
cells/well for 72 hours until they were confluent.  After washing cells with PBS, 
500μl of 0.2 mg/ml collagenase in serum free media was added to the cells and 
incubated at 37°C for 1 hr. Next, both cells and supernatant were processed as 
separate samples in a collagen I detection assay. The assay was performed based on 
the use of the Sirius Red dye according to the manufacturer’s instructions of a 
Sirius Red Total Collagen Detection Kit with final measurements by using a 
Promega plate reader. 
2.2.18. AAVP diffusion assay 
200 μl of ECM Gel from Engelbreth-Holm-Swarm murine sarcoma at 2.5 mg/ml 
or 5.0 mg/ml were added to a 48-well plate and allowed to set at 37°C. In the 
meantime fluorescently-tagged RGD4C.AAVP was prepared at a concentration of 
5μg/ml. Next, 50μl of the RGD4C.AAVP solution were taken up in a pipette tip, 
which was inserted at a fixed position into the ECM-gel matrix and left to diffuse 
through the material for 1 hour. Measurements were obtained at 1 hour post 
diffusion and at 30 minutes intervals thereafter. 
2.2.19. Statistical analysis 
GraphPad Prism software (version 5.0) was used to perform statistical analyses. 
Data were presented as mean±standard error of the mean (s.e.m). P values were 
generated by one-way or two-way ANOVA, considered significant when <0.05 
and denoted as follows: *p < 0.05, **p <0.01 and ***p < 0.001. 
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3. Optimizing a hybrid Adeno-associated virus/phage 
(AAVP) vector system for efficient gene delivery to 
mammalian cells 
3.1. Introduction 
Protein expression from a gene of interest introduced into cultured cells not only 
serves as a powerful tool to study protein function, but also has major impacts on 
the practice of medicine. Ex vivo gene therapy is a prime example whereby 
appropriate cells are genetically modified in vitro and placed back into the affected 
area of the patients. The expression of transferred transgenes can be transient or 
stable. Transient gene expression is commonly used to investigate the short-term 
(24-72 hours post-transduction) impact of alternations in gene expression, while 
the stable gene transfer generate long term gene expression in cell lines. Stable 
expression is one of the key factors in ex vivo gene therapy. For example, genetic 
modification of human Embryonic Stem Cells (hESCs) requires stable integration 
of a therapeutic gene into the cell genome or maintenance as episomal forms in the 
nucleus.175 Delivering transgenes into mammalian cells requires a gene carrier or 
vector. Viral vectors derived from animal viruses such as retrovirus, adenovirus, 
AAV, and HSV have emerged as vectors of choice for many applications today.  
However, they suffer several limitations including packaging capacity10 and 
complexity of production due to the need for costly manufacturing processes.11 
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Bacteriophage (or phage), a simple bacterial virus, has made contributions in the 
field of gene delivery.15 Because of their inherent simplicity, the use of 
bacteriophage as a gene delivery vector is an attractive concept. They are uniquely 
suited to modifications that use directed evolution to produce genetically 
optimized vectors for gene transfer.176 The high tolerance of phage coat protein 
mutations allows the insertion and display of foreign peptides.177 Phage-based 
vectors, among all other choices for in vitro gene transfer to cultured cells, is the 
simplest and least expensive technique since it does not require any specialized and 
sophisticated equipment.16 Recently, Hajitou et al introduced an improved version 
of a M13 phage-derived vector, which combined a mammalian gene cassette 
flanked by ITRs from AAV2 into the bacteriophage genome at a compatible site, 
named AAVP. They demonstrated gene transfer and expression in mammalian 
cells mediated by AAVP vector carrying mammalian transgene expression 
cassettes.26,171 The incorporation of ITRs from AAV2 is associated with improved 
fate of the delivered transgenes, maintenance of the entire mammalian transgene 
cassette, better persistence of episomal DNA and formation of concatamers of the 
transgene cassettes.  All these mechanisms resulted in increased transduction 
efficiency over conventional phage-based vectors.171 However, all subsequent 
improvement of AAVP has been exclusively done at the genome level, which is the 
last of many steps involved in the gene delivery process.  
Indeed, it is well-established that gene delivery efficacy depends on the ability of 
the vector to overcome a number of extra/intracellular barriers. Firstly, the vector 
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needs to access its receptor on the cell surface. Secondly, following internalization, 
the vector has to escape from the endosomes and be released into the cytosol. 
Thirdly, the vector must then be transported to the nucleus where gene expression 
occurs. Unfortunately, current AAVP vectors are unable to efficiently circumvent 
these obstacles to achieve transgene expression. 
In this study, we used an AAVP vector carrying a mammalian DNA cassette 
comprising a GFP or Luc gene with a cytomegalovirus (CMV) promoter to direct 
gene expression in mammalian cell lines. The aim of this study was to establish the 
optimal transduction conditions of the AAVP vector system and to investigate cell-
AAVP interactions which form a key parameter in vector attachment to cells and 
subsequently determine the vector tropism. We evaluated 1) the effect of genetic 
modification by displaying targeting ligands on the AAVP capsid and 2) chemical 
modification of AAVP capsid using transduction enhancing agents such as lipid 
agents (DOTAP, lipofectamine, Fugene), polycationic polymers (PEI, polylysine, 
DEAE.DEX, PB, PS), and CaPi. Finally, we assessed the combination of both 
genetic and chemical modification. 
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3.2. Results 
3.2.1. Acquisition of AAVP mammalian cell tropism by genetic 
modification is limited by saturation of transduction 
To create a mammalian cell tropism for the AAVP vector, we previously reported 
the genetically modified RGD4C.AAVP displaying the αv integrin-targeting 
peptides on the phage capsid.171 Herein, we sought to investigate the effect of 
increasing dose of RGD4C.AAVP on transduction efficiency. Therefore, 
RGD4C.AAVP-mediated transduction was conducted at concentration of 0 to 500 
μg of RGD4C.AAVP carrying Luc gene. NT.AAVP (unmodified capsid) was also 
included in this experiment as a negative control of transduction. Vectors were 
added to cells 3 days before measurement of the luciferase activity. The results 
showed a linear increase in transduction efficiency at AAVP doses of 0-50 μg for 
HEK293 cells and 0-200 μg for 9L and M21cells(Figure 3.1a, b, and c), reflecting 
unsaturated transduction efficiency. However, the results yielded dose-
independence at higher AAVP amounts. Indeed, the transduction efficiency no 
longer increased above the indicated doses, suggesting transduction saturation. For 
example, saturation of gene expression was observed in HEK293 cells at 50 µg 
RGD4C.AAVP (approximately 1.5 x 105 RLU or 300-fold over AAVP vector) 
(Figure 3.1a). However, the optimal concentration for HEK293 was determined 
to be 25 µg AAVP because one ideal factor for gene delivery is to use the least 
amount of vector possible to achieve efficient gene delivery.  No luciferase 
expression was observed in unmodified NT.AAVP-treated cells at any 
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concentration tested. These data suggest that improvement of AAVP-mediated 
gene transfer is limited by the saturation effect. 
 
Figure 3.1: Transduction with RGD4C.AAVP resulted in saturation of transgene 
expression in 3 different cell lines as determined by the luciferase activity. Cells a) 
HEK293 b) 9L or c) M21 were cultured in 48-well plates and transduced with increasing doses 
(μg/well) of RGD4C.AAVP carrying a Luc reporter gene to determine lowest concentration 
required to achieve transduction saturation. The results show the mean relative luminescence 
units of triplicate wells ±SEM, from one representative of three independent experiments.  
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3.2.2. Addition of cationic lipids slightly increased AAVP-mediated 
gene expression in mammalian cells 
Having shown that RGD4C.AAVP-mediated gene delivery efficacy is limited by 
saturation of transduction, we sought to investigate the mammalian cell tropism of 
AAVP by chemical modification of the capsid. To test whether cationic lipids had 
an effect on AAVP-mediated gene expression in mammalian cells, we analysed Luc 
gene expression in the HEK293 cells. Cells were transduced with NT.AAVP at a 
concentration of 25 µg/well with or without cationic lipids at different 
AAVP/cationic lipids ratios. Three different reagent formulations were tested: 
Fugene, Lipofectamine, and DOTAP. Levels of luciferase activity at 72 h post 
transduction were determined using a luciferase assay (Figure 3.2). The addition of 
cationic lipids increased AAVP-mediated gene expression in HEK293 cells. No 
cytotoxicity was observed in the concentration ranges of cationic lipids tested 
(Data not shown).  The maximal ratios for enhancing transgene expression for 
Fugene, Lipofectamine, and DOTAP were 1.0 µl/µg, 1 µl/µg and 4200 ng/µl with 
overall increases of 70- , 80-, and 20-fold, respectively compared with unmodified 
AAVP (Figure 3.2a, b, c). However, these cationic lipid-enhanced transduction 
levels are considered poor, as saturation transduction by RGD4C.AAVP was 
determined at 300-fold over unmodified AAVP for HEK293. Therefore, cationic 
lipids were not chosen for further studies. 
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Figure 3.2: Effects of cationic lipids on AAVP-mediated gene expression in vitro. 
HEK293 cells were harvested 72 h after treatment with AAVP carrying the Luc gene at a 
concentration of 25 µg/well mixed with a) Fugene, b) Lipofectamine, and c) DOTAP at various 
ratios. The results show the mean relative luminescence units (RLU) of triplicate wells + SEM, 
from one representative of three independent experiments, significant difference; n.s.-not 
significant, * p<0.05, ** p<0.01, ***p<0.001 (one way ANOVA with tukey's post hoc test).  
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3.2.3. Incorporation of AAVP in a calcium phosphate coprecipitate 
improved gene transfer to mammalian cells 
We hypothesized that delivery of AAVP in a CaPi coprecipitate would increase 
gene transfer to mammalian cells. We first optimized three critical parameters 
affecting AAVP-CaPi precipitate formation and transduction efficiency as well. We 
tested; i) the effect of CaCl2 concentration, ii) the presence of essential reagents to 
form the complex, and iii) the duration of the coprecipitate complex formation. 
AAVP-CaPi coprecipitate was prepared by adding HBS buffer containing 
phosphate ions to the AAVP/CaCl2 mixture prior to cell treatment. The cells were 
then incubated for 72 h and subsequently analyzed for luciferase activity. The data 
in Figure 3.3a show the effects of various concentrations of CaCl2 on the 
transduction efficacy. AAVP vectors coprecipitated with 250-300 mM CaCl2 
showed the highest transduction efficiency. AAVP-CaPi coprecipitate-mediated 
transduction at optimal ratio dramatically increased luciferase reporter gene 
expression up to 1,300-fold compared with AAVP alone. The data in Figure 3.3b 
show the duration of coprecipitate complex formation before its addition to cells. 
Immediate addition to cells after AAVP-CaPi preparation showed an optimal 
effect on transduction of HEK293 cells. Transduction efficacy significantly 
decreased with increasing incubation period of complex formation. Figure 3.3c 
confirms the formation and the cell surface attachment of insoluble AAVP-CaPi 
precipitates when AAVP were incubated with two essential reagents: HBS, and 
CaCl2. The precipitation could not be observed in the absence of either one or 
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both of them. The presence of both reagents required for the complex formation 
was confirmed by the successful transduction after day 3 post treatment (Figure 
3.3d). 
 
 
 
Figure 3.3: CaPi coprecipitation enhances AAVP-mediated gene transfer to HEK293 
cells. a) Effect on CaCl2 concentrations. AAVP vectors were mixed with increasing 
concentrations of CaCl2 before adding HBS to form the complex. The mixtures were then added 
to cells and Luciferase analysis was subsequently performed 3 days post transduction. b) Effect 
of complex formation time before addition to cells. AAVP-CaPi complexes were incubated for 
various times before they were applied to cells. c) Effect of HBS and CaCl2 on the formation and 
the cell surface attachment of AAVP-CaPi precipitates. Scale bars = 100 µm. d) Effect of HBS 
and CaCl2 on AAVP-mediated transduction. (300 mM CaCl2, 1X HBS buffer) Data represent the 
mean + SEM of triplicate samples from one representative experiments of three, significant 
difference; n.s.-not significant, * p<0.05, ** p<0.01, ***p<0.001 (one way ANOVA with tukey's 
post hoc test).  
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3.2.4. Mechanism by which calcium phosphate coprecipitation 
enhances AAVP-mediated gene transfer 
Following the hypothesis that the mechanism of enhanced efficacy of gene transfer 
by AAVP-CaPi complex is associated with higher affinity to the cell surface than 
the NT.AAVP vector alone, we carried out experiments to demonstrate the 
efficacy of AAVP particle adsorption to target cell membranes. HEK293 cells were 
treated with AAVP alone or an AAVP-CaPi coprecipitate. RGD4C.AAVP-treated 
cells served as a positive control as previous reports have shown an essential role 
of the RGD4C ligand, displayed on AAVP coat protein, in mammalian cell 
attachment and internalization.178 We performed immunofluorescence-staining 
assays with antibodies against the phage coat proteins (Figure 3.4a). The red 
colour represents fluorescence related to AAVP particles, and the blue shows 
fluorescence of DAPI-stained cell nuclei. Immunofluorescence images revealed 
great cell surface binding in cells treated with the AAVP-CaPi precipitate. No 
AAVP was observed on cells incubated with AAVP alone. We also carried out a 
supernatant-depletion assay by incubating the different AAVP preparations with 
cells, after which the supernatant containing the AAVP particles that did not attach 
to cells was collected and quantified by infection of host bacteria followed by 
colony counting. The surface-bound, non-internalized condition was achieved by 
incubating the cells at 4°C instead of 37°C. AAVP recovery was determined as 
percentage of input. As shown in Figure 3.4b, a large amount of AAVP (100% of 
AAVP input) was recovered while the AAVP-CaPi was almost completely 
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sequestered by cultured cells. Large amounts of the control RGD4C.AAVP were 
recovered when compared to the AAVP-CaPi complex. These data clearly show 
that the AAVP coprecipitation with CaPi results in increased binding to 
mammalian cells. 
Next, we set out to determine if there was increased cellular uptake of AAVP 
coprecipitated with CaPi. Flow cytometry was carried out to quantify internalised 
AAVP (Figure 3.4c). The coprecipitaion of AAVP with CaPi led to an increase in 
AAVP internalisation, as indicted by higher intracellular signals compared to cells 
incubated with AAVP alone. The data strongly suggest that coprecipitation of 
AAVP with CaPi indeed alters AAVP tropism for mammalian cells by mediating 
efficient AAVP binding to the cell surface and subsequent internalization. 
Interestingly, internalisation of AAVP-CaPi complex was not significantly different 
from those of RGD4C.AAVP despite higher efficiency in binding to cells, 
suggesting an additional mechanism that assists gene transfer to mammalian cells 
(See discussion). 
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Figure 3.4: CaPi facilitates interaction between AAVP and cell membranes. a) 
Immunofluorescence-based AAVP binding and internalization assay with cultured HEK293 
cells. Phage particles were detected by polyclonal rabbit anti-phage IgG followed by incubation 
with Alexa conjugated goat anti-rabbit IgG (red fluorescence). Scale bars = 100 µm. b) 
Supernatant-depletion assay. The number of free-unbound AAVP in the supernatant above the 
adherent cell layer was quantified by infection of host bacteria followed by colony counting and 
expressed as percentage of AAVP input.  c) Evaluation of AAVP internalization. HEK293 cells 
were treated with different AAVP preparations for 1 h. Cells were then collected and 
internalization efficiency was measured using flow cytometry. Untreated cells were used as 
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controls. Data represent the mean + SEM of triplicate samples from one representative 
experiments of three, significant difference; n.s.-not significant, * p<0.05, ** p<0.01, ***p<0.001 
(one way ANOVA with tukey's post hoc test). 
 
 
 
3.2.5. Enhancing AAVP-mediated gene transfer by addition of 
cationic polymers 
Next, optimal ratios of the complexes of AAVP with cationic polymers by gene 
transfer to mammalian cells were determined. We tested five cationic polymers: 
DEAE.DEX,  PEI, PDL, PB, and PS. Results showed that incorporation of 240-
440 ng of DEAE.DEX per 1 μg of AAVP greatly increased luciferase transgene 
expression, with maximal increase (2500-fold) at 350 ng/μg (Figure 3.5a). 
Transgene expression was also significantly increased by 80-360 ng of PEI per 1 μg 
of AAVP with maximal increase (1,500-fold) at 160 ng/μg (Figure 3.5b), and at 
80-320 ng of PDL per 1 μg of AAVP, with maximal increase (800-fold) at 200 
ng/μg (Figure 3.5c). However, not all cationic polymers tested were effective. PB, 
at optimal ratio 40 ng/µg, slightly increased transgene expression by 30-fold 
(Figure 3.5d). PS failed to enhance expression over a broad range of 
polymer/AAVP ratios (Figure 3.5e). Thus, complexes of AAVP with particular 
cationic polymers augmented gene transfer to mammalian cells. 
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Figure 3.5: Optimisation of AAVP/cationic polymer complexes. HEK293 cells were 
cultured in 48-well plates and treated with AAVP carrying the Luc gene, premixed with 
increasing ratios of cationic polymer per AAVP. Luciferase activity was analysed at day 3 post 
transduction. a) DEAE.DEX. b) PEI. c) PDL. d) PB. e) PS. The results show the mean relative 
luminescence units (RLU) of triplicate wells + SEM, from one representative of three 
independent experiments, significant difference; n.s.-not significant, * p<0.05, ** p<0.01, 
***p<0.001 (one way ANOVA with tukey's post hoc test). 
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3.2.6. Evaluation of cytotoxicity by the AAVP/polymer complex 
We sought to investigate whether the AAVP/polymer complex was toxic for the 
cells and whether the observed decrease in transgene expression at higher polymer 
content in the complex was due to cytotoxicity of the polymer at these higher 
concentrations. Therefore, cell viability assays were performed by using the same 
polymer/AAVP ratios range of 0-440 ng/μg. Cell viability was normalised as 
percentage of the control cells treated with AAVP alone without polymer (0 ng/μg 
of polymer/AAVP). At day 2 post treatment, cell viability assays (Figure 3.6a) 
revealed a significant decrease in cell survival in cells treated with AAVP 
complexed with high concentrations of PEI or PDL (Figure 3.6a, top and 
bottom), but no cytotoxicity was detected at lower polymer/AAVP ratios 
including the optimal ratios. However, the proportion of viable cells did not 
change significantly after treatment with increasing DEAE.DEX concentrations 
(Figure 3.6a, middle). Morphological characteristics of HEK293 cells were 
visualized by brightfield microscopy. Figure 3.6b shows normal morphology of 
confluent cells in treatments with AAVP alone and in cells treated with AAVP-PEI 
complexes at optimal PEI/AAVP ratio. There was a dramatic increase in the 
number of cells detaching from the substrate by the AAVP-PEI complex, at higher 
PEI/AAVP ratios. 
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Figure 3.6: Cell viability of HEK293 cells 48 h after being exposed to various ratio of 
polymer/AAVP. a)  The toxicity of AAVP-PEI (top), AAVP-DEAE.DEX (middle), and 
AAVP-PDL (bottom) was determined using the CellTiter-Glo® cell viability assay. HEK293 
cells were treated with AAVP, premixed with increasing ratios of cationic polymer per AAVP. At 
day 2 post treatment, cell viability was determined. Mean cell viability was normalised to non-
treated controls, with the mean of n=3 independent experiments shown (+ SEM), significant 
difference; n.s.-not significant, * p<0.05, ** p<0.01, ***p<0.001 (one way ANOVA with tukey's 
post hoc test).  b) Morphological characteristics of HEK293 cells following transduction with 
AAVP complexed with PEI, as visualized by using bright field microscopy. Scale bars = 100 µm. 
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3.2.7. Physiochemical properties of AAVP/polymer complex 
To gain an insight into the mechanism of the enhanced gene delivery efficacy by 
AAVP/polymer complexes, we explored the surface chemistry of the AAVP 
capsid. We first investigated the charge characteristics of AAVP particles by 
measuring their ζ-potential. The results show the negative charge of AAVP at 
physiological pH (Figure 3.7a). The data indicate that the AAVP vector possesses 
an acidic surface, with an isoelectric point of pH=3 as determined by zeta potential 
= f(pH). In order to characterize AAVP-polymer complex, the surface charge and 
the average sizes of AAVP complexed with cationic polymer were assessed 
(Figure 3.7a, b). As shown in Figure 3.7c, the addition of increasing cationic 
polymers concentrations led to a corresponding increase in the ζ-potential from a 
negative value to a positive value and thereafter the ζ-potential decreased 
significantly.  For example, incorporation of PDL resulted in an increase in ζ-
potential from -5 mV to +15 mV with 25 ng of PDL added per 1 μg AAVP in the 
solution, after which the ζ-potential decreased to reach near zero. As shown in 
Figure 3.7d, the increasing polymer concentrations resulted in an increase of the 
average size of complexes. No stable measurements could be taken with higher 
concentrations of polymer content in the complex (>40 ng/μg) either due to 
visible precipitation of the complex solution or formation of large particle 
aggregates at a ratio of 40 ng polymer per 1 μg AAVP. Taken together, these 
results indicate that negatively charged AAVP particles are incoporated physically 
with cationic polymers to form larger complexes. Under confocal microscopy 
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(Figure 3.7e), it was observed that the morphology of AAVP alone appeared as 
single particles. However, the addition of cationic polymers resulted in 
considerable aggregation of AAVP particles. 
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Figure 3.7: Physical characterization of AAVP/polymer complex. a) The ζ-potential of 
AAVP was measured by Zetasizer when varying phage titer. b) ζ-potential of AAVP as a 
function of pH. The isoelectric point of AAVP particles were determined at the cross point 
when the ζ -potential becomes zero. c) Investigation of cationic polymer (DEAE.DEX or PDL) 
and AAVP interaction by ζ -potential analysis. d) Average size distribution of AAVP or AAVP 
coated with polymers (DEAE.DEX or PDL) at various ratios as indicated. e) The appearance of 
AAVP/polymer complexes. Morphology of hybrid complexes and phage vectors alone were 
analyzed using confocal microscopy. AAVP particles were stained for immunofluorescence using 
anti-fd phage primary and goat anti-rabbit AlexaFluor-647 secondary antibodies. Scale bars = 1 
µm. 
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3.2.8. Incorporation of cationic polymers into AAVP facilitates 
vector interaction with cells 
It is well known that positive charges of gene delivery vectors can enhance their 
adhesion to negatively charged cell membrane, which increases the chances of cell 
internalization. We have determined that the AAVP/polymer complex possesses a 
positive charge. We therefore carried out supernatant-depletion assays and flow 
cytometry-based experiment to demonstrate that cationic polymers mediate 
efficient AAVP binding to the cell surface and internalization. Additionally, this 
may provide an explanation of why some polymers increased transduction 
efficiency while others did not. Significant depletion of AAVP in the external fluid 
phase above the adherent cell layer was observed in cells treated with AAVP 
premixed with DEAE.DEX, PDL, PEI, and PB (Figure 3.8a). Nearly 100% of 
the free cell-unbound AAVP was recovered from the supernatant of cells treated 
with AAVP alone as well as AAVP premixed with PS polymers. The addition of 
PS was unable to promote cell attachment, which is consistent with the previous 
luciferase study showing that PS failed to enhance luciferase gene expression. 
Internalisation assays revealed that incorporation of AAVP with particular 
polymers i.e. DEAE.DEX, PEI, PDL and PB (except for PS) allowed  cell entry, 
as indicted by higher intracellular signal than cell incubated with AAVP alone 
(Figure 3.8b). The data indicate that these polymers enable cellular internalization 
of AAVP. The results also suggest that the failure in internalization of AAVP 
premixed with PS was due to its inability to promote cell attachment.  
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To visualize AAVP/polymer complex binding, fluorescence immunostaining was 
performed on HEK293 cells, which were treated with AAVP uncomplexed or 
premixed with optimal concentrations of cationic polymer; DEAE.DEX, PEI, 
PDL, PB, and PS. Uncomplexed AAVP acted as a control to confirm that they are 
unable to bind to the cell surface in the absence of these cationic polymers. Anti-
Phage staining (red) revealed that AAVP premixed with DEAE.DEX, PDL, PEI, 
and PB co-localised with the HEK293 cell surface (Figure 3.8c). These results 
also suggest that low internalization of AAVP premixed with PB (Figure 3.8b) 
could be caused by the formation of relatively large aggregates (Figure 3.8c) that 
might inhibit the efficiency of cellular internalization, despite efficient binding to 
cells as determined by supernatant-depletion assay (Figure 3.8a). Fluorescence 
microscopy also revealed that no phage was observed on cells incubated with 
AAVP premixed with PS (Figure 3.8c). This is consistent with previous 
experiments demonstrating that the addition of PS cannot enable cell attachment 
(Figure 3.8a), internalization (Figure 3.8b) and therefore failed to increase 
transduction efficiency (Figure 3.5e). 
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Figure 3.8: Study of cell attachment and internalization by AAVP complexed with 
cationic polymers. a)  Supernatant-depletion assay. b) Evaluation of AAVP internalization. 
Data represent the mean + SEM of triplicate samples from one representative experiments of 
three, significant difference; n.s.-not significant, * p<0.05, ** p<0.01, ***p<0.001 (one way 
ANOVA with tukey's post hoc test). c) Visualization of AAVP colocalization with cell surface 
membrane in HEK293 cells 4 hour post transduction using immunofluorescence staining. Scale 
bars = 100 µm. 
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Figure 3.8 (cont): Study of cell attachment and internalization by AAVP complexed with 
cationic polymers 
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3.2.9. The proton buffer capacity of AAVP/polymer complex 
Polycations with strong proton buffering capacity can induce osmotic swelling and 
subsequent disruption of endosomal membrane via a mechanism termed the 
‘Proton sponge effect’.111  We performed an acid-base titration of AAVP/polymer 
complexes to evaluate their buffering capacity (Figure 3.9). The results of this 
study showed that AAVP alone displayed a titration curve similar to control NaCl 
and therefore has no buffering capacity without the presence of the polymer. 
DEAE.DEX or PEI alone, as well as AAVP complexed with DEAE.DEX or PEI 
elicited higher buffering capacity than AAVP alone. For example, approximately 
0.2 ml extra HCl was required to lower the pH of the solution containing AAVP-
PEI from 7.4 to 5.1 compared to control NaCl. Another important finding was 
that PDL combinations showed curves similar to the control NaCl solution 
indicating no buffering capacity compared with AAVP-DEAE.DEX and AAVP-
PEI. This result was consistent with the previous luciferase analysis that 
demonstrated higher transduction efficacies of AAVP-DEAE.DEX and AAVP-
PEI than AAVP-PDL. 
Transductions were also performed in the presence of bafilomycin A1 in order to 
investigate the proton sponge hypothesis. Bafilomycin A, a specific inhibitor of the 
vascuolar ATPase proton pump was used to inhibit the acidification of early 
endosomes and therefore prevent endosomal escape.179,180 The data displayed in 
Figure 3.9b indicate that there was a decrease in transduction efficiencies of 
RGD4C.AAVP-PEI and RGD4C.AAVP-DEAE.DEX in the presence of 
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bafilomycin A1. However, there was no significant difference in cell treated with 
RGD4C.AAVP-PDL with/without bafilomycin A1. The fact that the transduction 
efficiencies of RGD4C.AAVP-PEI and RGD4C.AAVP-DEAE.DEX transfections 
in the presence of bafilomycin A1 suffered more than RGD4C.AAVP-PDL 
suggested the involvement of the proton sponge effect for PEI and DEAE.DEX. 
This result was consistent with the proton buffer capacity as determined by the 
acid-base titration (Figure 3.9a) that demonstrated higher buffering capacity of 
AAVP-DEAE.DEX and AAVP-PEI than AAVP-PDL. 
 
 
 
 
 
 
 
 
 
 
P a g e  | 124 
 
 
Figure 3.9: Endosome buffering capacity of AAVP/polymer complexes. a) Acid-base 
titration curve of AAVP/polymer complexes. To assess the proton buffering capacity of AAVP 
complexed with DEAE.DEX, PDL or PEI, each polymer alone, AAVP alone and 
AAVP/polymer complexes were dissolved to their optimised ratios in water and adjusted to 
pH10. HCl was used to titrate the solutions to pH 3. The pH was measured by the pH metre. 
Tritation curve of NaCl was used as a control. Dashed lines represent the typical pH range in 
endosome (pH 7.0 – 4.0). b) The effect of bafilomycin A1 on transduction efficiency of 
AAVP/polymer complexes. HEK293 cell transductions were performed in the presence of 
bafilomycin A1. After 1 hour incubation with 25 µM bafilomycin A1, cells were transduced with 
AAVP/polymer complexes or the control RGD4C.AAVP. After 3 days cells were analysed for 
luciferase expression. Data represent the mean + SEM of triplicate samples from one 
representative experiments of three, significant difference; n.s.-not significant, * p<0.05, ** 
p<0.01, ***p<0.001 (one way ANOVA with tukey's post hoc test). 
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3.2.10. Combined genetic and chemical modifications further 
enhances gene transfer by AAVP 
Having shown that chemical modification with cationic lipids, CaPi and cationic 
polymers enhances AAVP-mediated gene delivery efficiency, we next sought to 
determine whether incorporation of genetic targeting into vector complexes can 
lead to further increase in transduction. We investigated the RGD4C-AAVP 
vector, which was genetically modified to display αv integrin-targeting RGD4C 
peptide on the pIII minor coat protein. The αv integrin receptor-expressing 
HEK293 cell line was chosen as it has previously been used for investigation of 
targeted RGD4C-AAVP.26,171 Firstly, optimal ratios of the complexes of non-
targeted NT.AAVP and targeted RGD4C.AAVP with cationic polymers by gene 
transfer to mammalian cells were determined (Appendix A). Results showed the 
superiority of the AAVP/polymer complexes for transduction of HEK293 cells 
compared to non-targeted NT.AAVP complexed with polymers and uncomplexed 
targeted/non-targeted AAVP. For example, incorporation of RGD4C.AAVP with 
optimal concentration of PEI greatly increased luciferase transgene expression, 
with maximal 5,500-fold increase compared to the control NT.AAVP as shown in 
Figure 3.10a, which was significantly higher than NT.AAVP-PEI and 
RGD4C.AAVP (1,500- and 100-fold, respectively). Maximal transduction 
efficiencies of RGD4C.AAVP-DEAE.DEX, and RGD4C.AAVP-PB resulted in 
4500-, 120-fold greater than NT.AAVP, respectively (Figure 3.10b, d). However, 
there were no significant differences in transduction efficacy between cells 
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transduced with non-targeted NT.AAVP and targeted RGD4C.AAVP, both of 
which were premixed with PDL (Figure 3.10c). In addition, the results of this 
study did not show any significant increase in transduction by the targeted 
RGD4C.AAVP that was coprecipitated with CaPi (Figure 3.10f), or premixed with 
cationic lipids at various ratios (Appendix A). 
Next, to further explore the superiority of the targeted RGD4C.AAVP, we treated 
HEK293 cells with RGD4C.AAVP vectors carrying a GFP reporter gene, which 
were complexed with various DEAE.DEX ratios.  This was compared to control 
non-targeted NT.AAVP and transduction efficacy was subsequently assessed. The 
RGD4C.AAVP-DEAE.DEX complexes resulted in much higher transduction 
efficacy than the non-targeted AAVP-DEAE.DEX complexes. A dose response of 
GFP expression at increasing concentrations of polymer is shown in Figure 3.11. 
Levels of GFP expression increase with increasing DEAE.DEX/AAVP ratios. At 
similar ratios, the transduction efficacy of the targeted AAVP was clearly higher 
than those of the non-targeted AAVP. 
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Figure 3.10: The superiority of the optimised RGD4C.AAVP/polymer complexes for 
transduction of HEK293. Cells were transduced with RGD4C.AAVP, carrying Luc gene, 
complexed with a) PEI, b) DEAE.DEX, c) PDL, d) PB, e) PS, and f) CaPi at optimal ratios and 
compared to control non-targeted AAVP. Analysis of luciferase activity was performed 3 days 
post transduction. The results show the mean relative luminescence units of triplicate wells 
±SEM, from one representative of three independent experiments, significant difference; n.s.-
not significant, * p<0.05, ** p<0.01, ***p<0.001 (two way ANOVA with tukey's post hoc test). 
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Figure 3.11: GFP expression observed after the targeted RGD4C.AAVP-DEAE.DEX 
complex treatment of HEK293 cells. Cells were treated with RGD4C.AAVP, carrying GFP, 
complexed with DEAE.DEX at various DEAE.DEX/AAVP ratios and compared to control 
non-targeted AAVP. Scale bars = 100 µm. 
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3.2.11. Evaluation of efficacy in a 3D multicellular spheroid 
It has been reported that multicellular spheroids better mimic the 
microenvironment of tissues because they exhibit different characteristics 
compared to monolayer cultures. These three dimensional (3D) cultures serve as 
more relevant model systems for a better investigation of gene delivery vectors 181. 
We therefore evaluated the efficacy of AAVP/polymer complexes in a 3D 
multicellular spheroid in addition to traditional monolayer cultures. HEK293 
spheroids were first transduced with the non-targeted or targeted AAVP vectors 
carrying Luc gene premixed with various DEAE.DEX/AAVP ratios to determine 
the optimised ratio of the complexes. Luciferase activity was analyzed at day 10 
post transduction and revealed that DEAE.DEX significantly increased gene 
expression by the targeted RGD4C.AAVP when compared to the non-targeted 
AAVP (Figure 3.12a). Next, spheroids were incubated with GFP carrying vectors 
integrated with optimized DEAE.DEX/AAVP ratios and compared to controls 
RGD4C.AAVP and non-targeted AAVP without polymers (Figure 3.12b). GFP 
expression was examined at day 10 post transduction. While, non-targeted 
AAVP/polymer complexes and RGD4C.AAVP or non-targeted AAVP alone 
showed minimal GFP expression, analysis of the targeted 
RGD4C.AAVP/DEAE.DEX complexes revealed a dramatic increase of GFP 
expression. The data are consistent with our findings from luciferase activity 
assays. Overall, the targeted RGD4C.AAVP/polymer complexes showed better 
transduction efficacy than the non-targeted AAVP/polymer complexes in a 3D 
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multicellular spheroid, in agreement with results obtained with monolayer culture. 
The data also prove that the cationic polymer is should be used in AAVP-guided 
gene transfer to spheroids. 
 
 
 
Figure 3.12: Transduction study using multicellular spheroids to evaluate 
AAVP/polymer complexes. a) Analysis of luciferase activity in multicellular spheroids. 
HEK293 cells were cultured in 96-well plate and incubated until single spheroids were formed. 
Spheroids were transduced with the non-targeted or targeted AAVP vectors carrying the 
Luciferase reporter gene premixed with various DEAE.DEX ratios. Luciferase expression was 
assessed at day 10 post transduction. b) GFP expression observed after AAVP/polymer 
complex treatment of multicellular spheroids. HEK293 were cultured in 96-well ULA plate in 
order to form spontaneous singular spheroids. Spheroids were treated with the optimised 
DEAE.DEX/AAVP complexes carrying GFP reporter gene and compared to controls, 
uncomplexed RGD4C.AAVP and non-targeted AAVP. GFP expression was analyzed at day 10 
post-transduction using a fluorescent microscope. Scale bars = 0.5 mm. 
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3.2.12. Stable expression derived from cells transduced with 
AAVP/polymer complexes 
Finally, we investigated whether transgene expression could be sustained if 
AAVP/polymer complex-transduced mammalian cells were maintained under 
selective pressure. Previous investigations demonstrated that including an 
expression cassette encoding a dominant-selectable marker in the AAVP vector 
allowed the selection of stably transduced cells.182,183  Results shown above 
demonstrated that the combination of both chemical and genetic modifications of 
AAVP vectors greatly enhanced gene delivery to mammalian cells. We therefore 
attempted to establish the utilization of our novel targeted AAVP/polymer system 
as a gene delivery vector for scientific research.  We aimed to determine the 
efficacy of transgene expression mediated by RGD4C.AAVP/polymer complex by 
using it for stable cell line production. The RGD4C.AAVP/polymer complex 
contains an expression cassette that allows selection of cells in the presence of the 
antibiotic puromycin. To rule out the possibility that our novel vector system is 
specific to a particular cell line we used MCF-7 and 9L cells in addition to 
HEK293 cells. Following determination of transient transduction efficiency, 
HEK293, MCF-7, and 9L cells were treated with the targeted RGD4C.AAVP 
carrying GFP premixed with optimized ratios of polymers and incubated in media 
supplemented with puromycin at 500 μg/ml for 14 days. Stably transduced cells 
were grown in colonies and the expression of GFP protein was visualised by a 
fluorescence microscope. Nearly all colonies were positive for GFP activity. As 
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shown in Figure 3.13, representative images of puromycin-resistant colonies of 
HEK293, MCF-7, and 9L cells expressing GFP arise from cultures transduced 
with the RGD4C.AAVP/polymer complexes.  GFP-positive and negative colonies 
were counted. 
 
Figure 3.13: Formation of stable clones derived from the AAVP/polymer complex-
transduced cells. HEK293, MCF7 and 9L cells were treated with RGD4C.AAVP vectors, 
carrying the puror gene and GFP reporter gene, premixed with optimised polymers. Stably 
transduced cells were selected using puromycin resistance and grown in colonies. Scale bars = 
100 µm. 
 
3.2.13. Stability of stable cell line formation 
Following cell transduction with the RGD4C.AAVP complexed with cationic 
polymers in the presence of puromycin for 14 days, GFP-expressing colonies were 
counted under the microscope with and without a GFP filter. The results obtained 
from three different cell lines indicated that the nature of the cells itself is a critical 
factor that determines the number of resistant clones obtained. 9L cells produced 
the highest number of puromycin-resistant colonies followed by HEK293 and 
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MCF-7, respectively (Figure 3.14). Out of five polymers tested, PDL, PEI, and 
DEAE.DEX resulted in the increased number of puromycin-resistant colonies in 
HEK293 cells (32±5,18±1, and 15±3 clones/well, respectively) compared to cells 
transduced with the RGD4C.AAVP alone that yielded a low number of resistant 
clones (3±1 clones/well), suggesting that transduction with particular polymers 
achieved higher efficiency than without a polymer. Unexpectedly, the addition of 
PB and PS inhibited the formation of resistant clones.  
To investigate the stability of GFP expression, resistant colonies were pooled and 
placed in media without antibiotics. All three pooled cell lines maintained GFP 
expression after culture for at least 20 passages in the absence of puromycin 
(Figure 3.15).  These results demonstrate the effectiveness of the AAVP/polymer 
vector system in the creation of functional stable cell lines. Taken together, these 
studies indicate that the AAVP/polymer vector system provides a powerful tool 
for efficient production of stable mammalian cell lines over currently established 
systems. 
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Figure 3.14: The effect of cationic polymers on the yield of puromycin-resistant colonies. 
Three different cell lines: HEK293, MCF-7, and 9L cells were transduced with the targeted 
RGD4C.AAVP alone or complexed with five different cationic polymers. Resistant colonies 
were counted after 14 days of selection with puromycin. Data represent the mean + SEM of 
triplicate samples from one representative experiments of three, significant difference; n.s.-not 
significant, * p<0.05, ** p<0.01, ***p<0.001 (one way ANOVA with tukey's post hoc test). 
 
 
Figure 3.15: Fluorescent images of GFP positive stable cell lines. After selection with 
puromycin for 14 days, resistant colonies were pooled and placed in media without antibiotics. 
All three stable cell lines maintained GFP expression after culture for at least 20 passages in the 
absence of puromycin. 
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3.3. Discussion 
Binding to the cell surface is the first element that determines viral tropism.184 This 
process is necessary for the internalisation of vectors since the transgene must be 
transported from the cell surface to the nucleus. The effectiveness of phage-
derived vectors for gene delivery to mammalian cells is limited partly due to the 
lack of binding to cells that do not express a receptor recognized by 
bacteriophages. In fact, phages have no intrinsic tropism for eukaryotic cells as 
they have evolved to infect bacteria only.185 In order to develop a phage-based 
vector, it is therefore necessary to introduce novel tropism. Previous investigations 
demonstrated that tropism for mammalian cells can be conferred on bacteriophage 
by fusing their coat proteins to a cell-targeting ligand, such as basic fibroblast 
growth factor (BGF2), transferrin, or epidermal growth factor (EGF). In this 
respect, phage-based vectors have been successfully adapted for targeted gene 
delivery to mammalian cells.178 Our group has also established an essential role of 
the RGD4C ligand, displayed on AAVP coat protein, for mammalian cell 
attachment and internalization.26,171 However, we found transduction saturation as 
a limitation of RGD4C.AAVP-mediated gene delivery to mammalian cells. The 
saturated transduction by these vectors could result, at least in part, from the 
limited number of available cell surface receptors that are targeted by the 
RGD4C.AAVP. It has also been suggested that higher amounts of the targeting 
compounds has to be administered than can be accommodated by the receptors to 
drive the binding interaction.186 This theory was supported by our results 
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demonstrating the low affinity of RGD4C.AAVP to cell surfaces as determined by 
a supernatant-depletion assay and fluorescence staining. A relatively high amount 
of RGD4C-AAVP is thus required to overcome the relative repulsion between 
cells and AAVP in order to achieve transduction.  The weak and reversible 
interaction between RGD ligands and integrin receptors187 is weakened due to 
inherent properties of the bacteriophage. The negatively-charged amino acid 
residues (Glu2, Asp4, and Asp5) of the major coat protein pVIII are responsible 
for an overall large negative charge on uncomplexed phage viral particles.188 
Consequently, phage particles are repelled to some extent by the negatively charged 
cell membranes of mammalian cells. Therefore, the ideal condition (infinite 
binding affinity) in which RGD4C.AAVP particles can bind the target cell equals 
the number of available integrin receptors is virtually impossible to achieve.  
The first aim of this study was to examine if tropism for mammalian cells can be 
conferred to AAVP by chemical modification in addition to genetic modification. 
By delivering AAVP vector in a CaPi coprecipitate or including cationic polymers 
in the complex, we were able to alter tropism for mammalian cell. We 
demonstrated the higher affinity of these chemically modified AAVP compared to 
conventional RGD4C.AAVP for the cell surface as determined by the cell binding 
assays, resulting in higher transduction efficacy according to reporter gene 
expression. This study produced results that are consistent with the findings of a 
number of previous reports in this field. It has been reported that combinations of 
adenovirus, retrovirus and AAV with cationic molecules improved transduction 
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efficiency due to enhanced cell attachment in some cell types that are recalcitrant 
to infection due to the lack of virus receptors.189-192 Moreover, transduction 
efficiency of these viral vectors was improved by coprecipitation with CaPi. These 
studies demonstrated that the virus-CaPi complex was efficaciously bound to 
cells.193-197 
Surface charge plays an important role in particles' interactions with charged 
phospholipid head groups or protein domains on cell membranes.198 In this study, 
we showed that the complexation of AAVP with cationic polymers generates 
positively charged AAVP complexes allowing better adsorption on cell-membrane 
surfaces. It is well known that cationic particles bind to negatively charged 
molecules on the cell membranes, in contrast to neutral and negatively charged 
particles that display low affinity of interactions.199   
Another important aspect of cationic polymers is their ability to increase cell 
membrane permeability. PDL, PEI, and DEAE.DEX induced the formation of 
transient, nanoscale holes in living cells allowing a greatly enhanced exchange of 
materials across the plasma membrane.200 Other groups also confirmed the pore 
formation in membranes by cationic particles.201,202  However, the size of 
AAVP/polymer complexes seemed to be relatively larger than the reported pore 
size which should not be able to assist the AAVP entry to cells. However, we 
believe that this phenomenon is associated with cytotoxicity observed at high 
concentrations of cationic polymers. It was suggested that uncontrolled cationic 
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density may compromise the plasma membrane’s integrity, leading to pore 
formation, membrane thinning and/or erosion and, subsequently, cytotoxicity.116 
The first interaction between a gene delivery vector and a cell is crucial to promote 
subsequent endocytosis. In general, endocytosis can be subcategorized into 
macropinocytosis and receptor-mediated endocytosis.203,204 The former is a major 
non-specific endocytotic process (also called adsorptive-mediated endocytosis) 
observed in macrophages, tumour and other growth factor or phorbol ester-
stimulated cells that engulf solute macromolecules.205 Receptor-mediated 
endocytosis is thought to be the major route for engulfment of targeted gene 
delivery vectors.203,206 This process can be characterized into two categories: 
caveolae-mediated and clathrin-mediated endocytosis, both of which are triggered 
by a specific interaction between ligands and receptors on the plasma 
membranes.204,206 Endocytosis occurs either by clathrin or caveolae depending on 
the cell type and/or type of molecules that are being engulfed.207 Previously, our 
group demonstrated that endocytosis of targeted RGD4C.AAVP is clathrin-
dependent via specific interaction between RGD4C ligands and αv integrin 
receptors. In contrast, positively charged AAVP/polymer complexes are thought 
to be endocytosed via adsorptive endocytosis.  Previous reports have demonstrated 
that non-specific engulfment is induced by electrostatic interactions between 
positively charged molecules and negatively charged plasma membrane.104,208 
Another interesting finding in this study was despite higher binding affinity of the 
chemically modified AAVP than the RGD4C.AAVP, there was no significant 
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difference in internalization. This suggests that additional benefits of chemical 
modification can possibly promote subsequent steps for AAVP-mediated gene 
delivery beyond internalisation. 
Although it is generally believed that the cell tropism for virus largely relies on the 
presence of their cell surface receptors and/or coreceptors, multiple-step 
intracellular events appear to be another potential factor for determining the 
transduction efficiency of virus.209 After delivery vectors are endocytosed, they are 
immediately transported into endocytic vesicles. Regardless of endocytosis 
pathways, all vesicles formed during internalization will fuse or at least interact 
with early endosomes.210 Delivery vectors trapped in endosomal compartments 
which become continuously acidified from neutral to pH6 are then trafficked to 
late endosomes where the pH drops to 5-6 through the action of ATP-dependent 
proton-pumps.206 Subsequently, late endosomes fuse with lysosomes, resulting in 
further pH reduction to 4 and exposure to digestive enzymes. Vectors that fail to 
escape these acidic compartments will be eventually degraded.206,207,211 Mammalian 
viruses are known for their efficacious ability to deliver nucleic acid into host cells, 
as they have evolved sophisticated endosomal escape mechanisms that take 
advantage of the acidic environment. Bacteriophages, however, have no such 
strategy because they have evolved to infect bacteria only. 
Our findings that higher transduction efficacies of AAVP coprecipitated with CaPi 
than RGD4C.AAVP (despite insignificant difference in cell internalization of 
AAVP particle) suggests an additional strategy that promotes gene transfer. A 
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possible mechanism for this may be explained by the increase of osmotic pressure 
through vector-CaPi complexes that promote endosomal escape. It is hypothesized 
that the degradation of CaPi by hydrolytic enzymes in an acidic environment 
results in release of Ca2+ and PO4
3-, which increases osmotic pressure via water 
uptake. Eventually, the endosome is disrupted, releasing vectors into the cytosol.212 
Furthermore, we observed higher transduction efficacy of AAVP complexed with 
cationic polymers than RGD4C.AAVP, although there was no difference in cell 
entry, suggesting an additional mechanism. The proton sponge phenomenon has 
been observed in certain cationic polymers with a high pH buffering capacity over 
a wide range of pH and proposed as a mechanism for endosomal escape of 
cationic molecules with proton sponge properties.213 During the maturation and 
acidification of endosomal compartments, cationic molecules will become 
protonated and continuously sequester protons supplied by the v-ATPase (proton 
pump). The proton pumping action leads to the retention of chloride ions, 
increasing osmotic pressure and hence water influx. Subsequent endosomal 
swelling and rupture cause the release of particles and their contents into the 
cytosol.111 
We tested this hypothesis by studying the acid-base titration curve of AAVP 
complexed with cationic polymers. High buffering capacity was observed in AAVP 
complexed with PEI and DEAE.DEX but not with PDL. We also carried out 
transductions in the presence of bafilomycin A1 which inhibit vector endosome 
eacape via proton sponge mechanism179,180 and observed a decreased transduction 
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efficiency of RGD4C complexed with PEI or DEAE.DEX but not with PDL. 
This also accords with earlier observations, which showed that strongly charged 
amino group-containing polymers, including PEI, achieved high transfection 
efficiency. In contrast, PDL failed to display desirable transfection efficiency as it 
does not possess buffering capacity.27,52,214 A previous study showed significant 
chloride ion accumulation, volume expansion and membrane lysis in the strongly 
buffering polyamines in PEI-containing endosomes, but not the ones with non-
buffering polylysine.215 These findings provide direct support for the proton 
sponge hypothesis and rationale for the design of AAVP/polymer complex as a 
gene delivery vector. However, over-controlled administration of cationic polymers 
results in cytotoxicity.  Lysosomal swelling and rupture not only releases the cargo 
to the cytosol, but also causes spillage of lysosomal content, triggering intracellular 
Ca2+ release. This enhances the permeability transition pores in mitochondria, 
leading to decreased ATP production and cellular apoptosis.216 
The most interesting finding was that a combined genetic and chemical 
modification of AAVP capsid further enhances gene transfer. The interaction of a 
virus with cell surface initiates a chain of dynamic events that enable virus entry 
into the cells. In simplest forms, the mammalian virus binds to a cell surface 
receptor and directly induces the subsequent endocytosis. For example, the SV40, a 
polyomavirus, binds the cell surface via major histocompatibility complex 1 
(MHC-1) that directly triggers endocytosis via caveolae pathway.217 However, 
several viruses have multiple attachments. For example, adenovirus utilizes the first 
P a g e  | 142 
 
high-affinity interaction between the globular knob of the C-terminal domain of 
the viral fibre protein and the cellular CAR, followed by the second low-affinity 
interaction between the RGD motif on the viral penton base and integrin 
receptors. Together they form a strong connection between the cell and the virus, 
leading to endocytosis.110 In this regard, the AAVP was genetically and chemically 
modified to exploit multiple attachments for mammalian cell tropism. The 
RGD4C.AAVP/polymer complex uses its positively charged capsid (higher affinity 
than the parental AAVP displaying RGD4C is hampered by electrostatic repulsion 
force) for attachment to negative charged cell surfaces, followed by internalization 
by αv integrins.  
In this study we expanded the utility of AAVP/polymer complex as gene transfer 
vectors for selection of cell lines that stably maintain expression of the reporter 
gene. The generation of stable cell lines has been exploited for a broad spectrum of 
applications, such as gene function study218, drug discovery assays or the 
production of recombinant proteins.219 In contrast to transient gene expression, 
stable expression usually depends on integration of gene of interest into the target 
cells genome or episomal maintenance in the nucleus, allowing long term, defined 
and reproducible expression of the gene of interest. Previous studies established 
the utilization of RGD4C.AAVP as gene delivery vector for the selection of stably-
transduced cells.182,183 The persistent transgene expression is associated with the 
presence of genetic cis-elements ITR from the animal virus AAV2, allowing the 
formation of monomeric or concatemeric extrachromosomes and a rare event of 
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chromosomal integration of the gene of interest.171,220 Two culture systems used for 
generating a stable cell lines include batch culture and limiting dilution. In a batch 
culture system, a mixed population of drug resistant cells is selected and directly 
used for experimental analysis with the advantage of generating fast results. To 
generate clonal cells, the resistant cells are diluted to isolate single clones. The so-
called limiting dilution allows for conduction for the study that requires a defined 
and homogeneous cell system. In this study we generated stable cell lines using the 
batch culture system as proof-of-concept. The RGD4C.AAVP/polymer vector 
system allows us to use pools of cells surviving selection, typically following 14 
days of culture. The high number of resistant clones with high percentage of 
positive clones saves considerable time and eliminates the need for screening a 
large number of colonies to identify positive clones. Taken together, these studies 
indicate that the RGD4C.AAVP/polymer complex is a powerful tool for efficient 
production and selection of stable transformants in mammalian cells. 
3.4. Conclusion 
Bacteriophage-based vectors suffer from low transduction efficiencies for 
mammalian cells, due to low viral binding to the cell surface or subsequent gene 
transfer steps. Integrating phage-based gene delivery with biomaterials is a 
promising strategy to overcome a number of these challenges associated with 
AAVP mediated gene delivery. Chemical modification of AAVP capsid can be 
employed to modulate the tropism of viruses or promote endosomal escape, both 
of which benefit transduction. Two efficient methods include CaPi coprecipitation 
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and complexation with cationic polymers. In the former method, AAVP particles, 
CaCl2, and a phosphate buffer are mixed; the AAVP-CaPi complexes, precipitate 
on the cells, then enter cells through endocytosis. The latter protocol is based upon 
the negative charge of AAVP particles and positively charged polymers leading to 
the formation of a complex that adheres to the cell surface, followed by 
endocytosis. This technique benefits from advantages such as simple and rapid 
preparation steps, low cost and reproducibility. Next, we demonstrated that 
combined genetic and chemical modification of AAVP further enhance gene 
delivery efficacy. In this system, polymer complexed-RGD4C.AAVP was most 
effective in gene delivery. However, cells show different sensitivities to the toxicity 
of these compounds. Therefore, proper ratios of transduction enhancing reagents: 
AAVP must be determined for each cell line. We also reported transient and stable 
transduction of mammalian cells via AAVP-mediated gene delivery. Our results 
represent an important step forward in the development of bacteriophages as gene 
delivery vehicles. 
 
 
 
 
 
 
 
P a g e  | 145 
 
4. A bacteriophage-based gene therapy vector for 
malignant glioma 
4.1. Introduction 
Over 20,000 malignant tumours of the CNS are diagnosed every year in the United 
States221 and 9000 in the United Kingdom.222 Of these cases, glioblastoma 
multiforme (GBM) is the most aggressive brain tumour with a dismal prognosis 
and extremely low percentage of survivors.223 Although the number of reported 
glioblastoma cases is small compared to other solid tumours, the survival rate 
remains low due to their aggressive nature. Despite advances in diagnosis and 
treatments consisting of surgical resection followed by radiotherapy and 
chemotherapy, the prognosis has been largely unchanged over the last 30 years.224 
The median survival time for patients is approximately 12 months after initial 
diagnosis. Only a small proportion of patients survive more than 36 months.225 For 
example, approximately 13,000 new patients are diagnosed with glioblastoma in the 
United States every year. Half of patients die within one year and 90% within 3 
years of diagnosis.221 These statistics highlight the urgency of developing effective 
therapeutic strategies against this devastating disease. Impact of surgery is often 
compromised due to the lack of a defined tumour edge in the brain tissue and the 
tendency for local invasion of the surrounding normal brain by infiltrating tumour 
cells, making complete eradication of the tumour by surgery virtually impossible.  
Additionally, it may also cause recurrence of glioblastoma either at original site or 
at distant satellite regions in the brain or CNS.226  Another major factor that 
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contributes to the dismal prognosis for patients with glioblastoma is the ineffective 
delivery of therapeutic agents to tumours.  
An additional problem is the tight junctions between ECs of CNS vessels, the so-
called blood brain barrier (BBB), which is considered a major impediment to 
systemic treatment of glioblastoma.227 To overcome this problem, researchers from 
the US National Institutes of Health (NIH) introduced a new delivery method, 
which relies on continuous infusion of molecules via intracranial catheters, known 
as convection-enhanced delivery (CED).228 This technique has emerged as a 
leading investigational delivery method for the treatment of brain tumours, 
allowing for delivery of high concentrations of therapeutic agents directly into 
brain tumours.229, Recently, Ksendzovsky et al demonstrated that this method can 
be exploited successfully and safely to distribute bacteriophage in the brain.230 
However, such injection protocols can be technically demanding, requiring 
extreme precision and accuracy to deliver therapeutic compounds as parenchyma-
invading tumour cells can be released even when using small-diameter catheters.231 
Moreover, local administration by direct injection of vector to a disease site can 
sometimes lead to undesired widespread distribution to normal tissues.34 The 
accuracy and targeting capacity of therapeutic payloads themselves or their delivery 
protocols can be significantly improved. It is therefore necessary to develop 
efficient and safe vectors capable of discriminating malignant from healthy cells. 
Due to the resistance of glioblastoma to conventional therapeutic approaches, it is 
important to investigate other options. Gene therapy is an alternative approach for 
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glioma treatment, and has been in development for the past two decades with a 
strong record of success in pre-clinical studies and an increasing number of models 
in clinical investigations.232 Several clinical behaviours and histopathological 
features of GBM make them particularly amenable to local gene therapy 233, 
defined as the direct transfer of therapeutic genes into tumour cells.234 In most 
cases, GBM are single, localized lesions of rapidly proliferating cells in a 
background of non-proliferating cells. Metastasis of glioblastoma outside the CNS 
is very rare, and if recurrence occurs, it happens in the close vicinity of the original 
lesion.233   
The experiments carried out in this chapter serves as an investigation of smart 
bacteriophage vector-mediated gene delivery to glioblastoma in two dimensional 
(2D) and three dimensional (3D) cell culture systems. The latter of more closely 
resembles in vivo tumour microenvironments and serves as a more clinically relevant 
model.  3D cell culture systems are currently used for earlier stages of drug 
screening to reduce the need for in vivo studies.235,236 Luc and GFP reporter genes 
were used for quantitative analysis and optical monitoring of gene expression. To 
assess therapeutic efficacy, the enzyme-prodrug suicide gene therapy system, 
HSVtk, was used to kill malignant cells. 
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Figure 4.1: Schematic diagram of the smart bacteriophage complex. We reported a novel 
hybrid multi-component vector designated as a smart bacteriophage complex that combines the 
advantages of three gene delivery vectors: the filamentous M13 bacteriophage, the genome of 
rAAV and cationic polymers. (a) Negatively charged RGD4C.AAVP vectors were 
electrostatically assembled with cationic polymers to form smart bacteriophage complexes. A 
diagram presents recombinant filamentous bacteriophage with genetically modified genome. (b) 
A proposed mechanism of the smart bacteriophage complex trafficking. Positively charged 
complexes bind to negatively charged cell membrane surfaces. Vectors are then internalized into 
cells following vector attachment and escape from endosome via a proton sponge effect 
mechanism. 
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4.2. Results 
4.2.1. Analysis of transgene expression mediated by the smart 
bacteriophage complex in glioblastoma cell lines 
We assessed the transduction efficiency of the smart bacteriophage complex  and 
compared it to the well-characterised RGD4C.AAVP. A schematic diagram of the 
smart bacteriophage complex and its proposed mechanism of trafficking were 
shown in Figure 4.1. Non-targeted NT.AAVP vector was included in these 
experiments as controls.  We performed these studies by transducing the 9L and 
C6 cells, both of which are rat glioma cell lines known to express high levels of the 
αv integrin receptors.
237,238 To rule out the possibility that the results are a cell type-
specific or species-specific, we further assessed efficacy on SNB-19 and LN229, 
which are human glioblastoma cell lines.239 We first sought to determine the 
optimal ratio of the cationic polymer to RGD4C.AAVP by keeping the latter fixed 
at 25 μg per well and adding increasing concentrations of cationic polymers using 
the RGD4C.AAVP vector carrying Luc reporter gene (See appendix A). 
Moreover, we assessed the suitability of different cationic polymers, namely PDL, 
DEAE.DEX, and PEI, which have previously been shown to dramatically enhance 
AAVP-mediated transduction in Chapter 3. Quantification of luciferase activity in 
4 different glioblastoma cell lines at 72 hr post transduction showed that maximum 
gene transfer levels were achieved with the DEAE.DEX polymer in 9L, C6, SNB-
19, and LN229 cells at polymer concentrations of 60, 120, 100, and 40 ng/μg, 
respectively. As shown in Figure 4.2a, treatment with optimal ratios of smart 
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bacteriophage RGD4C.AAVP-DEAE.DEX complexes resulted in ~10.3-, ~9.2-, 
~19.8-, and ~5.1-fold increase of Luc gene expression compared to 
RGD4C.AAVP alone in 9L, C6, SNB-19, and LN229 cells, respectively. Addition 
of PDL resulted in ~8.04-, ~2.7-, and ~2.5-fold increase of transduction efficacy 
in 9L, SNB-19, and LN229 at optimal ratio of 40, 80, and 20 ng/μg, respectively, 
but failed to enhance expression in C6 cells (Figure 4.2b).  At optimal ratios of 60 
and 20 ng/μg (PEI/AAVP) showed a ~9.13- and ~4.0-fold increase of Luc 
expression compared to non-complexed RGD4C.AAVP in SNB-19 and LN229 
cells, but failed to improve transgene expression in 9L and C6 (Figure 4.2c). 
Polybrene and protamine sulfate failed to enhance expression in all cell lines tested 
despite a broad range of polymer concentrations (Data not shown). The polymer-
complexed RGD4C.AAVP (i.e. RGD4C.AAVP-PDL and RGD4C.AAVP-
DEAE.DEX) was later designated as the smart bacteriophage complex. 
To further explore the superiority of the smart bacteriophage (RGD4C.AAVP-
PDL and RGD4C.AAVP-DEAE.DEX) complexes, we used RGD4C.AAVP 
vector carrying the GFP reporter gene. At day 5 post transduction, representative 
microscopic imaging of 9L and LN229 cells, as shown in Figures 4.3a and 4.3b, 
respectively, revealed a dramatic increase in GFP expression in cells transduced 
with the smart bacteriophage complex compared with the original RGD4C.AAVP. 
No GFP expression was observed in cells treated with the control NT.AAVP. 
These data confirm that integration of cationic polymers with the RGD4C.AAVP 
P a g e  | 151 
 
vector resulted in a smart bacteriophage complex that significantly boosted gene 
delivery to glioblastoma cells. 
 
 
 
 
 
Figure 4.2: Characterization of glioblastoma cell transduction by the polymer-complexed 
AAVP. Luciferase activity was analysed in 9L, C6, SNB19, and LN229 glioblastoma cells 3 days 
after treatment with NT.AAVP (uncomplexed or polymer-complexed) and RGD4C.AAVP 
(uncomplexed or polymer-complexed). a) DEAE.DEX/AAVP ratios of 60, 120, 100, and 40 
ng/µg for 9L, C6, SNB-19, and LN229, respectively. b) PDL/AAVP ratios of 40, 60, 60, and 20 
ng/µg for 9L, C6, SNB-19, and LN229, respectively. c) PEI/AAVP ratios of 60, 60, 60, and 20 
ng/µg for 9L, C6, SNB-19, and LN229, respectively.. The results show the mean relative 
luminescence units of triplicate wells ±SEM, from one representative of three independent 
experiments, significant difference; n.s.-not significant, * p<0.05, ** p<0.01, ***p<0.001 (tne 
way ANOVA with tukey's post hoc test). 
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Figure 4.2 (cont.): Characterization of glioblastoma cell transduction by the polymer-
complexed AAVP 
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Figure 4.3: GFP expression observed after complex treatment of glioblastoma cell lines 
with the smart bacteriophage. 9L (a) and LN229 (b) cells were cultured as monolayers and 
transduced with the smart bacteriophage complex; RGD4C.AAVP complexed with the 
optimised polymer/AAVP ratios (40 ng PDL/μg AAVP and 60 ng DEAE.DEX/μg AAVP). 
Uncomplexed RGD4C.AAVP and non-targeted AAVP (NT.AAVP) were used as controls. GFP 
expression was assessed using a fluorescent microscope at day5 post transduction. Scale bar = 
100 µm. 
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4.2.2. Kinetics of Luc gene expression following transduction of 
glioblastoma cells by a smart bacteriophage complex 
Having shown that PDL and DEAE.DEX boost gene expression by AAVP in 
glioblastoma cells, we sought to assess the effect of various concentrations of 
AAVP. Therefore, the RGD4C.AAVP vector was mixed with the two polymer 
formulations in optimal ratios previously identified and used to transduce 9L cells 
(Figure 4.4a). Quantification of luciferase gene expression indicated that smart 
bacteriophage complexes allowed higher levels of transduction at all 
RGD4C.AAVP doses tested. Thus, complexation of AAVP with cationic polymers 
requires lower AAVP concentration to achieve transduction levels similar to 
uncomplexed RGD4C.AAVP. For example, the level of transduction obtained 
with uncomplexed RGD4C.AAVP at a concentration of 350 μg/well, (i.e. 1x105 
RLU), can be achieved with a concentration of only 25 μg/well, if the 
RGD4C.AAVP is complexed with DEAE.DEX. Finally, the levels of transduction 
increased as the concentrations of smart bacteriophage augmented to reach 
plateau.  
Next we carried out a time course analysis the transduction efficacies of smart 
bacteriophage complexes in 9L cells over a period of 5 days. A considerable 
increase in expression of the Luc transgene was detected in 9L cells transduced 
with the smart bacteriophage complex i.e. RGD4C.AAVP-PDL and 
RGD4C.AAVP-DEAE.DEX., as shown in Figure 4.4b. Luc gene expression 
increased dramatically over time, while it remained low in cells transduced by 
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uncomplexed RGD4C.AAVP, and no Luc gene expression was detected in control 
NT.AAVP-transduced cells. 
 
 
 
Figure 4.4: Kinetics of Luc gene expression following transduction of glioblastoma cells. 
a) Effect of various RGD4C.AAVP vector concentrations used to form the complex while 
keeping the optimal ratio. Transductions were performed at fixed cationic polymers/AAVP 
ratios with RGD4C.AAVP complexed with PDL (40 ng polymer/μg AAVP) and DEAE.DEX 
(60 ng polymer/μg AAVP) and compared with side by side with uncomplex RGD4C.AAVP. At 
day 3, Luc expressions were quantified. b) Time course of Luc expression in smart bacteriophage 
complex-transduced cells. 9L cells were treated with the RGD4C.AAVP premixed with PDL or 
DEAE.DEX (RGD4C.AAVP-PDL and RGD4C.AAVP-DEAE.DEX, respectively), 
RGD4C.AAVP alone (RGD4C.AAVP), and non-targeted AAVP (NT.AAVP). The luciferase 
expression was monitored daily over a time course of 5 days following vector transduction. The 
results show the mean relative luminescence units of triplicate wells ±SEM, from one 
representative of three independent experiments. 
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4.2.3. Physical Characterization of the smart bacteriophage complex 
Having defined the optimal ratio that produced the maximal level of gene 
expression in 9L cells, we analyzed the zeta potential, size, and the appearance of 
the smart bacteriophage complex. The aim was to confirm that the positively 
charged smart bacteriophage complex increased gene transfer to glioblastoma 
mainly by aggregation and efficient binding of phage to the negatively charged cell 
membranes. We observed the zeta potential shifts from a negative value for 
uncomplexed RGD4C.AAVP, to a positive value for the smart bacteriophage 
complex following hybridization with PDL and DEAE.DEX (Figure 4.5a). These 
data proved the positive charge of the smart bacteriophage complex in contrast to 
the negatively charged surface of the uncomplex RGD4C.AAVP.  
Formation of the smart bacteriophage complexes was confirmed by the 
measurement of particle size. Size measurement of the smart bacteriophage 
complex in Figure 4.5a revealed that RGD4C.AAVP-PDL at optimal ratio of 40 
ng/µg (PDL/RGD4C.AAVP), has an average diameter of 7-fold greater than the 
uncomplexed RGD4C.AAVP. As shown in Figure 4.5b, size distributions of the 
smart bacteriophage complexes; RGD4C.AAVP-PDL and RGD4C.AAVP-
DEAE.DEX were in the range of 750-1125 and 750-2000 nm respectively. These 
data also suggest the self-assembly of the AAVP and the cationic polymers yields a 
monodisperse product.  
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Figure 4.5 Physical characterization of the smart bacteriophage complex. a) Effect of 
cationic polymer on RGD4C.AAVP particle size and ζ-potential. Average diameter and zeta 
potential of RGD4C.AAVP vector alone or complexed with PDL (left) or DEAE.DEX (right) 
at optimal ratio of polymer/AAVP (40 or 60 ng/μg, respectively). All values are reported as 
mean ± standard error, b) Size distribution of RGD4C.AAVP, RGD4C.AAVP-PDL (left) and 
RGD4C.AAVP-DEAE.DEX (right), c) Effect of polymer concentration on size of the smart 
bacteriophage complex. Immunofluorescence images of cells treated with RGD4C.AAVP alone 
(left) or RGD4C.AAVP-PDL formed at a PDL/AAVP ratio of 25 ng/μg (middle) and 50 ng/μg 
(right). Fixation was performed 4 hours post-transduction and immunofluorescence performed 
using anti-phage primary and goat anti-rabbit AlexaFluor-594 secondary antibodies. Scale bar = 
100 µm. 
 
 
 
 
 
P a g e  | 158 
 
Subsequent experiments were performed to determine whether the complex is 
dependent on the amount of polymer incorporated into the complex at several 
polymer/AAVP ratios. Fluorescence images support the size results obtained by a 
qNano analyser. RGD4C.AAVP alone (Figure 4.5c) was noticeably smaller than 
smart bacteriophage complexes (RGD4C.AAVP-PDL) formed at an PDL/AAVP 
ratio of 25 ng/μg and 50 ng/μg. Similar results were also obtained for 
DEAE.DEX (data not shown) 
4.2.4. Investigation of smart bacteriophage complex cell 
accessibility and entry 
Next cell membrane-phage vector interactions were characterized by a 
supernatant-depletion assay. As shown in Figure 4.6a, there was a significant 
depletion of AAVP in the supernatant (up to 94%) when cells were incubated with 
the smart bacteriophage complex i.e. RGD4C.AAVP-PDL and RGD4C.AAVP-
DEAE.DEX. In contrast, cells incubated with RGD4C.AAVP vectors had only 
10% depletion, showing that only a small fraction of uncomplexed vectors could 
reach the cell surface. No depletion was observed with the control NT.AAVP due 
to it’s the lack of targeting ligands. Recovered AAVP vectors from the supernatant 
were detected and counted as the formation of infected E.coli colonies on plates as 
shown in Figure 4.6b. The smart bacteriophage complex yielded much smaller 
number of colonies than the parental RGD4C.AAVP and the NT. AAVP. 
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Figure 4.6: Investigation of the smart bacteriophage complex extra/intracellular 
processing. a) The cell membrane-phage vector interaction was characterized using a 
supernatant-depletion assay. Unbound AAVP in the medium above an adherent cell layer were 
quantified by infection of host bacteria followed by colony counting. Data represent the mean + 
SEM of triplicate samples from one representative experiments of three, significant difference; 
n.s.-not significant, * p<0.05, ** p<0.01, ***p<0.001 (one way ANOVA with tukey's post hoc 
test). b) Representative images of recovered AAVP vectors detected by the formation of infected 
E.coli colonies on plates. c) Confocal fluorescent microscopy of 9L cells after treated with 
different vectors. Cells were first immunofluorescently stained for extracellular phages using anti-
fd phage primary and goat anti-rabbit AlexaFluor-594 (red arrows) secondary antibodies prior to 
permeablization and staining for intracellular particles using the same primary and goat anti-
rabbit AlexaFluor-647 secondary antibodies (green arrows). Scale bar = 10 µm. 
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Confocal microscopy also revealed that a large number of smart bacteriophage 
complexes can bind to cell surfaces, whereas a few AAVP particles were observed 
on cell surfaces incubated with RGD4C.AAVP. There were no phage on cells 
incubated with the NT.AAVP (Figure 4.6c), suggesting AAVP accumulation on 
the cell membranes, and its subsequent depletion from the supernatant. Altogether, 
these results suggest that in contrast to the low affinity of RGD4C.AAVP, smart 
bacteriophage complexes can efficiently bind to cell surfaces. Confocal analysis 
also revealed that complexes adsorbed on cellular membranes are taken into the 
cell as single particles, presumably by endocytosis (Figure 4.6c). 
4.2.5. Formation of a smart bacteriophage complex and its 
resistance to antibody neutralization 
To rule out the possibility that addition of cationic polymers simply reflects 
neutralization of negative charges on target cell surfaces, we pretreated 9L cells 
with cationic polymers before addition of RGD4C.AAVP. The resultant 
transduction efficacies were compared with those obtained from transduction with 
the preformed smart bacteriophage complex. As shown in Figure 4.7a, exposure 
of cells to cationic polymers before addition of RGD4C.AAVP resulted in 
significantly lower transduction efficiency compared to transduction with the 
preformed complex. Improved levels of transduction were achieved when 
RGD4C.AAVP was complexed directly with cationic polymers, before addition to 
the culture medium. The requirement for this preincubation step with cationic 
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polymers led us to speculate that active complex formation or aggregation events 
has to occur to produce smart bacteriophage complexes. 
To assess if the smart bacteriophage complex was protected to any extent from 
neutralising antibodies, antiserum raised against filamentous bacteriophage was 
added to the uncomplexed RGD4C.AAVP and the smart bacteriophage complex 
preparation before transduction. The effect on resultant transduction efficacies 
were noted. RGD4C.AAVP alone and the smart bacteriophage complex were 
preincubated with neutralizing anti-fd phage antiserum in a range of concentrations 
and used to transduce to 9L cells. At the same concentration of anti-phage 
antiserum, transduction efficiencies of smart bacteriophage complexes were clearly 
higher than those of the uncomplexed RGD4C.AAVP as shown in Figure 4.7b. 
This result provides evidence that the addition of cationic polymers to the surface 
of the AAVP renders it less susceptible to antibody neutralization in vitro. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P a g e  | 162 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Effect of polymer complex formation on AAVP-mediated gene delivery to 
glioblastoma cells. a) Effect of preincubating target cells with cationic polymers on 
transduction with RGD4C-AAVP. The vector (25 μg/well) was used to transduce 9L cultures 
that had received a 30-min pre-exposure with PDL or DEAE.DEX (black column). 
Transductions with RGD4C.AAVP complexed directly with PDL or DEAE.DEX at optimal 
ratios before addition to cells were also performed (red column). At day 3 Luc expressions were 
quantified. b) Effect of anti-phage neutralising serum on the enhancement of transduction seen 
with the smart bacteriophage complex. 9L cells were treated with uncomplexed RGD4C.AAVP 
or the smart bacteriophage complex in the presence of a range of dilutions. At 72 h cultures were 
analysed for Luc expression. Serum dilutions are shown below the columns. Data represent the 
mean + SEM of triplicate samples from one representative experiments of three, significant 
difference; n.s.-not significant, * p<0.05, ** p<0.01, ***p<0.001 (two way ANOVA with tukey's 
post hoc test). 
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4.2.6. The smart bacteriophage complex retains targeting and 
specificity of gene delivery to glioblastoma cells 
We sought to explore the targeting properties of the smart bacteriophage complex 
to confirm that transduction and cell internalization are specific and mediated by 
interaction between the RGD4C ligand and ɑv integrin receptors. Targeted gene 
delivery to 9L cells by smart bacteriophage complexes was compared to complexes 
which had been used as negative controls for targeting and contained either non-
targeted NT.AAVP or a mutant version of RGD4C (RGE4C, D---E).  As shown 
in Figure 4.8a, cell transduction efficiency by the polymer-complexed 
RGE4C.AAVP and polymer-complexed non-targeted.AAVP were not significant 
compared to that of the polymer-complexed RGD4C.AAVP.  
Next, we compared the transduction efficacy between the 9L tumour cells and the 
normal C2C12 myoblast mouse cell line using smart bacteriophage complexes 
prepared with increasing concentrations of either PDL or DEAE.DEX. The 
expected patterns of Luciferase gene expression were reproduced in 9L transduced 
with the smart bacteriophage complex (Figure 4.8b). Neither RGD4C.AAVP-
PDL nor RGD4C.AAVP-DEAE.DEX could transduce C2C12 cells despite 
numerous attempts using a wide range of polymer concentrations (Figure 4.8b). 
Finally, we confirmed that inability to transduce C2C12 cells is due to the lack of αv 
integrin receptors for the RGD4C ligand. In contrast to 9L cells, the C2C12 
myoblast cells lack expression of this integrin (Figure 4.8c). Taken together, these 
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findings confirm that gene delivery by the smart bacteriophage complex is targeted, 
specific and dependent on αv integrin receptors. 
 
Figure 4.8: Evaluation of the specificity of glioblastoma transduction by smart 
bacteriophage complexs. a) Comparison of transduction efficacies of complexes containing 
non-targeted AAVP, mutant RGE4C.AAVP or RGD4C.AAVP in 9L cells. Data represent the 
mean + SEM of triplicate samples from one representative experiments of three, significant 
difference; n.s.-not significant, * p<0.05, ** p<0.01, ***p<0.001 (one way ANOVA with tukey's 
post hoc test). b) Assessment of targeted gene transfer by smart bacteriophage complexes in the 
normal C2C12 myoblast cell line using a range of polymer concentrations c) Immunofluorescence 
staining of ɑv integrin receptors in 9L and C2C12 cells with anti-ɑv integrin primary and 
AlexasFluor488 secondary antibodies. Scale bar = 100 µm. 
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4.2.7. Enhancement of the HSVtk/GCV - mediated cell death by 
the smart bacteriophage complex 
To assess the tumour-killing efficacy of smart bacteriophage complexes, we used 
an RGD4C.AAVP vector carrying the HSVtk gene. We compared the 
uncomplexed RGD4C.AAVP vector with the smart bacteriophage complex. 
HSVtk suicide gene therapy was induced at day 3 post-transduction by treatment 
with GCV for 5 days. After 3 days post GCV treatment, morphological 
characteristics of 9L cells were visualized with a bright field microscope. Ethidium 
homodimer-1 was used to stain dead cells visualized by a fluorescence microscope. 
Nucleic acids of membrane-compromised cells were labelled with ethidium 
homodimer-1 yielding red fluorescence.  Figure 4.9a shows normal morphology 
of confluent cells with a small number of dead cells in cells treated with non-
targeted NT.AAVP  in the presence of GCV. There was a dramatic increase in the 
number of dead cells by the smart bacteriophage complex compared to the 
uncomplexed RGD4C.AAVP. At day 5, cell viability was determined as shown in 
Figure 4.9b. GCV induced 70% cell death in cells transduced with the 
uncomplexed RGD4C.AAVP, and completely eradicated cells transduced with the 
smart bacteriophage complexes. No cell death was observed in NT.AAVP-
transduced cells in the presence of GCV or in any treatment in the absence of 
GCV. These results demonstrate that smart bacteriophage complex has acquired 
an enhanced anti-tumour effect. 
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Figure 4.9: HSVtk/ganciclovir (GCV)-mediated cell death by smart bacteriophage 
complex. a) Following HSVtk/GCV therapy, morphological characteristics of 9L cells were 
visualized under the microscope. Cells were also stained with the reagents in the LIVE/DEAD® 
Cell Viability/Cytotoxicity Assay Kit and visualized under the fluorescence microscope. Dead 
cells fluoresce red-orange. Scale bar = 100 µm. b) Evaluation of tumor cell killing by the smart 
bacteriophage complex, RGD4C.AAVP, and the non-targeted AAVP in 9L cells in the absence 
or presence of GCV. Cell viability was determined by the CellTiter-Glo® cell viability assay. 
Mean cell viability was normalised to non-treated controls, with the mean of n=3 independent 
experiments shown (+ SEM). Statistical analysis was performed using two way ANOVA with 
tukey's post hoc test, n.s.-not significant, * p<0.05, ** p<0.01, ***p<0.001. 
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4.2.8. Efficacy of smart bacteriophage complexes in a 3D 
multicellular glioblastoma tumour spheroids 
In vitro tissue spheroids were employed to simulate 3D tumours. 3D spheroids are 
considered valid models to mimic features of in vivo tumour environments 
including avascular, hypoxic regions, and micrometastases.240,241 Many tumours are 
solid and inhibit the ability of therapeutic agents to penetrate central regions.242,243 
The in vitro 3D tumour spheroid model was therefore established in this study to 
imitate the avascular regions and to evaluate and confirm the efficacy of gene 
transfer by smart bacteriophage complexes. We first assessed transduction 
efficacies by using AAVP carrying the GFP reporter gene and monitored GFP 
expression within the spheroids. Spheroids were incubated with the smart 
bacteriophage complex and compared to uncomplexed RGD4C.AAVP and 
NT.AAVP. While the original RGD4C.AAVP and non-targeted AAVP showed 
minimal or no GFP expression, respectively in the spheroids at day 15 post 
transduction, treatment with smart bacteriophage complexes yielded dramatic 
increase of GFP expression (Figure 4.10). In 9L spheroids (Figure 4.10a), PDL 
polymer was the most efficient polymer, whereas in LN229 spheroids (Figure 
4.10b), DEAE.DEX showed greater GFP expression. These data also show that 
the 3D spheroid models can overcome the limitation of cell confluency in 2D 
monolayers and allow monitoring of gene expression over a longer time period 
post vector transduction. 
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Next, application of HSVtk/GCV suicide gene therapy in the 3D model of 9L 
tumour cells resulted in pronounced regression of the 9L spheroid volumes by 
smart bacteriophage complexes, upon GCV treatment, compared to the 
uncomplexed RGD4C.AAVP (Figure 4.11a). Subsequently, measurement of cell 
viability in the spheroids showed that smart bacteriophage complexes achieved 
higher tumour killing, 98% for RGD4C.AAVP-PDL and 91% RGD4C.AAVP-
DEAE.DEX, than the uncomplexed RGD4C.AAVP that induced 67% cancer cell 
killing (Figure 4.11b, c). These findings clearly confirm that gene delivery 
efficacies of smart bacteriophage complexes are superior to the established 
RGD4C.AAVP. 
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Figure 4.10: Transduction of 3D tumour spheroids by the smart bacteriophage complex. 
The spheroids were treated with smart bacteriophage complexes (i.e. RGD4C.AAVP-PDL and 
RGD4C.AAVP-DEAE.DEX) or uncomplexed RGD4C.AAVP and control non-targeted AAVP 
carrying the GFP reporter gene. Representative images showing GFP expression in the spheroids 
were taken at day 15 post transduction. a) 9L b) LN229 cells-derived spheroids. Scale bar = 0.5 
mm. 
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Figure 4.11: Therapeutic efficacy of the smart bacteriophage complex in 9L tumour 
spheroid models. a) Measurement of the spheroid volumes following transduction with non-
targeted AAVP, RGD4C.AAVP or the smart bacteriophage complex carrying the HSVtk gene. 
GCV was added daily and images were taken at day 5 following addition of GCV. b) Evaluation 
of cell viability in the spheroids at day 7 post GCV treatment, by using the CellTiter-Glo® cell 
viability assay. Data represent the mean + SEM of triplicate samples from one representative 
experiments of three, significant difference; n.s.-not significant, * p<0.05, ** p<0.01, ***p<0.001 
(one way or two way ANOVA with tukey's post hoc test).c) Phase contrast images showing the 
size of the spheroids. Scale bar = 0.5 mm. 
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4.3. Discussion 
Advances in gene transfer technologies have had major impacts within the field of 
cancer gene therapy. In 2006, Hajitou et al. developed a hybrid prokaryotic-
eukaryotic vector, which is a combination between the filamentous bacteriophage 
and AAV designated as AAVP.244 Incorporation of ITRs from AAV in the single 
stranded genome of bacteriophage is associated with improved fate of delivered 
transgenes i.e. the conversion of single stranded DNA to double stranded DNA, 
better persistence of episomes and concatamers, resulting in subsequent enhanced 
gene delivery efficacy over conventional phage-based vectors.244 The 
RGD4C.AAVP vector was originally developed for anti-cancer gene therapy. It has 
been assessed and showed promising results in a range of animal models of cancer, 
including mice, rat, and pet dogs with natural tumours.245 Despite promising results 
in these studies, the transduction efficacy of RGD4C.AAVP vector is still poor. 
Indeed such genetic improvement is actually one last step of a series of steps 
involved in gene delivery processes. Therefore, the attachment, entry, and 
intracellular trafficking of the vector remain barriers that AAVP vector has to 
overcome.  
In the previous chapter, we demonstrated that the low affinity between AAVP 
vectors and cell surfaces is a limitation of cell accessibility. Stoneham et al. 
previously identified the endosomal-lysosomal pathway as another barrier to 
efficient gene delivery and demonstrated that disturbing this partway is a promising 
strategy for improving gene transfer by AAVP.246 In order to obtain the ideal gene 
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delivery vector system capable of overcoming these barriers, we combined the 
attributes of different types of vectors and therefore introduced the novel hybrid 
multi-component vector designated as the smart bacteriophage complex. 
Specifically, we combined the advantages of three gene delivery vectors: the 
filamentous M13 bacteriophage, the genome of a recombinant AAV and cationic 
polymers. In this novel gene delivery platform, i) the phage particle serves as a 
vehicle displaying targeting peptides on its capsid to maintain vector specificity, ii) 
the rAAV cassette allows amplification and long-term expression of the transgene, 
and iii) cationic polymers create positively charged AAVP particles resulting in 
enhanced attachment to negatively charged eukaryotic cell surfaces.  Additionally 
we yielded evidence that endosomal escape of smart bacteriophage complexes 
occur via a proton sponge mechanism.  
The limitations of chemotherapy in systemic glioblastoma treatment, referred to as 
chemoresistance, may be partially due to the presence of BBB that acts as a 
physical and biochemical barrier. Thus, it hinders the transport of conventional 
systemic drugs into the CNS.247 One of the most widely used chemotherapeutic 
drugs to treat glioblastoma is TMZ. Although TMZ in combination with 
radiotherapy and surgery improves the overall survival in patients with 
glioblastoma,  the prognosis of patients remains poor, with a median survival of 
about one year after diagnosis.248 In addition, the presence of subpopulations of 
tumour cells with stem cell-like properties is another factor underlying  
glioblastoma chemoresistance.249 Glioblastoma is therefore considered to be fatal 
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and incurable by conventional therapies250, and has attracted considerable attention 
as a target for gene therapy.251 We sought to use this novel vector system for 
glioblastoma gene therapy. 
In contrast to cancers in other parts of the body, glioblastoma is an attractive target 
for local gene therapy because of its restricted anatomical location and absence of 
metastases outside the CNS. This allows delivery of vectors directly to the desired 
site with only a small risk of systemic toxicity.233 Although these methods have 
yielded promising results in preclinical studies and satisfied safety profiles in phase 
I/II clinical trials252, only a handful are currently being investigated in phase III 
clinical trials231. One of many barriers limiting the use of gene therapy in clinical 
trials includes unique anatomical barriers of the CNS that limit the spatial 
distribution of the therapeutic payload. Despite direct delivery, the gene transfer 
efficacy to glioblastoma with currently available gene delivery vectors remains 
poor, partly due to the low expression of cognate receptors for viral vectors that 
enable the efficient internalization. For example, the poor expression of the CAR 
receptor on primary glioblastoma limits Adenovirus5-based gene therapy.253 
Previous investigations found that αvβ3 and αvβ5 are expressed on glioma cells 
and vasculature.254 The RGD motif is an essential binding motif for αv integrin 
receptors255, thus making it a promising ligand for glioblastoma targeting.256 We 
previously reported the therapeutic feasibility of αv integrin-mediated glioblastoma 
treatment, as well as the potential of using RGD4C.AAVP as a targeted gene 
carrier in the treatment of glioblastoma.237 In the present work, we designed smart 
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bacteriophage vectors by complexing RGD4C.AAVP with cationic polymers. This 
complex had high binding affinities with glioblastoma cell lines tested, facilitating 
highly efficacious targeted gene delivery against glioblastoma compared to the 
previously reported RGD4C.AAVP vector.  
We examined gene delivery efficacy of smart bacteriophage complexes and used 
four glioblastoma cell lines to demonstrate that our findings are not specific to a 
particular cell line. Our results clearly indicate that the transduction efficacy of 
smart bacteriophage complexes were significantly higher than the uncomplexed 
RGD4C.AAVP vector. However, different polymers have different efficacies 
despite producing similar trends. For example, a higher transduction efficiency of a 
particular polymer in a cell line was found to be lower in a different cell line. We 
also noticed that DEAE.DEX retained higher specificity than PDL. It is important 
that optimization is required in order to maximize the therapeutic efficacy. 
Furthermore, we have demonstrated the efficacy of smart bacteriophage 
complexes in a novel in vitro environment that mimics in vivo tumour 
microenvironments. The 3D spheroids have gained increased attention in cancer 
research as an in vitro model to reduce the need for in vivo studies. Several methods 
have been used to produce multicellular spheroids, for example hanging drop, 
liquid overlay on agar, and rotary culture system.257 Our studies, we used a 96-well 
ULA plate to generate single spheroids of similar size with high reproducibility 
across different experiments.236 We have shown that the smart bacteriophage 
complex is able to transduce glioblastoma spheroids with higher efficacy than the 
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conventional RGD4C.AAVP. The transduction efficacy of RGD4C.AAVP vector 
is markedly reduced when transgene expression of 3D spheroids were compared to 
2D monolayers. Tumour spheroids more closely resemble in vivo tumour 
microenvironments in terms of gene expression profiles, cell-cell interactions, 
concentration gradients, hypoxic regions, and extracellular matrix 
deposition.236,240,258,259 A possible factor that may contribute to lower activity is that 
penetration into the solid structure of spheroids was a limitation to RGD4C.AAVP 
particles. Previous studies have highlighted major differences and outcomes of 
using 2D and 3D culture models, showing that 3D cultures are more resistant to 
drug treatments compared to conventional 2D cultures. This reflects the 
importance of drug screening and testing in clinically relevant in vitro models.235 
The presence of a BBB would potentially limit the delivery of the smart 
bacteriophage complex as well as other macromolecules. In future investigations, 
the use of CED is suggested to be a delivery method of choice for evaluating the in 
vivo efficacy of smart bacteriophage complexes to treat glioblastoma. Previous 
investigations of CED have demonstrated that a wide range of therapeutic 
substances can be delivered and distribution to the target site.  This includes 
conventional chemotherapeutic drugs260-262, monoclonal antibodies263,264, targeted 
toxins265-267, proteins268, viruses269,270, nanocarriers271-274, and filamentous 
bacteriophage.230 However, injection protocols can be technically demanding, 
requiring high precision and accuracy to deliver the therapeutic compounds231 
Moreover, local administration by direct injection of vector to a diseased site  can 
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sometimes lead to undesired, distribution to other tissues.34 The accuracy and 
targeting capacity of the therapeutic payloads themselves or their delivery protocols 
can be significantly improved. In this study, we confirmed that transduction of 
glioblastoma cells by the smart bacteriophage complexes remains specific and 
occurs through binding of the RGD4C ligand to the ɑv integrin receptors 
overexpressed on glioblastoma cells. In addition, localized delivery of smart 
bacteriophage complexes to glioblastoma cells can maintain elevated AAVP 
concentrations in the tumour environment through efficient binding to cells. As a 
result, unwanted distribution to distant tissues can be avoided. 
Gene therapy for glioblastoma treatment using different gene transfer vectors 
combined with different strategies has been investigated as an alternative approach 
to conventional chemotherapy. Retroviral and adenoviral vectors have been most 
popular for the delivery of therapeutic genes into glioblastoma.223 However, 
alternative vehicles such as stem cells, nanoparticles and liposome, have also been 
extensively developed, with some having reached clinical testing stages.251 Several 
strategies include pro-drug activation/suicide gene therapy, anti-angiogenic gene 
therapy, correction of gene defects, induction of apoptosis, inhibition of tumour 
invasion, oncolytic virotherapy, antisense and RNAi-based approaches and gene 
therapy to enhance chemo- and radiotherapy.251  
The enzyme-prodrug suicide gene therapy system is the most commonly used 
approach against glioblastoma in preclinical studies as well as in clinical trials.231 In 
this respect, the cytotoxic suicide gene ‘HSVtk’ is the most extensively investigated 
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suicide gene therapy system against glioblastoma.231 As proof of concept, 
application of the smart bacteriophage vector carrying HSVtk resulted in 
eradication of glioblastoma upon ganciclovir treatment, which was significantly 
more efficacious than the established RGD4C.AAVP vector system. HSVtk 
converts the inactive prodrug GCV into a toxic GCV-triphosphate that is 
subsequently incorporated into the DNA of actively proliferating cells, blocking 
DNA replication.232 One advantage of this system is the induction of a ‘bystander 
effect’, which can be observed when there is a transfer of toxic metabolic products 
of GCV from the originally transduced cells to non-transduced tumour cells at 
nearby sites through intercellular gap junctions.275 We also observed this 
phenomenon, despite a small fraction of transduced cells expressing GFP, 
complete tumour eradication occurred when tumour cells were transduced with the 
smart bacteriophage complex carrying HSVtk in combination with GCV 
treatment, indicating the potency of the bystander effect. The spread of 
cytotoxicity has been shown to be dependent on connexin-mediated intercellular 
communication.276-278 Phagocytosis of dead tumour cell-derived apoptotic vesicles 
by live tumour cells cause them to undergo apoptosis as well.279 In addition, the 
immune system also contributed to the bystander effect, resulting in significant 
tumour regression in vivo.280-283 It has been shown that significant therapeutic 
efficacies have been observed in a xenograft glioma model when approximately 
10% of tumour cells are transduced with HSVtk.284,285 
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Another major hurdle for successful clinical gene therapy for glioblastoma is the 
immune response elicited by viral vectors.231 Host immune responses have been 
implicated as a major problem in clinical trials.286,287 A number of extensively used 
viral vectors are based on mammalian viruses and natural exposure of mammals to 
parental viruses has led to pre-existing immunity against the recombinant vectors. 
A number of strategies currently under investigation to protect the vector from 
neutralizing antibodies and to potentially mitigate immune responses against the 
vector to allow repeated administration. A promising strategy for overcoming this 
hurdle is to use polymers to shield viral vectors from components of the host 
immune system, potentially reducing inflammatory and immune responses.34 For 
example, Adenoviral vectors were chemically modified with polymers to reduce 
immune response. Polymer-modified Ad vectors can evade pre-existing anti-Ad 
antibodies, allow for repeated administration of vector.288 Although no severe 
immune responses or any safety concerns have been reported when bacteriophages 
were administered to human for treatment of bacterial infection17,289,290, there is the 
evidence for the immunogenicity of bacteriophage in animal studies. Induction of 
anti-phage antibody response was observed in mice after single administration of 
filamentous bacteriophage.291-293 Three mouse monoclonal antibodies recognize 
epitopes of major coat protein pVIII of filamentous phage.294 A polyclonal rabbit 
antiserum was also shown to bind to the N-terminal region of the pVIII coat 
protein.295 In this study, the smart bacteriophage complex proved to be more 
resistant to the neutralizing antibody compared to the naked RGD4C.AAVP. This 
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suggests that polymer-mediated modification of the AAVP surface potentially 
addresses the immunogenicity problem by masking AAVP particles from immune 
components. 
4.4. Conclusion 
The novel hybrid multi-component vector termed the smart bacteriophage was 
generated by complexing cationic polymers with the AAVP vector displaying the 
RGD4C ligand and carrying an AAV ITR-flanked mammalian DNA cassette. We 
tested if the smart bacteriophage complex was applicable to glioblastoma gene 
therapy. A study of the expression of reporter genes, as well as the assessment of 
therapeutic efficacy using the HSVtk/GCV system clearly indicated that the smart 
bacteriophage complexes were superior to the established RGD4C.AAVP vector. 
The original RGD4C.AAVP vector was developed for cancer gene therapy and has 
shown promising results as assessed in a number of animal models of cancer 
including mice, rats and pet dogs with natural tumours. Another important 
attribute of the smart bacteriophage complex is its ability to resist neutralization by 
antibodies, which potentially should allow it to achieve efficacy with repeated 
vector administrations. We conclude that the innovative combination of different 
types of vectors into a single particle provides significant extension to the 
development of novel gene delivery platforms, which can be used as tool for 
glioblastoma gene therapy. 
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5. Controlled Extracellular Matrix Degradation in Cancer 
Improves the effectiveness of gene delivery by AAVP 
5.1. Introduction 
Fundamental differences existing between malignant and normal cells have 
encouraged the specific design of gene delivery vectors capable of efficiently 
targeting cancer cells to improve gene delivery efficiency.186 The higher than 
normal expressions of tumour-specific markers on cancer cell membranes can be 
used as docking sites to concentrate therapeutic agents at tumours. Engineering 
bacteriophage to actively target specific receptors has improved specificity, yet it 
remains a challenge to increase the efficacy.24 The RGD4C-displaying hybrid 
vector AAVP targeted to αv integrins, which are overexpressed in cancer cells and 
cancer-associated endothelial cells, have been successfully used for delivering 
therapeutic/imaging genes selectively to tumours.171-174  
An important factor to consider in cell targeting is the accessibility of the receptors 
that are targeted by the probe.186  In fact, the extracellular obstacles make up the 
first-line bottle neck which the vector has to confront before reaching its receptor. 
Extracellular matrix (ECM), composed of fibrous proteins (collagen, elastin, 
fibronectin and laminin) and glycosaminoglycans (GAGs) such as hyaluronan, is 
secreted locally and assembled into a network in close association with the 
membrane of the cell that produced them. A complex network structure of ECM, 
represents a major barrier for the delivery of therapeutic agents.296 We 
hypothesized that ECM molecules occupy the binding sites of the AAVPs and 
P a g e  | 181 
 
create another barrier for gene delivery. We therefore propose to enhance 
accessibility of receptors through ECM clearance by using enzymes to degrade the 
hindering molecules.  
In addition, unique structural properties of solid tumours compared with healthy 
tissues restrict transport and distribution of therapeutic compound throughout 
malignant tissues. Following the tumour accumulation of the therapeutic agents 
facilitated by the well-known enhanced permeability and retention (EPR) effect 
found in the abnormal tumour vasculature297, the ability to subsequently diffuse 
into the individual cancer cells remains a significant challenge. In solid tumours, 
there is a huge increase in ECM components which creates fibrosis and often 
encapsulates the tumour in a shell of structural fibres consisting of a structural 
collagen network embedded in a gel of glycosaminoglycans.296 The ECM 
composition, structure, and distribution play a crucial role in the transport 
properties in tumours.298 We hypothesized that in addition to physical masking of 
receptors, ECM in solid tumours affects the effectiveness of AAVP-mediated gene 
delivery through blocking diffusion of AAVP vectors to malignant cells. 
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5.2. Results 
5.2.1. Optimizing collagenase and hyaluronidase concentrations 
We first compared the effect of collagenase and hyaluronidase on the transduction 
efficiency of AAVP. To rule out the possibility that these effects might be cell line 
or species specific, we conducted experiments on the 9L rat glioma, the human 
M21melanoma and the human MCF-7 breast adenocarcinoma cell lines. 
Transduction efficiencies as a function of collagenase or hyaluronidase 
concentration (Figure 5.1a and 5.1b, respectively) were studied by using AAVP 
vectors carrying the Luc reporter gene. Luciferase activity was quantified after 72 
hours by using a luciferase assay kit. Results showed that pretreatment of 9L cells 
with 0.2 mg/ml of collagenase and 0.4 mg/ml of hyaluronidase greatly increased 
luciferase transgene expression, with maximal 3- and 2-fold increases, respectively 
(Figure 5.1a, b). Collagenase also increased the luciferase gene expression in M21 
and MCF-7, with maximal increase (2.2- and 7.4-fold, respectively) at 0.3 mg/ml, 
whereas hyaluronidase had no effect (Figure 5.1a, b). It is also important to note 
that ECM depletion did not affect the cell specificity of RGD4C.AAVP as the 
non-targeted NT.AAVP remained unable to transduce cells despite a range of 
enzyme concentrations used. 
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Figure 5.1: Characterization of ECM depletion effects in 9L, M21, and MCF-7 cell lines. 
Cells were pretreated with a range of a) collagenase and b) hyaluronidase concentrations for 1 hr 
followed by AAVP transduction in order to determine the maximal level of transgene 
expression. Luciferase activity was quantified by Steady-Glo® luciferase assay kit at 72 hr post 
transduction. The results show the mean relative luminescence units of triplicate wells ±SEM, 
from one representative of three independent experiments. Statistical analysis was performed 
using two way ANOVA with tukey's post hoc test, n.s.-not significant, * p<0.05, ** p<0.01, 
***p<0.001. 
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5.2.2. Effect of collagenase treatment on collagen content 
The above results indicate that degradation of the structural collagen network is 
more important than degradation of hyaluronan in order to improve the gene 
delivery by AAVP. Consequently, we set out to measure the collagen content in 
cells before and after enzymatic treatment with collagenase. A Sirius Red assay was 
carried out to measure the levels of collagen type I remaining on the cells before 
and after enzyme treatment as well as the levels of collagen I released into the 
media resulting from collagenase treatment. We found that the cellular collagen of 
9L, M21, and MCF-7 was significantly reduced by 50-80% after application of 
collagenase, and subsequently released into the cell media (Figure 5.2a-c). These 
findings thus confirm that enzymatic depletion of ECM can be used to modulate 
the cellular microenvironment. 
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Figure 5.2: Collagen depletion assay in cancer cells using Sirius Red dye as a detector. 
Cells were incubated with 0.2 mg/ml collagenase for 1 hour and controls had no intervention 
.Collagen levels remaining on the cells or released into the supernatant fraction were quantified. 
Each condition was measured in triplicate and statistics were obtained by unpaired student t-test, 
***, p<0.001. Data were presented as mean ± SEM. a) 9L b) M21 and c) MCF-7 cells. 
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5.2.3. Enzymatic degradation of ECM significantly increases AAVP 
transduction efficiency and demonstrates transgene 
expression in a time dependent manner 
Having proven that ECM degradation is effective across multiple species and cell 
lines, we carried out further experiments focusing on the 9L glioblastoma model as 
both collagenase and hyaluronidase were effective to enhance the transduction 
rate. We next determined if a combination application of both enzymes would 
result in an even higher transduction efficiency compared to that of each enzyme 
alone. Using either collagenase or hyaluronidase alone resulted in luciferase 
expression levels of ~2.7- and 2.6-fold increase higher than without any enzymatic 
treatment, respectively (Figure 5.3a). Interestingly, combination treatment with 
both enzymes gave a further significant increase of up to 5-fold of RGD4C.AAVP 
when compared to transduction in the absence of ECM depletion (Figure 5.3a).  
Next we monitored gene expression daily over the course of 5 days post 
transduction by sequential luciferase assays in order to determine whether such 
improvements in gene delivery by AAVP upon ECM depletion occur over time 
(Figure 5.3b). Although luciferase expression in all groups continued increasing 
over time, there was a significant difference in transgene expression between the 
control RGD4C.AAVP alone and the combination enzyme treatment (Figure 
5.3b). These results demonstrate that ECM depletion can result in a long-lasting 
enhanced gene expression from RGD4C.AAVP vector. 
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As shown in Figure 5.3c, fluorescence microscopic analysis of transgene 
expression 72 hours post transduction using RGD4C.AAVP vector carrying the 
GFP reporter gene supported the results obtained from the luciferase assay. 
Comparing collagenase or hyaluronidase alone caused a gain in GFP expression 
that was higher than transduction without any enzyme treatment and the 
combination treatment with both enzymes further enhanced transgene expression 
(Figure 5.3b). 
Taken together, these results confirm that depletion of the ECM through 
enzymatic degradation by collagenase or hyaluronidase enhances transgene 
expression from RGD4C.AAVP and combination treatment with both enzymes 
further increases AAVP gene delivery efficacy. 
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Figure 5.3: ECM depletion enhances targeted RGD4C.AAVP transduction efficacy. a) 
luciferase gene expression at day 3 post transduction in 9L cells after treatment with different 
enzymes in combination with non-targeted (NT.AAVP) or targeted AAVP (RGD4C.AAVP). 
The results show the mean relative luminescence units of triplicate wells +SEM, from one 
representative of three independent experiments, significant difference; n.s.-not significant, * 
p<0.05, ** p<0.01, ***p<0.001 (one way ANOVA with tukey's post hoc test). b) Time course 
luciferase gene expression over 5 days with targeted RGD4C.AAVP alone or following treatment 
with collagenase alone (0.2 mg/ml), with hyaluronidase alone (0.4 mg/ml) or with combination 
of both collagenase and hyaluronidase. Similar enzymatic treatments were included with the 
control non-targeted AAVP (NT.AAVP) vector. The results show the mean relative 
luminescence units of triplicate wells ±SEM, from one representative of three independent 
experiments c) GFP expression in 9L cells under different enzymatic regimes. Images were 
visualized by fluorescence microscopy 3 days post vector transduction. (0.2 mg/ml collagenase 
and/or 0.4 mg/ml hyaluronidase). Scale bar = 100 µm. 
 
P a g e  | 189 
 
 
 
5.2.4. Removal of ECM promotes AAVP internalization into cells 
To demonstrate the feasibility of our hypothesis that ECM molecules occupy the 
binding sites of the RGD4C.AAVP vectors and therefore ECM clearance could 
enhance accessibility of the receptors, leading to increased binding and subsequent 
cell uptake, we set out to determine whether there was increased cell internalization 
after pretreatment of 9L cell cultures with collagenase and hyaluronidase. An 
AAVP internalization assay was carried out by which the AAVP cellular load was 
determined by intracellular phage immunochemistry followed by flow cytometry 
quantification of the signal. The results showed that there was a considerable 
increase in AAVP internalization following ECM depletion over treatment with 
RGD4C.AAVP alone in the absence of enzyme treatment. Removal of collagen 
and hyaluronan allowed up to 37% increase in AAVP endocytosis (Figure 5.4a), 
manifesting as higher intracellular AAVP signal as well as enhanced AAVP signal 
counts/10,000 cells (Figure 5.4b). These results therefore cement proof of ECM 
as a physical barrier to efficient RGD4C.AAVP entry into mammalian cells. 
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Figure 5.4: Cellular internalization of AAVP is boosted by ECM clearance. a) Flow 
cytometric analysis of AAVP uptake was carried out in 9L cells after ECM depletion. Cells were 
treated either with a combination of collagenase (0.2mg/ml) and hyaluronidase (0.4 mg/ml) 
without any enzyme (control) for 1 hour before transduction with either non-targeted NT.AAVP 
or RGD4C.AAVP. Fixation was conducted 4 hours post-transduction and immunofluorescence 
performed using anti-phage primary and goat anti-rabbit AlexaFluor-647 secondary antibodies. 
Gating threshold was set at 10,000 events of total cell population. Data represent the mean + 
SEM of triplicate samples from one representative experiments of three, significant difference; 
n.s.-not significant, * p<0.05, ** p<0.01, ***p<0.001 (two way ANOVA with tukey's post hoc 
test). b) Representative results showing the shift in mean fluorescence intensity and AAVP 
positive cell counts between control condition and enzyme combination treatment. 
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5.2.5. AAVP/HSVtk and GCV treatment in ECM depletion leads to 
enhanced tumour cell killing 
To determine whether the enhanced gene transfer that we reported above 
following ECM depletion through enzymatic degradation would improve the 
efficacy of gene therapy, we transduced 9L cells with AAVP vectors carrying the 
HSVtk cytotoxic gene in combination with GCV treatment. Cell viability was 
assessed by quantification of ATP levels through the luminescence cell viability 
assay. We found that collagenase or hyaluronidase pretreatment enhanced the cell 
killing by RGD4C.AAVP when compared to control condition in the absence of 
enzymatic pretreatment, eliminating up to 80% of cancer cells after GCV 
treatment (Figure 5.5a).  Interestingly, combinations of both enzymes dramatically 
enhanced tumour cell death by RGD4C.AAVP to 98% (Figure 5.5a). No cell 
death was detected in conditions without GCV or with application of the non-
targeted NT.AAVP, suggesting that such tumour killing remains specific and 
targeted to cancer cells. Morphological analysis confirms the extent of the tumour 
cellular destruction; showing how ECM depletion causes extensive cell death when 
compared to vector alone (Figure 5.5b). Importantly, extensive destruction of 
tumour cells by RGD4C.AAVP can be observed in cells pretreated with both 
collagenase and hyaluronidase. These data demonstrate that combining ECM 
depletion with AAVP transduction can lead to strong anticancer efficacy. 
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Figure 5.5: ECM degradation results in significant cell-killing effects by targeted 
RGD4C.AAVP mediated HSVtk/GCV gene therapy. a) 9L cell viability measured after ECM 
treatment in conjunction with transduction by non-targeted- and targeted RGD4C.AAVP 
carrying the HSVtk suicide gene. Media containing 20µM GCV was added and renewed daily for 
5 days starting 72 hours after transduction. Cell killing was quantified by the CellTiter-Glo® cell 
viability assay and viability was expressed as percentage of matched experimental conditions (0.2 
mg/ml of collagenase and 0.4 mg/ml of hyaluronidase) of cells in the absence of GCV. Mean 
cell viability was normalised to non-treated controls, with the mean of n=3 independent 
experiments shown (+ SEM), significant difference; n.s.-not significant, * p<0.05, ** p<0.01, 
***p<0.001 (two way ANOVA with tukey's post hoc test).  b) Morphological characteristics of 
9L cells after enzymatic treatment and RGD4C.AAVP/HSVtk transduction. Differences in cell 
viability are visualized by the number of dead cells seen in different treatments. Scale bar = 100 
µm. 
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5.2.6. Multicellular tumour spheroid (MCTS) models showed 
increased targeted gene transfer by RGD-AAVP in 
combination with ECM depletion 
Tumour spheroids are recognized as superior tools over monolayer cell culture 
systems as models for cancer investigation.241 Spheroids closely mimic solid 
tumours, including parameters such as ECM composition and thus drug transport 
in tumours. As such, AAVP gene therapy was applied to the spheroid model to 
investigate whether ECM degradation would prove efficacious for situations 
resembling in vivo solid tumour environments. Tumour spheroids were pretreated 
with a range of collagenase or hyaluronidase concentrations followed by AAVP 
transduction and a liciferase assay. Maximal levels of luciferase activity were 
observed with 0.2 mg/ml of collagenase and 1 mg/ml of hyaluronidase; with 
activity dropping sharply with further increases in concentration (Figure 5.6a, b). 
The optimal concentrations were therefore used in further experiments of 
combination treatment on the spheroid model showing a significant 2.6-fold 
increase of transduction efficacy over control conditions in the absence of enzyme 
pretreatment (Figure 5.6c) These findings support that ECM effects are highly 
relevant in in vivo situations and confirm that ECM removal should be considered 
to improve RGD4C.AAVP diffusion and delivery especially in environments 
involving solid tumours. 
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Figure 5.6: Effect of ECM depletion on RGD4C.AAVP transduction in tumour spheroid 
models. Concentration gradient curve of ECM degrading enzymes in 9L tumour spheroids 
generated by quantification of post-transduction day 3 luciferase gene expression through 
Steady-Glo® assay. RGD4C.AAVP carrying Luc gene was applied to spheroids that underwent 
a) collagenase or b) hyaluronidase  treatment. c) Quantification of luciferase activity following 
treatment with enzymatic combination versus control treatment in tumour spheroids. The results 
show the mean relative luminescence units of triplicate wells +SEM, from one representative of 
three independent experiments, significant difference; n.s.-not significant, * p<0.05, ** p<0.01, 
***p<0.001 (one and two way ANOVA with tukey's post hoc test). 
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5.2.7. The ECM represents a major obstacle to AAVP vectors and 
the transport is determined by the ECM concentration 
Increased ECM deposition resulting from the desmoplastic reaction is a 
characteristic observed in solid tumours and presents a transport barrier that 
restricts drug penetration, thereby limiting the efficacy of delivery vehicles for 
cancer therapy.299 To test our hypothesis that the lower transduction efficiency of 
RGD4C.AAVP prior to ECM depletion was due to limited transport of 
RGD4C.AAVP particles through the tumour ECM, we performed diffusion assays 
to investigate the impact of ECM barriers on AAVP movement by looking at 
different concentrations of ECM network. The tumour-derived ECM was used as 
a model system and diffusion of fluorescently-tagged AAVP particles in two 
different concentrations of ECM-gel matrix was measured using fluorescence 
microscopy. We observed that higher ECM concentration (5.0 mg/ml) reduced the 
diffusion area of AAVP compared to lower concentrations (2.5 mg/ml). 
Fluorescently-labeled AAVP diffused through the 2.5 mg/ml ECM 2.6 times faster 
and covered an area 3 times larger when compared to the 5.0 mg/ml ECM 
(Figure 5.7a, b). These findings confirm that the ECM presents a major barrier to 
AAVP. 
 
 
 
 
P a g e  | 196 
 
 
Figure 5.7: Effect of ECM on AAVP transport and diffusion. a) AAVP diffusion assay was 
performed using fluorescently labelled AAVP and tracked through the tumour-derived ECM gel 
matrix in order to investigate the impact of ECM barriers on AAVP movement. Two ECM 
concentrations were investigated (2.5 and 5.0 mg/ml). AAVP was tracked using fluorescent 
microscopy. AAVP diffusion was measured for a total time of 6h and expressed as diffusion area 
per field of view (FOV). b) Representative images demonstrating the diffusion of fluorescently 
labelled AAVP in different concentrations of ECM gel. Scale bar = 0.5 mm. 
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5.2.8. Losartan improves targeted gene transfer by RGD4C.AAVP 
Systemic delivery of collagenase has been investigated and shown efficacious to 
enhance tumour perfusion in in vivo models.300 However, we sought to use clinically 
approved drugs that could be used for lessening ECM in order to accelerate our 
findings to translational applications. Losartan is a FDA approved treatment for 
hypertension and has been proven to have anti-fibrotic effect by inhibition of 
collagen type I synthesis.301 Luciferase assays were performed to examine if 
losartan could be a possible substitution for collagenase. Cells were treated with a 
range of losartan concentrations overnight before transduction with AAVP vectors 
carrying the Luc gene. A maximal gene expression increase of 2.4-fold above the 
baseline transduction level (in the absence of losartan) was observed in cells 
pretreated with losartan at a concentration of 100 μM (Figure 5.8). This 
demonstrates that losartan is a viable replacement for collagenase and can be a 
potentially superior ECM-modulatory procedure especially when side effects and 
safety issue are considered. 
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Figure 5.8: The effect of losartan on RGD4C.AAVP transduction. Gene delivery efficacy of 
RGD4C.AAVP was quantified, 3 days post vector transduction, by luciferase assay with Steady-
Glo® assay kit after 9L pretreatment with the drug losartan. Cells were incubated overnight with 
increasing concentrations of losartan and transduced the following day with targeted or control 
non-targeted AAVP vectors carrying the Luc gene. The results show the mean relative 
luminescence units of triplicate wells ±SEM, from one representative of three independent 
experiments, significant difference; n.s.-not significant, * p<0.05, ** p<0.01, ***p<0.001 (one 
way ANOVA with tukey's post hoc test). 
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5.3. Discussion 
Herein, we have demonstrated the potential use of ECM removal as a strategy to 
improve targeted gene transfer to cancer cells by a hybrid RGD4C.AAVP 
bacteriophage-based vector. As can be seen from increases in transduction 
efficacies after ECM depletion; ECM-vector interactions are important players in 
gene delivery to target cells and are first-line determinants in success gene delivery.  
In active drug targeting, targeting ligands are attached to therapeutic agents to act 
as homing devices for binding to receptor structures expressed at the target site.302 
ECM molecules occupy receptors which serve as binding sites of AAVP vectors. 
Our experiments are the first proof of concept that ECM clearance can be used 
specifically in phage vector-based gene transfer to improve transduction efficacies. 
As we have shown, specific amounts of collagenase and hyaluronidase are able to 
significantly enhance gene transfer efficacy of AAVP. However, high levels of 
enzymes, especially collagenase, seem to be non-advantageous to transduction. 
The present study indicates that degradation of the structural collagen network is 
more important than degradation of hyaluronan in order to improve the gene 
delivery by RGD4C.AAVP. A possible explanation is the shared receptor by 
AAVP and collagen fiber. Cell attachment to ECM is achieved through the action 
of cell surface receptors. Naive collagen produced by normal cells binds to their 
α1β1, α2β1, α10β1, and α2β1, and α11β1 integrin receptors.
303,304 However, altered 
integrin expression is often observed during different stages of tumour 
progression.305 For example, integrin αvβ3 is a receptor for tumour-associated ECM 
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including proteolyzed/denatured collagen in which cryptic RGD-sites in the 
relaxed collagen triple helix are exposed, and recognised by the RGD-directed αvβ3 
integrins.306,307 Incidentally, these are the same receptors that mediate 
RGD4C.AAVP internalization through the RGD motif. Therefore, collagen fibre 
is a barrier to RGD4C.AAVP through physical masking of target receptors on 
malignant cells.  
A major obstacle is the transport and delivery of sufficient amount of gene delivery 
vectors to the target cells. In solid tumours, vectors have to extravasate across the 
capillary wall into ECM and move through the ECM to reach the individual cancer 
cells.308 The high interstitial fluid pressure (IFP) in tumours hinders fluid flow into 
the tumour from blood capillaries of abnormal tumour vasculature. As a result, 
insufficient convection transport of therapeutic agents force drugs to be 
transported primarily by diffusion mechanism.309-311 However, the diffusion of 
particles through the complex structure of ECM to reach malignant cells is a 
significant problem for relative large particles such as nanoparticles and viruses.108 
The fluid saturated gel-like extracellular space in solid tumours is composed of 
fibrous macromolecules, including collagen and glycosaminoglycans (GAGs). 
Here, we have demonstrated a greater degree of AAVP diffusion in lower 
concentrations of ECM-gel matrix compared to higher concentrations, suggesting 
ECM as a barrier to AAVP transport. 
Collagen is the major protein component of the ECM and the collagen network is 
a significant barrier to the delivery of therapeutic macromolecules.298,312,313 The 
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collagen content in solid tumours is significantly higher than in normal tissues, 
resulting in a relatively dense extracellular space.314 Recent studies point out 
collagen as a likely target for modification to improve delivery of therapeutic 
agents.315-318 Pretreatment of tumour spheroids with collagenase enzyme improved 
the penetration of nanoparticles through the cellular mass.319  
Although collagenase is more efficient to increase gene transfer efficacy than 
hyaluronidase, additive effects could be achieved when both enzymes are 
synergistically applied. These additive effects can be explained, as collagen and 
hyaluronan are separate ECM entities. We have investigated the effect of the 
combination of enzyme treatment and gene therapy by AAVP in glioblastoma 
model, in this study, as this tumour type remains a challenge due to very limited 
therapeutic options and short survival of glioblastoma patients.231 Several collagen 
types have been reported to be overproduced by glioblastoma cells and by 
endothelial cells during brain tumor angiogenesis, but are not significantly present 
in the normal brain tissue.320 As well as collagen, hyaluronan is constitutively 
produced by glioma cells and its production is increased during cell proliferation 
promoting glioma invasion.321-323  
We have also investigated the feasibility of ECM depletion in a spheroid tumour 
model which has superior properties for resembling in vivo environments of solid 
tumours.324 Cells cultured on conventional two-dimensional plates lack the in vivo 
tumour environment. Multicellular spheroid models have been widely used to 
investigate many aspects of solid tumours and have proven particularly useful in 
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understanding the transport of anti-cancer nanomedicines.325,326 The spheroid 
models is particularly compelling as a more realistic model in these experiments as 
they better reflect possible resistance to the AAVP’s penetration and cell 
accessibility, by virtue of their metabolic activities (hypoxia and poor core 
vascularization) and possible interactions with the ECM.241 By proving ECM 
modulation therapy in multicellular tumour setting, we hereby demonstrate that the 
strategy is relevant for in vivo situations.  
Degradation of some ECM proteins, including collagen and hyaluronan, by the 
application of ECM-degrading enzymes has improved the penetration of drugs or 
nanoparticles through solid tumours.108 Collagen depletion improves the 
intratumoural dispersion of nanomedicines, including monoclonal antibodies, 
liposomal doxorubicin, 10-500 kDa dextran, and herpes simplex virus, due to 
reduced IFP and enhanced extravasation.315-318 A recently FDA-approved 
recombinant human hyaluronidase in pegylated formulation, PEGPH20 
(Halozyme Therapeutics) is being investigated in an ongoing clinical trial with 
advanced solid tumours327,328, suggesting that hyaluronidase can be an effective and 
clinically feasible anti-cancer drug. Earlier clinical trials suggest that hyaluronidase, 
given in combination with chemotherapy, does not pose significant toxicity to 
normal tissues.329-331 However, the use of collagenase is currently not FDA-
approved for cancer treatment in human as the clinical utility of enzymatic 
degradation is uncertain.108 High levels of interstitial metalloproteinase especially 
collagenase have been found to correlate with a poor patient prognosis in a variety 
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of cancers.332,333 ECM degradation may promote cancer progression, invasion, and 
metastasis in some cancers.332,334 The complex ECM composition and the 
substantial heterogeneities in tumour microenvironment make it difficult to select 
the type and optimal dose of enzyme, for example the acidic microenvironment in 
solid tumours may diminish enzyme activity.317,335 It may be advantageous to find a 
more practical method to target the ECM. Losartan provides the benefits of 
reducing ECM barriers and IFP while avoiding potential toxicity of direct 
collagenase activity. Losartan has been originally used as an angiotensin II type I 
receptor antagonist in clinical use for hypertention. It has also been shown to have 
anti-fibrotic activity mediated by knock-on effects on the transforming Growth 
Factor-β1 (TGF-β1) pathway through thrombospondin-1 (TSP-1) resulting in 
inhibition of collagen type I synthesis.336,337 Its combination with oncolytic HSV or 
liposomal doxorubicin (Doxil) has proven efficacious in mouse xenograft models 
of cancers.301 It has also been shown limited side effects338, offering a better safety 
profile than systemic administration of collagenase. 
5.4. Conclusion 
ECM in solid tumours affects the effectiveness of RGD4C.AAVP-mediated gene 
delivery through blocking diffusion and/or physical masking of target receptors on 
malignant cells. In this study, the effect of ECM modulation on transduction 
efficiency of RGD4C.AAVP was investigated in cancer cells. We further evaluated 
the therapeutic effects of co-administering AAVPs carrying the HSVtk suicide 
gene in conjunction with ECM removal. We have also substantiated this strategy 
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through a more realistic cell culture model of multicellular spheroid tumour model 
and through the FDA- approved drug, lorsartan. The present results showed that 
ECM modulation could enhance transduction efficiency by AAVP vectors. These 
findings support the potential use of ECM depletion as a strategy to enhance gene 
delivery in tumours. 
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6. New generation of Multi-functional Filamentous 
Bacteriophage for peptide and gene delivery 
6.1. Introduction 
The concept of multifunctional vectors capable of simultaneously performing 
multiple functions has emerged and attracted the attention of a large and diverse 
number of investigations.  Such functions include the delivery of therapeutic 
agents, biomarker-based targeting, the avoidance of extra-/intracellular barriers, 
and reporting of therapeutic efficacy (optical imaging).339  The advantages of using 
a multifunctional system are associated with complementing or synergistic effects 
and less administration of adjuvants.340  
To date, the development of a vast majority of multifunctional vehicles largely 
relies on synthetic conjugates using coupling chemistries to introduce functional 
moieties into different genetic or molecular constructs.341 These synthetic 
processes are complicated and usually very system-specific, which limits cross-
system application. Furthermore, many materials are not suitable for clinical 
application due to poor biocompatibility and potential toxicity resulting from the 
use of inorganic materials or surfactants.340 
The filamentous bacteriophage contains a core comprised of circular single 
stranded DNA encapsulated in approximately 2700 copies of the major coat 
protein pVIII and minor coat proteins (3-5 copies each) pIII, pVI, pVII and pIX 
capped at the tips of the virion. In certain aspects, they can be regarded as efficient 
machines that can be developed into the potential nanomedicines.188 A number of 
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characteristics make them well suited for constructing a multifunctional particle, 
offering novel solutions to the challenges of improving the efficacy of drug 
delivery to cells. In contrast to other materials, bacteriophages can be intentionally 
modified using routine genetic engineering techniques because their structure and 
function are encrypted in their genomic DNA.342 The desired ligands (e.g., 
peptides, proteins, or antibodies) can be displayed on the bacteriophage capsid in a 
site-specific manner and carry a large payload of a cytotoxic drug. Another point of 
contrast to the sophisticated and poorly controlled synthesis procedures used to 
incorporate peptides and antibodies to targeted vehicles, the phage-based approach 
involves a simple yet powerful and precise mechanism of biosynthesis and self-
assembly.343  The production of phage vectors is simple and cost effective because 
they are easily produced with high titres in the supernatant of host E.coli cultures 
and can be purified on a large scale. Finally, bacteriophages have long been 
administered intranasally, topically, orally, subcutaneously and intravenously to 
humans; for example, they are used to treat pathogenic bacterial infections and 
only minor side effects have been observed in over 12 years of use.290,344 Certain 
phage preparations have recently been approved by the Food and Drug 
Administration of USA as antibacterial food additives.345 
We have therefore developed a novel bacteriophage, which exhibits a number of 
novel functions. To demonstrate the simultaneous expression of functional foreign 
peptides displayed on the capsid of the multifunctional bacteriophage, we used 
three well-characterized peptides: i) the double cyclic RGD4C peptide, ii) a 
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streptavidin-binding peptide (SBP), and iii) gold-binding peptide (GBP). The 
mammalian DNA cassette flanked by ITRs from AAV2 was incorporated into the 
phage genome to confirm its use for the delivery of transgenes.  
Next, we used the multifunctional phage to construct an ideal bacteriophage vector 
capable of combining multiple strategies for overcoming the mammalian cell 
barriers to phage into a single particle, in addition to effective transgene 
expression. Therefore, we have generated multifunctional bacteriophage-based 
vectors as a proof-of-concept prototype; this particular phage simultaneously 
carries the RGD4C ligand for specific targeting in vivo, a tetrapeptide AKAS for the 
avoidance of plasma protein adsorption and a DNA cassette for transgene 
expression. 
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Figure 6.1: A schematic representation of a multifunctional phage particle model system. 
The phage is tetrafunctional, displaying a targeting RGD4C ligand on the pIII minor coat protein 
and multiple copies of gold binding and streptavidin-binding peptides on the surface. 
Additionally, a mammalian transgene cassette, driven by the CMV promoter, was also inserted in 
the bacteriophage genome to allow transgene expression by the multifunctional phage. 
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6.2. Results 
6.2.1. Construction and characterization of a multifunctional 
display model system 
To construct the trifunctional phage, the plasmid DNA of two existing phages 
which share similar genetic backbones and contain unique restriction sites at 
similar locations were chosen to construct a multifunctional display model system. 
The fUSE5 (GenBank Accession number: AF218364) bears a single gene III and 
f88.4 (GenBank Accession number: AF218363) that contains two genes VIII, 
encoding two different types of pVIII molecules namely wild type and the 
recombinant one bearing a foreign DNA insert. A chimera between fUSE5 and 
f88.4 was constructed prior to introducing sequences encoding the desired 
peptides on different coat protein genes by using a subcloning strategy and site-
directed mutagenesis. The double cyclic RGD4C ligand is displayed on the pIII 
minor coat protein. The coding sequences of the streptavidin binding peptide were 
fused in frame with the recombinant VIII gene. The coding sequence of the gold-
binding peptide was inserted into the genome of the modified vector through gene 
fusion with the wild type major coat protein pVIII. Thus, the resulting phage 
particle simultaneously displayed an RGD ligand at the phage end, and multiple 
copies of gold binding peptide and streptavidin-binding peptide on the surface as 
schematically shown in Figure 6.1. Sequencing analysis of all recombinant 
plasmids was carried out to confirm the presence of the correct orientation of the 
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insert and to determine if any mutations occurred during cloning. Four phage 
vectors were constructed in this study and are shown in Figure 6.2. 
 
Figure 6.2: schematic representation of four phage vectors used in this study. a) Insertless 
phage carrying a mammalian transgene cassette, without any ligand on display. b) bifunctional 
phage, displaying the RGD4C ligand and carrying a mammalian transgene cassette. c) 
Trifunctional phage, simultaneously carrying RGD4C, streptavidin-binding peptide (SBP), and 
mammalian transgene cassettes. d) Tetrafunctional phage, simultaneously displaying RGD4C, 
streptavidin-binding peptide (SBP), gold-binding peptide (GBP) and mammalian transgene 
cassettes. 
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6.2.2. Cell surface αv integrin receptors binding characteristics of 
the multifunctional phage 
In order to demonstrate that all moieties displayed on the pIII and recombinant as 
well as on wild type pVIII proteins are functional, we performed various binding 
assays. Firstly, we validated the function of the RGD4C targeting ligand displayed 
on the pIII minor coat protein by assessing binding and internalisation to cells 
expressing αvβ3 integrin receptors. Immunofluorescence and confocal microscopy 
using antibodies against the phage capsid were performed on highly αvβ3 integrin-
expressing M21 cells.346 As shown in Figure 6.3, we demonstrated that targeting 
and internalization capabilities of the RGD4C peptide remained intact and 
functional in the multifunctional phage as well as in the trifunctional and 
bifunctional phages. The insertless phage showed background signal only. 
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Figure 6.3: Immunofluorescence-based phage binding and internalization assay. Cultured 
human M21 melanoma cells were incubated with different phage preparations, all carrying a 
phage input of 1 mg/well. The red colour represents fluorescence from phage staining, and the 
blue colour shows fluorescence of DAPI-stained cell nuclei. 
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6.2.3. Analysis of the streptavidin binding capacity of the 
multifunctional phage 
In vitro phage binding assays were used to assess the functionality of the 
strptavidin-binding peptide displayed on the surface of the multifunctional phage. 
Unbound phages were recovered from the streptavidin coated plate by infection of 
host bacteria E.coli K91. As shown in Figure 6.4, the trifunctional 
(RGD4C.SBP.AAV-GFP) and tetrafunctional phage (RGD4C.SBP.GBP.AAV-
GFP), both of which display streptavidin-binding peptides had higher and similar 
levels of binding to immobilized streptavidin as determined by the greater number 
of bacterial transducing units. In contrast, insertless phage (AAV-GFP) and 
bifunctional phage (RGD4C.AAV-GFP) did not show any binding. 
 
Figure 6.4: The streptavidin binding capacity of the multifunctional phage. Different 
phage constructs were incubated with immobilised streptavidin and washed prior to infection of 
E.coli K91. Shown are the mean from triplicate wells. Data represent the mean + SEM of 
triplicate samples from one representative experiments of three, significant difference; n.s.-not 
significant, * p<0.05, ** p<0.01, ***p<0.001 (one way ANOVA with tukey's post hoc test). 
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6.2.4. Testing the colloidal gold binding capacity of the 
tetrafunctional phage 
Colloidal gold was used in this study to assess gold-multifunctional phage 
interactions. First, we carried out a dot blot-diffusion assay to evaluate the 
functionality of the gold binding peptide displayed on the capsid of the 
multifunctional phage (Figure 6.5a). Different phage preparations were directly 
added onto the nitrocellulose membrane, after which the solution of colloidal gold 
was added on top of phage dotted on the membrane. The ability to bind to gold 
was determined by the diffusion pattern formation of colloidal gold on the 
membrane. Significant staining was observed in the dot of tetrafunctional phage 
(RGD4C.SBP.GBP.AAV-GFP), suggesting its effective colloidal gold binding 
capacity (Figure 6.5a). No staining was observed in dots of insertless, bifunctional 
and trifunctional phage, where gold colloids tend to move from a region of high 
concentration of phage to the peripheral regions of lower concentration of gold 
colloids (Figure 6.5a). This indicates that insertless, bifunctional and trifunctional 
phages, all of which lack the gold-binding peptide on the surface, did not bind to 
gold. 
To confirm the gold binding capacity of the multifunctional phage, we performed 
a precipitation test in which phage suspension solutions were mixed with a  
colloidal gold suspension (Figure 6.5b). After overnight incubation, a visible 
precipitate was observed in the mixture of the tetrafunctional phage 
(RGD4C.SBP.GBP.AAV-GFP) with the gold colloidal suspension (Figure 6.5b), 
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indicating that the gold colloids formed aggregates. The mixtures with the 
insertless phage remained clear as shown in Figure 6.5b). 
 
 
 
Figure 6.5: The gold binding capacity of the multifunctional phage. a) Dot blot of phage-
binding gold colloids. Dots (from left to right) represent insertless, bifunctional, trifunctional, 
and tetrafunctional phages. b) Precipitation assays were carried out to visualize precipitate 
formation upon mixing a gold colloidal solution with the phage. Photographs of insertless and 
tetrafunctional phages mixed with 10-nm colloidal gold overnight are shown. 
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6.2.5. Evaluation of transgene expression by the multifunctional 
phage 
To examine that the multifunctional phage can deliver transgenes into mammalian 
cells, we carried out cell transduction experiments on HEK293 cells.  This was 
previously used as a standard in vitro model for transduction by the well-
characterized RGD4C.AAVP. We used vectors carrying the GFP reporter gene, 
which provides a convenient way to visualize gene expression. Analysis of GFP 
expression showed GFP expression in cells transduced with the multifunctional 
phage (Figure 6.6). No GFP expression was observed in the insertless phage-
transduced cells (Figure 6.6). The data prove that multifunctional phages 
successfully mediate transgene expression in mammalian cells. 
 
Figure 6.6: GFP expression by the multifunctional phage in HEK293 cells. GFP 
expression was visualized under a fluorescent microscope. Shown are representative images of 
cells at day 5 following transduction with insertless and multifunctional phages. Scale bar = 0.5 
mm. 
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6.2.6. Construction and production of a multifunctional phage, 
carrying RGD4C, a tetrapeptide AKAS and a transgene 
cassette 
Next, to investigate whether the multifunctional phage can be used to enhance 
phage-based applications in gene delivery, we assessed gene transfer efficacy. One 
major extracellular barrier to systemic gene delivery vectors is the formation of a 
“protein corona” caused by non-specific plasma protein adsorption to vectors.347 
One way to tackle this problem is to introduce zwitterionic properties, known for 
being resistant to plasma protein adsorption, onto the particle surface.348,349 We 
generated the RGD4C.AKAS.AAV-GFP by introducing a tetrapeptide (AKAS) to 
the N-terminus of each copy of the major coat protein as schematically shown in 
Figure 6.7. This genetic modification resulted in an additional zwitterionic 
property of the surface of the bacteriophage.350 To engineer this new phage, we 
used the original vector in which the sequence encoding the RGD4C ligand has 
already been fused in frame with gene III.22 The first genetic engineering step was 
to introduce the tetrapeptide AKAS between residues Gly3 and Asp4 of the N-
terminal region of the major coat protein pVIII using site-directed mutagenesis. 
The correct insertion of the AKAS nucleotide sequence of the resultant plasmid 
(RGD4C.AKAS) was confirmed by sequencing analysis. Next, the transgene 
cassette (GFP reporter gene) flanked by ITRs from AAV was inserted into the 
intergenic region of RGD4C.AKAS vector. Finally, a positive clone was used for 
phage production followed by phage purification (See materials and methods). 
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Similar to the original RGD4C.AAV-GFP phage, the new phage can be produced 
with high titres and within a workable range. These data show that fusion of the 
AKAS tetrapeptide with N-terminus of pVIII major coat protein did not affect 
phage production. 
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Figure 6.7: The zwitterionic surface of filamentous bacteriophage. a) The AKAS 
tetrapeptide insertion allows the phage surface to mimic the zwitteronic character.350 The wild 
type major coat protein pVIII of phage includes 3 carboxylate groups bearing side chains at its 
N-terminus (left) and an insertion of a 4-mer peptide into each copy of pVIII results in a 
zwitterionic surface. b) Construction of the multifunctional phage, simultaneously carrying 
RGD4C, a tetrapeptide AKAS and a transgene cassette. 
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6.2.7. Display of the tetrapeptide AKAS alters the surface of the 
multifunctional RGD4C.AKAS.AAV-GFP phage 
A general characteristic of zwitterionic materials is their both positive and negative 
charged moieties on the same side chain, maintaining total charge neutrality.351-353 
To confirm that the AKAS peptide neutralized the negatively charged phage 
capsid, we carried out an experiment to demonstrate that the new multifunctional 
phage surface has different charge properties compared to the parental one, as 
determined by its cationic polymer binding capacity. We incubated the phages with 
the positively charged DEAE.DEX polymers and expected the lower affinity of 
the new phage to DEAE.DEX polymer. After overnight incubation on 
DEAE.DEX-coated plate, the unbound phages were recovered from the 
supernatant by infection of K91 followed by colony counting. As shown in Figure 
6.8, insignificant number of the RGD4C.AAV-GFP phage was recovered as 
compared to the RGD4C.AKAS.AAV-GFP phage, suggesting that the original 
vector was almost completely sequestered by the DEAE.DEX polymers. 
Interestingly, 30% of the RGD4C.AKAS.AAV-GFP phage was recovered (Figure 
6.8). These results clearly demonstrate that the surface of the newly generated 
phage is genetically modified to reduce the binding capacity to positive charged 
molecules. 
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Figure 6.8: The cationic polymer binding capacity of multifunctional 
RGD4C.AKAS.AAV-GFP phage. a) Percentage of phage recovery from the DEAE.DEX-
coated plate (phage recovery in term of percentage of input). Phages were incubated overnight 
on the cationic DEAE.DEX- coated plates. The supernatant containing unbound phage particles 
were recuperated and used to infect E.coli K91Kan. b) LB-agar plates showing the colony 
formation between the parental RGD4C.AAV-GFP phage and the RGD4C.AKAS.AAV-GFP 
phage. One representative plate of each phage and each dilution are shown. Data represent the 
mean + SEM of triplicate samples from one representative experiments of three, significant 
difference; n.s.-not significant, * p<0.05, ** p<0.01, ***p<0.001 (one way ANOVA with tukey's 
post hoc test). 
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6.2.8. Phage incubation with fibrinogen decreases the transduction 
levels of RGD4C.AAV-GFP phage while the efficacy of the 
multifunctional RGD4C.AKAS.AAV-GFP remains intact 
Fibrinogen is extensively used as a model protein to assess the protein adsorption 
resistance of biomaterials.354 Therefore, in this study the protein-fouling resistant 
property of RGD4C.AKAS.AAV-GFP phage was tested by cell transduction after 
phage incubation with fibrinogen proteins. Thus, we transduced the 9L cells with 
the RGD4C.AAV-Luc and RGD4C.AKAS.AAV-Luc phages under normal 
conditions or following incubation with fibrinogen for 60 mins (Figure 6.9). No 
differences in Luc expression were detected in normal transduction conditions 
(Figure 6.9). Interestingly, a 2.2- fold decrease in Luciferase activity was observed 
in RGD4C.AAV-Luc-transduced cells compared with RGD4C.AKAS.AAV-Luc-
transduced cells after incubation with fibrinogen (Figure 6.9). This result 
suggested that the multifunctional phage with the altered surface is able to avoid 
non-specific binding to fibrinogen. 
 
6.2.9. Resistance of the multifunctional phage to antibody 
neutralization 
To uncover further improvements and advantages acquired by the multifunctional 
RGD4C.AKAS.AAV-Luc phage, we evaluated the effect of a neutralizing antibody 
against bacteriophage on the transduction efficiency of the multifunctional phage. 
9L cells were transduced with the RGD4C.AAV-Luc and RGD4C.AKAS.AAV-
Luc phage in the presence of anti-phage antibody and the Luciferase activity was 
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determined 3 days post-transduction (Figure 6.10). The results showed a 
significant transduction difference in the presence of the anti-phage antibody 
(1:8000). We observed 2.5-fold higher transduction efficiency in 
RGD4C.AKAS.AAV-Luc-treated cells compared to cells transduced with 
RGD4C.AAV-Luc phage (Figure 6.10). These data indicated that the novel 
multifunctional phage gained potential to escape from the neutralizing antibodies 
against the capsid of the parental phage vector. 
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Figure 6.9: Luciferase expression following phage incubation with fibrinogen. The 9L 
cells (60-80% confluent in 48-well plates) were transduced with phages carrying the Luc reporter 
gene (25μg/well). Two conditions were assessed: cells treated directly with the phages stock 
solution (left bars) or cells treated with the remaining phage after 60 minutes incubation with 
fibrinogen (right bars). The results show the mean relative luminescence units of triplicate wells 
±SEM, from one representative of three independent experiments, significant difference; n.s.-
not significant, * p<0.05, ** p<0.01, ***p<0.001 (two way ANOVA with tukey's post hoc test). 
 
 
 
Figure 6.10: Effect of anti-phage antibody on luciferase expression in cells transduced 
with RGD4C.AAV-Luc or RGD4C.AKAS.AAV-Luc phage. The 9L cells (60-80% confluent 
in 48-well plates) were transduced with 25μg/well of phages solution containing complete media 
and a serial dilution of anti-phage antibody concentrations. The results show the mean relative 
luminescence units of triplicate wells ±SEM, from one representative of three independent 
experiments, significant difference; n.s.-not significant, * p<0.05, ** p<0.01, ***p<0.001 (two 
way ANOVA with tukey's post hoc test). 
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6.2.10. Mutations in the N-terminus of the major coat protein pVIII 
of the multifunctional phage affect infectivity 
Phage concentration was measured by spectrophotometric quantification of DNA 
and protein. After being adjusted to an identical phage particle number, clones 
were assayed for infectivity by counting colonies (colony forming units; cfu) 
formed on LB agar plates. Although phage of all constructs tested were assembled 
and released, there was a difference in their ability to infect bacteria.  As well as the 
phage without capsid modification, phages bearing either engineered pIII or 
recombinant pVIII alone formed similar number of colonies (Figure 6.11). 
Surprisingly, one of the selected peptides (GBP) displayed on wild type pVIII 
yielded lower number of colonies whereas AKAS remained intact and similar to 
the unmodified phage (Figure 6.11).  This suggests that the insertion of a 
particular sequence on wild type pVIII can affect its ability to infect bacteria. 
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Figure 6.11: The effect of coat protein mutations on the multifunctional phage infectivity. 
The phage particle number was calculated from measuring protein and DNA by 
spectrophotometry (adapted from protocol by George P. Smith et al.). An aliquot of phage 
stocks being previously adjusted to an identical particle number was incubated with host K91 
E.coli. The infected cells were plated onto LB plates containing 50 μg/ml kanamycin and 40 
μg/ml tetracycline. Infectivity (colony forming units/μl) was calculated from the number of 
colonies that grew on the plates overnight. Data represent the mean + SEM of triplicate samples 
from one representative experiments of three, significant difference; n.s.-not significant, * 
p<0.05, ** p<0.01, ***p<0.001 (one way ANOVA with tukey's post hoc test). 
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6.3. Discussion 
We found that the wild type, recombinant major (pVIII) and minor (pIII) coat 
proteins provide the ability to display a wide range of foreign peptides of differing 
sizes. Therefore, it is possible to design novel bacteriophage constructs depending 
on which foreign proteins need to be displayed on the outer capsid. In this study, 
we proved the possibility of constructing multifunctional phage, showing that all 
moieties displayed on the phage capsid remain intact and functional by displaying 
the RGD4C ligand, streptavidin-binding and gold-binding peptides, and carrying a 
mammalian DNA cassette expressing the GFP or Luc reporter gene.  
The double cyclic RGD4C ligand identified by injection of phage peptide libraries 
into the circulation of mice bearing human breast carcinomas355,356 are displayed on 
the pIII minor coat protein. This peptide contains an embedded RGD motif found 
in a number of extracellular matrix proteins ligands and allows targeting of tumour 
vasculature.  
The coding sequences of streptavidin-binding peptide (ANRLCHPQFPCTSHE) 
were fused in frame with recombinant pVIII coding gene. This 15-mer 
streptavidin-binding peptide motif has previously been screened through a f88-
cys5 phage display library for specific binding on immobilized streptavidin.357 The 
coding sequence of gold-binding peptide (VSGSSPDS) was isolated by panning a 
type 8 phage display library on gold surface358, which was then inserted into the 
genome of the modified vector through gene fusion with the wild-type major coat 
protein pVIII. This gold binding motif contains four serine residues, each of which 
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contains a hydroxyl group on the side chain. Hydroxyl-rich peptides have been 
reported to have high affinity to gold lattices.359,360 
As a proof of concept, the resultant phage that simultaneously displays RGD4C, 
streptavidin binding, and gold binding peptides could be effectively internalised by 
αvβ3 integrin-expressing cells, and bind to gold nanoparticles and immobilised 
streptavidin as well. These results demonstrate that our multifunctional phage 
prototypes can be useful carriers for functional peptides, and for use in a number 
of applications such as the delivery of molecules such as therapeutic peptides. A 
broad spectrum of novel anticancer peptides have been reported and used for 
therapy or identified for potential application. This includes necrotic, apoptotic, 
function-blocking, antiangiogenic and immunostimulatory peptides.361  
Bacteriophages can be therefore used as a scaffold for constructing multifunctional 
nanocarriers, which may permit a cocktail of anti-cancer agents to be loaded onto a 
single carrier. 
We also reported that by incorporating transgene expression cassette, our 
prototype vector showed transgene expression in mammalian cell lines. We utilized 
the mammalian gene cassette flanked by ITRs from AAV2. Our group previously 
showed that incorporation of ITRs is associated with improved fate of delivered 
transgenes, maintenance of the entire mammalian transgene cassette, better 
persistence of episomal DNA, and formation of concatamers of the transgene 
cassette, resulting in increased transduction efficiency over conventional phage-
based vectors.171 Such vector is therefore useful for a number of applications such 
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as gene therapy and vaccine development. Recent investigations have shown that 
phage particles can be applied either to deliver a vaccine expression cassette cloned 
into their genome (DNA vaccine technology) or to display specific antigenic 
peptides on their surface via a translational fusion with the capsid protein. The 
combination of the two strategies above may result in a promising tool to create 
cocktail vaccines.362  Our prototype multifunctional phage capable of 
simultaneously carrying peptides and delivering transgenes may be ideally suited for 
this application. 
One possible strategy for efficient transgene expression is the development of a 
multifunctional vector that integrates multiple ligands and peptides to escape a 
series of significant barriers to the delivery of therapeutic/imaging genes by 
bacteriophage into target cells.  
One important extracellular barrier to systemic delivery of bacteriophage is its 
rapid removal from the circulation by cells of the RES and neutralizing 
antibododies after intravenous administration.363 In general, it is acknowledged that 
non-specific protein adsorption is the first event that occurs in blood-biomaterial 
interactions, which may contribute to the stimulation of intrinsic cascade, leading 
to the immune response and therefore compromise the therapeutic efficacy. 
Plasma proteins play an important role in the identification of foreign bodies in the 
blood stream.364 Once the gene delivery vectors are systemically administered, they 
are immediately coated by plasma proteins, which form a protein corona.365 The 
binding of proteins that serve as opsonins are recognized to increase phagocytosis 
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by immune cells. These proteins include fibrinogen, immunoglobulin G, 
complement factors, etc.366,367 It has been reported that the filamentous 
bacteriophage can non-specifically bind to a number of proteins (around 35% of 
proteins in the human genome)368 Filamentous phages present three solvent-
exposed acidic residues within the N-terminal five positions of the ~2700 copy, 
major coat protein pVIII. This acidic region contributes to a net negative charge of 
the phage surface, and can cause nonspecific interactions with proteins having an 
abundance of positively charged residues.368 
One way to address this problem is to introduce zwitterionic properties, known for 
conferring resistance to plasma protein adsorption on the particle surface.348,349 
This design follows a previous study which demonstrated that the introduction of 
the AKAS tetrapeptide, with an additional lysine residue inserted into every copy 
of the pVIII phage protein, can neutralize the negative charge of the filamentous 
phage by generating a zwitterionic surface.368 The AKAS peptide has been 
originally developed to reduce background binding for effective phage display 
technology368 and to allow phage display of membrane-associated proteins.350  
We sought to prove that the efficacy of multifunctional phages is enhanced 
through overcoming the obstacle of non-specific protein binding.  We generated a 
multifunctional phage that displays the targeting RGD4C ligand on the pIII minor 
coat protein, carries the AKAS tetrapeptides on the pVIII major coat protein and 
expresses a transgene through a mammalian cassette inserted in phage genome. 
The protein-fouling resistant property of RGD4C.AKAS.AAV-GFP phage was 
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tested and the results proved the capability of genetic modification to reduce the 
amount of fibrinogen adhesion compared with the original RGD4C.phage. 
Moreover, we also showed that in addition to chemical modification as shown in 
the previous chapter the phage’s ability to resist to antibody neutralization can be 
acquired by such genetic modification of the phage capsid. The altered surface of 
phage is believed to prevent the antibody recognition of epitopes on the major 
coat protein pVIII. 
We further investigated whether the multifunctional phage could be modified to 
further improve its gene delivery efficiency. We realised that the major intracellular 
barriers to bacteriophage-based gene transfer are vector inactivation in the acidic 
lysosome178, and transport of the bacteriophage to the nucleus of mammalian 
cells.369 Our first attempt was to construct a phage which displays an endosomal 
escape peptide (EEP) or nuclear localization signal (NLS) on wild type major coat 
protein pVIII. Unfortunately, we failed to obtain these plasmid constructions and 
sequencing analysis revealed that they tended to mutate randomly (data not 
shown). This observation can be attributed to the previously reported dependence 
on both the size and charge of the foreign peptides expressed on the phage 
particle.370 A previous investigation has shown that the display of positively 
charged peptides on the major coat protein pVIII was less efficient than that of 
neutrally charged peptides.370 Unfortunately, most NLS sequences contain a high 
proportion of positively charged residues (i.e. lysine and arginine), which gives rise 
to the overall positive charge of NLS., for example, the classical NLS 
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(PKKKRKV) derived from SV40 large tumour antigen and Tat peptides 
(GRKKRRQRRRPQ) derived from the transactivator of transcription (TAT) of 
the HIV-1.371 Indeed, the N-terminus of the major coat protein pVIII of 
bacteriophages can accommodate no more than 10 amino acid residues of foreign 
peptides as it has a tendency to affect phage assembly and production.372 Any 
genetic modification of the major coat proteins pVIII must be able to 
accommodate their biological roles during the phage lifecycle, including 
transcription, translation, membrane insertion, signal peptidase cleavage, assembly 
and extrusion, and infection.373,374 The genetic sequence will be more stable, and 
phages can be produced if the interactions between modified pVIII are biologically 
favourable within this context. In contrast, if the insert peptide makes pVIII 
interactions less favourable, it will be more likely to mutate and/or produce fewer 
number of phage particles.375  
Protein translation was another process that may impose strong limitations on the 
allowed insert sequence. Our observation that the NLS sequence containing lysine 
residue repeats could not be expressed can be attributed to the previously shown 
dependence of protein translation accuracy in the E.coli host.376 The repetitive use 
of amino acids with high copy number of pVIII proteins results in recruiting the 
pool of available corresponding tRNA isoacceptors and therefore slowing the 
translation process. As a result, the single stranded phage DNA accumulates, thus 
causing host cell death.376-378 Our observation that mutations of phage vectors after 
attempts to engineer pVIII to display repeated lysine residue-containing NLS 
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peptide (data not shown) is in agreement with the previous study that this 
phenomenon is common in long stretches of repeated residues.379 These 
explanations supported our observation that the positively charged NLS containing 
lysine residue repeats and the 23 amino acid long histidine-rich peptide H5WYG 
(GLFHAIAHFIHGGWHGLIHGWYG) cannot be displayed on the major coat 
protein pVIII. Among our several attempts, only certain peptides such as AKAS 
tetrapeptide could be constructed successfully and displayed on the produced 
phage particles. 
One solution to overcome this limitation is to use a phage that bears two pVIII 
genes, producing two different types of pVIII protein. Due to increased 
expressional flexibility, recombinant pVIII allows the display of a variety of 
proteins on the virion surface while the wild type pVIII is used to support phage 
assembly. In our preliminary study, we constructed the phage vectors carrying NLS 
and H5WYG on recombinant pVIII and obtained high titres of the new phage 
constructs. However, viability of the resultant phage does not guarantee efficient 
incorporation of engineered pVIII into phage particles. Although we observed a 
small improvement in transduction efficacies by these newly generated vectors, the 
levels were not satisfying. Even though the recombinant pVIII offers greater 
flexibility, limitations still exist. Problems associated with the efficiency of fusions 
to pVIII that can be incorporated into the phage particle have been reported.  
Most large proteins are displayed below one copy per phage particle.380 Inefficient 
display of large polypeptides on pVIII is partially limited by both the size and the 
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properties of the phage extrusion channel formed by pIV proteins on the outer 
bacterial membrane.374,381 A phage carrying a large peptide on pVIII may be too 
large in diameter to pass through the 6-9 nm exit pore of pIV.382 
A possible solution to efficiently display large peptides or proteins on most of the 
pVIII major coat protein is by chemical conjugation. This method gives the phage 
coat protein an ability to carry a large payload of molecules of interest. The 
molecule is linked to the phage through a chemical linker.383 The payload capacity 
of phage particle can be improved further by introducing extra functional groups, 
which serve as a carrier for construction of chemical conjugates with a wide range 
of molecules of interest on every copy of the major coat protein of the phage.  
For example, the filamentous bacteriophage was genetically modified to display 
two additional glutamate residues in the N-terminal of pVIII protein and was used 
for amine-terminated cadmium selenide quantum dots (QDs) via the carboxylic 
acid side groups on the engineered coat protein. This glutamic acid-rich phage (4E 
phage) exhibited increased conjugation to QDs compared with the wild type 
phage. This study demonstrated that genetic engineering is essential to improve the 
biotemplating.384 Interestingly, the E4 phage is another example of successful 
display of repeating residues on pVIII that do not cause mutations that affect 
phage production as discussed above.379 This was due to the large number of Glu 
isoacceptors in E.coli cells375 and to the favourable negative charge at pVIII N-
terminus region. 
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However, incorporation of molecules using a chemical method is often hampered 
by cross-reactivity or non-specific interactions with other functional groups 
present on the phage capsid, and requires multistep of synthesis and purification 
processes.385 To overcome this limitation, sortase-mediated chemo-enzymatic 
reactions were used to covalently attach a variety of moieties to bacteriophage coat 
proteins.386 The widely used sortase A includes SrtAaureus from Staphylococcus aureus 
and SrtApyogenes from Streptococcus pyogenes. Sortase enzymes attach oligoglycine or 
oligoalanine-containing peptides to substrates that contain LPXTG sequence or 
LPXTA sequence in the case of SrtAaureus and SrtApyogenes.
387,388 The reaction is site-
specific as certain motifs are required to be displayed on the coat proteins in order 
to serve as substrates for sortase. These motifs are small and therefore can be 
easily displayed on the phage coat protein.389 Hess et al. demonstrated that by using 
this method, phage coat proteins can be functionalized with entities ranging from 
small molecules (e.d., fluorophores, biotin) to correctly folded proteins (e.g., GFP, 
antibodies, streptavidin) in a site-specific manner.386 It is therefore possible to 
utilize this strategy to address problems associated with peptide properties (charge, 
size etc.). Consequently, this will increase the repertoire of proteins that can be 
expressed on pVIII, allowing newer multifunctional bacteriophages with desired 
multiple functions to be generated. 
Another aspect of multifunctional bacteriophage is its infectivity after a series of 
genetic modifications of its capsid. Our findings are in agreement with a previous 
study showing that the display of peptides on wild type pVIII affects their ability to 
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infect bacteria. Interestingly, the infectivity of  phages bearing both wide type and 
fusion pVIII remain intact because the deleterious effects of the fusion are 
attenuated by the presence of the wild type coat protein.390 Indeed, pIII minor coat 
protein is necessary for the infection process as the N-terminal domain of pIII 
minor coat protein initiates translocation of the phage genome into host becteria.390 
However, previous investigations demonstrated that large peptides (up to 38 amino 
acids long) can be introduced into the-N-terminus of pIII without the loss of 
phage infectivity or particle assembly.391,392 Thus, the display of the short RGD4C 
peptide on pIII protein of multifunctional phages did not affect their ability to 
infect bacteria. 
6.4. Conclusion 
We have designed a multifunctional filamentous phage (see Figure 6.1) that has 
potential to simultaneously carry multiple functions within a single virus particle. (i) 
It displays the targeting ligand on the pIII minor coat protein to bind a mammalian 
cell surface receptor, (ii) serves as a genetic carrier of foreign functional peptides to 
be displayed on the wild-type pVIII major coat protein, (iii) allows the display of 
large foreign peptides on the virion surface by the recombinant pVIII protein, and 
(iv) delivers a mammalian transgene cassette inserted in an intergenic region of the 
phage genome for expression in mammalian cells. In order to assess the function 
of the multifunctional phage in promoting phage-based gene delivery, we 
combined multiple solutions to overcome extracellular and intracellular hurdles to 
phage-mediated gene transfer into a single phage particle. Here, we proved the 
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ability of genetic modifications to reduce the amount of fibrinogen adhesion when 
compared to the original AAVP. In conclusion, the bacteriophage scaffold can 
potentially be used as a platform to generate a multifunctional gene transfer vector. 
The success of these strategies will present a breakthrough in gene delivery by 
bacteriophage and bring to fruition the promise of phage technology as a realistic 
and efficient systemic tissue-targeted delivery of genes. 
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7. General Discussion 
The objective of the vectorology platform is to construct and produce gene 
delivery vectors to be used in various applications such as in basic research, gene 
therapy, cellular therapy and DNA vaccine. In order to make great progress in 
vectorology, it is of paramount importance to develop effective vectors capable of 
delivering a gene of interest to target cells to achieve sufficient and sustained 
transgene expression, with minimal toxicity. The design of gene delivery vectors 
has followed two parallel paths. One has taken advantage of animal viruses which 
have highly evolved their gene delivery capacity. Viral vectors have therefore 
received considerable attention and become powerful tools of gene transfer. 
However, the clinical application of viral vectors is limited because of unfavourable 
immunological features and mutagenic integration for some viruses. Their natural 
tropism is regarded as a double-edged sword. As viruses have highly evolved to 
infect their specific host cells, retargeting them to the desired tissue have frequently 
failed. Additionally, high security laboratory standards are often required. The 
other path has been to identify non-viral carriers capable of packaging and 
delivering DNA to target cell for transgene expression. The main limitation for this 
approach has been poor efficiency of gene delivery.  
Recently, phage has been exploited as gene-delivery vectors for mammalian cells. 
As shown in Table 7.1, bacteriophage-based vectors have many of the desirable 
properties of both animal viral and non-viral systems without the significant 
drawbacks. For example, bacteriophage lacks natural tropism for mammalian cells 
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which is a major concern for animal viral vector targeting. The genetic or structural 
modification of the phage coat proteins can be easily manipulated, allowing 
selective targeting of mammalian cell receptors and subsequent tissue-specific 
transduction. Phage production is simpler and more cost effective than many 
existing systems. 
Bacteriophage has come a long way since its first application as antibacterial and is 
further being engineered into new exciting phage-based therapeutics such as 
targeted gene delivery vectors. Bacteriophages have been used clinically to treat 
human bacterial infections since the early years following their first discovery by 
Frederick Twort and Felix d'Hérelle in 1915 and 1917, respectively.393  Although 
the use of phage therapies for bacterial diseases continued in the Soviet Union and 
Eastern Europe, it almost disappeared due to the discovery of antibiotics.394 More 
recently, the field has been reactivated as the prevalence of antibiotic-resistant 
bacterial strains continues to rise.363 Bacteriophages have also been used as tools in 
genetic research, and the discovery of specific target-binding peptides or proteins, 
and vaccine development.395 However, the greatest limitation of phage-mediated 
gene transfer to mammalian cells is low efficiency compared with typical viral 
vectors which has restricted its use. 
An impressive amount of effort has been put into the improvement of 
bacteriophage to be used as a safe selective and efficient vector for gene delivery to 
mammalian cells. These improvements include 1) conferring mammalian cells 
tropism to bacteriophage by inserting a mammalian DNA cassette and displaying a 
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cell targeting ligand, 2) enhancing persistence of transgene expression by 
incorporating regulatory genetic elements from mammalian viruses, and 3) 
providing the precise control of spatial and temporal gene expression which is 
important in determining the safety and efficacy of gene transfer. In 1999, Larocca 
et al first described phage-mediated gene delivery to mammalian cells. Specifically, 
they adapted filamentous bacteriophage vectors by inserting a CMV regulated GFP 
reporter gene and genetically targeting cell surface receptors with either FGF2 or 
EGF ligands, and demonstrated that such phage undergo receptor-mediated 
endocytosis, resulting in the expression of transgenes in mammalian cells.185 In 
2006, Hajitou et al introduced a new generation of phage-based vector by 
incorporating genetic elements from AAV2. With the display of RGD4C targeting 
peptide on its surface coat as an N-terminal fusion to pIII and the incorporation of 
ITR from AAV into its genome, cell transduction efficiency was dramatically 
improved. This AAVP hybrid vector showed superior gene delivery over 
conventional bacteriophage vectors with long-term transgene expression in vivo.171 
In 2012, a double-targeted bacteriophage vector was reported by Kia et al. The 
ligand-directed targeting of AAVP vectors was combined with transcriptional 
targeting using the tumour specific promoter of the stress-inducible glucose-
regulated protein 78 (Grp78) in one single phage vector. The double-targeted 
vector provides sustained and long-term transgene expression compared to the 
conventional phage carrying the CMV promoter. They also showed the superior 
tumour transduction in vivo after systemic delivery with tumour killing using 
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HSVtk/GCV suicide gene therapy.182 In this study, we have placed an emphasis on 
the vectorology platform, namely chemical or genetic engineering of the 
bacteriophage capsid as well as their evaluation in vitro.  
Previous studies as aforementioned have been performed to engineer phage 
particles, aimed at modifying the tropism by capsid manipulation mostly through 
genetic modification to incorporate the mammalian cell surface receptor-targeted 
ligand into phage capsid. We have demonstrated that in addition to genetic 
modification, chemical modification of the capsid proteins allows alternating the 
tropism of the bacteriophage, leading to the production of phage-based vectors 
able to transfer genes to mammalian cells. We also demonstrated that chemical 
modification also influences the subsequent barriers to gene delivery and the 
efficiency of transduction can be dramatically improved. Depending on the curtain 
material used, the phage vector acquires endosomal escape capability. 
Despite considerable progress in the development of phage vectors for gene 
delivery, more advances must be made in order to increase the efficiency of the 
overall gene transfer process. The most interesting finding in this study was that a 
combined genetic and chemical modification of AAVP capsid further enhances 
gene transfer. We have thus introduced the novel hybrid multi-component vector 
termed the smart bacteriophage generated by complexing cationic polymer with 
the AAVP vector displaying the RGD4C ligand and carrying an AAV ITR-flanked 
mammalian DNA cassette (Figure 7.1). In addition to the transient expression, we 
expanded the utility of such combined chemical and genetic modified-
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bacteriophage as gene transfer vectors for selection of cell lines that stably 
maintain expression of the reporter gene. More importantly, we showed that this 
novel vector provides significant extension to the development of novel 
therapeutic platforms, which can be used as a tool for cancer gene therapy. 
Previous investigations have determined the extent of the bottleneck of each of 
extracellular and intracellular barriers and yielded mechanistic information useful 
for designing the vector to overcome these barriers.396 To date, the design of gene 
delivery vectors has placed an emphasis on the development of multifunction 
vectors able to execute multiple tasks to simultaneously overcome delivery 
obstacles. In this study, we have generated multifunctional bacteriophage-based 
vectors as a proof-of-concept prototype. We used the multifunctional phage to 
construct an ideal bacteriophage vector capable of combining multiple strategies 
for overcoming the mammalian cell barriers to phage into a single particle.  
Gene delivery approaches can be manipulated at multiple levels. In addition to the 
vectorology platform, we demonstrated that the manipulation of target cells could 
improve the delivery efficacy. Recently, there has been a renewed interest in the 
tumour microenvironment because of its role in a drug delivery obstacle.296 We 
showed that the ECM affects the effectiveness of phage-based vectors through 
blocking diffusion and/or physical masking of target receptors on malignant cells 
and ECM modulation could therefore enhance transduction efficiency by AAVP 
phage vectors. These findings support the potential use of ECM depletion as a 
strategy to enhance phage-mediated gene delivery in tumours. 
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Table 7.1: A comparison of features of phage vectors with animal and synthetic vectors. 
Bacteriophage-based vectors offer an attractive alternative to various viral and synthetic vectors, 
because they can potentially overcome the drawbacks of either approach.  (Larocca and Baird, 
2001) 
 
 
Figure 7.1: Schematic representation of the proposed pathway of the AAVP/polymer 
complex-mediated transduction. The polymer component of the hybrid vector mediates cell 
attachment via electrostatic attraction, in which the polymers generate positive charge of 
bacteriophage capsid. Following receptor-mediated endocytosis and entrapment in acidic 
endosome, the vector escape is promoted by the proton sponge mechanism mediated by cationic 
polymers.  
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Different and promising strategies have been proposed in this study. We have 
developed these new methodologies as promising tools that gene delivery with 
bacteriophage-based vector has evolved rapidly from bacteria to successful gene 
delivery to mammalian cells. Given that these different strategies demonstrated the 
promising improvement of AAVP-mediated gene expression in 2D and 3D cell 
culture models, these will be the likely candidates to be taken to in vivo studies. 
Furthermore, it can be hypothesized that combination of these strategies could 
further improve or may be significantly greater than a single strategy. 
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Appendix A 
Optimisation of AAVP/cationic lipids. HEK293 cells were cultured in 48-well 
plates and treated with NT.AAVP or RGD4C.AAVP carrying the Luc gene, 
premixed with increasing ratios of cationic polymer per AAVP. Luciferase activity 
was analysed at day 3 post transduction. a) Fugene. b) Lipofectamine. c) DOTAB. 
The results show the mean relative luminescence units of triplicate wells +SEM, 
from one representative of three independent experiments. 
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Optimisation of AAVP pretreated with chemical reagents. HEK293 cells were 
cultured in 48-well plates and treated with AAVP carrying the Luc gene, premixed 
with increasing ratios of chemical reagents per AAVP as indicated in the figure. 
Luciferase activity was analysed at day 3 post transduction. The results show the 
mean relative luminescence units of triplicate wells ±SEM, from one representative 
of three independent experiments. 
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Optimisation of AAVP/cationic polymer complexes in glioblastomas. Cells 
were cultured in 48-well plates and treated with AAVP carrying the Luc gene, 
premixed with increasing ratios of cationic polymer per AAVP. Luciferase activity 
was analysed at day 3 post transduction. The results show the mean relative 
luminescence units of triplicate wells ±SEM, from one representative of three 
independent experiments. 
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Appendix B 
 
 
gtgaaaaaattattattcgcaattcctttagttgttcctttctattctcactccgtctgt 
V  K  K  L  L  F  A  I  P  L  V  V  P  F  Y  S  H  S  V  C 
gattgtaggggggattgtttttgtgaaactgttgaaagttgtttagcaaaacctcataca 
D  C  R  G  D  C  F  C  E  T  V  E  S  C  L  A  K  P  H  T 
gaaaattcatttactaacgtctggaaagacgacaaaactttagatcgttacgctaactat 
E  N  S  F  T  N  V  W  K  D  D  K  T  L  D  R  Y  A  N  Y 
gagggctgtctgtggaatgctacaggcgttgtggtttgtactggtgacgaaactcagtgt 
E  G  C  L  W  N  A  T  G  V  V  V  C  T  G  D  E  T  Q  C 
tacggtacatgggttcctattgggcttgctatccctgaaaatgagggtggtggctctgag 
Y  G  T  W  V  P  I  G  L  A  I  P  E  N  E  G  G  G  S  E 
ggtggcggttctgagggtggcggttctgagggtggcggtactaaacctcctgagtacggt 
G  G  G  S  E  G  G  G  S  E  G  G  G  T  K  P  P  E  Y  G 
gatacacctattccgggctatacttatatcaaccctctcgacggcacttatccgcctggt 
D  T  P  I  P  G  Y  T  Y  I  N  P  L  D  G  T  Y  P  P  G 
actgagcaaaaccccgctaatcctaatccttctcttgaggagtctcagcctcttaatact 
T  E  Q  N  P  A  N  P  N  P  S  L  E  E  S  Q  P  L  N  T 
ttcatgtttcagaataataggttccgaaataggcagggtgcattaactgtttatacgggc 
F  M  F  Q  N  N  R  F  R  N  R  Q  G  A  L  T  V  Y  T  G 
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5647 in fd-tet 
     XhoI 
AGCTCGAGCTTACTCCCCA 
tac promoter 
TCCCCCTGTTGACAATTAATCATCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTC 
gene VIII translation initiation region 
TTAATGGAAACTTCCTC ATG AAA AAG TCT TTA  
                   M   K   K   S   L   
 
GTT CTT AAA GCA TCT GTT GCT GTT GCG ACT CTT GTT 
 V   L   K   A   S   V   A   V   A   T   L   V 
                     HindIII                                                        
PstI 
                     stuffer                          
CCT ATG CTA^AGC TTT GCC AAC GTC CCT GCA^GAA GGT GAT GAC CCG GCT AAA 
 P   M   L   S   F   A ^ N   V   P   A   E   G   D   D   P   A   K 
                  Signal Peptidase 
GCT GCT TTT GAC TCT CTT CAG GCT TCT GCT ACT GAA TAC ATC GGC TAC GCT 
 A   A   F   D   S   L   Q   A   S   A   T   E   Y   I   G   Y   A 
TGG GCT ATG GTG GTT GTT ATC GTT GGT GCT ACT ATT GGC ATC AAA CTT TTC 
 W   A   M   V   V   V   I   V   G   A   T   I   G   I   K   L   F 
AAA AAA TTC ACT TCT AAA GCG TCT  
 K   K   F   T   S   K   A   S 
                  trpA terminator                                                                                    
NheI 
TAATG  AACTCAGATACCCAGCCCGCCTAATGAGCGGGCTTTTTTTT  AAGCTAGCTT 
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Construction of RGD4C.fUSE5.f88.AAV-GFP plasmid 
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Appendix C 
Reagents set up 
 PEG/NaCl 500 g of PEG (Sigma) and 584.5 g of NaCl (Sigma) in 
2,380 ml H2O (double-distilled) and store at 4°C 
50x TAE buffer 242g of Tris, 100mL of 0.5M EDTA pH 8.0 and 57.1mL 
of Glacial Acetic Acid (Ficher). Add enough H2O to 
dissolve solids, then bring up to final volume of 1000mL. 
autoclaved and stored RT. 
0.5M EDTA pH 8.0 186.1g of EDTA (Ficher) in 900ml of H2O and stir until 
completely dissolved. Adjusted the pH with NaOH, then 
bring up to 1000 ml, autoclaved and stored RT. 
LB broth 18 g of LB powder (Sigma) in 1000 ml of H2O, sterilise by 
autoclaving. 
LB agar 9 g of LB powder and 9 g of agar in 450 ml of H2O, 
sterilise by autoclaving, Let agar cool to ~55°C, then add 
antibiotics before pour plates 
TB medium 9.6 g of tryptone (Sigma), 19.2 g of yeast extract (Sigma)  
and 3.2 ml of glycerol in 1 liter of H2O. Autoclave, add 
100 ml of TB supplements and 50 mg of kanamycin 
(Sigma). 
TB supplement 23.1 g of KH2PO4 (Sigma) and 125.4 g of K2HPO4 
(Sigma) in 1 liter of H2O (double-distilled). Filter through 
0.22 µm filter units and store at 4°C 
 
